Crystalline form of (R)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamide)-2-methylphenyl)-N-isopropylnicotinamide and method of use thereof

Abstract

The crystalline form of the compound of formula (I) and its pharmaceutical composition are provided herein. Methods of using the crystalline form and pharmaceutical composition to treat cancer and viruses (e.g., coronavirus), as well as other diseases and disorders involving protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), are also provided herein. [Formula 1] JPEG2026513203000160.jpg23170

Description

[Technical Field]

[0001] Cross-reference of related applications

[0001] This application claims the interests and priority of International Patent Application PCT / CN2023 / 085125, filed on 30 March 2023, the contents of which are incorporated herein by reference in their entirety. [Background technology]

[0002] background

[0002] Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is an eIF2 kinase involved in misfolding protein responses, regulating protein synthesis, helping cells mitigate the effects of endoplasmic reticulum stress, and participating in tumorigenesis, cancer cell survival, and viral infections (e.g., coronavirus). Therefore, PERK-modulating compounds (e.g., PERK inhibitors) are considered useful for treating a wide range of pathological conditions, diseases, and disorders, including but not limited to various cancers. The development of solid-state forms, including crystalline forms, of PERK inhibitors that provide the physicochemical properties necessary to manufacture drug products with required stability and efficacy is a major challenge due to the unpredictability of the results of solid-state screening given for compounds, and the subsequent unpredictability of the physicochemical properties of any identified solid-state forms. Therefore, there is an unmet need for novel solid-state forms of PERK inhibitors that provide the required physicochemical properties. [Overview of the Initiative] [Means for solving the problem]

[0003] overview

[0003] This disclosure provides crystalline forms (e.g., crystalline salt form and crystalline free base form) of compounds of formula (I). [ka]

[0004] [

[0004] ] The present disclosure further provides a pharmaceutical composition comprising a crystalline form (e.g., a crystalline salt form or a crystalline free base form) of the compound of formula (I) described herein. The salt form or pharmaceutical composition of the compound of formula (I) of the present disclosure is useful for the treatment of the conditions, diseases, or disorders (e.g., cancer) described herein.

[0005] [

[0005] ] In one aspect, the present disclosure provides a fumarate salt of the compound of formula (I). [[Chemical formula]] <匡

[0006] [

[0006] ] In another aspect, the present disclosure provides a crystalline fumarate salt of the compound of formula (I). [[Chemical formula]]

[0007] [

[0007] ] In another aspect, the present disclosure provides a crystalline monofumarate salt of the compound of formula (I). [[Chemical formula]]

[0008] [[ID=匡33]] [

[0008] ] In another aspect, the present disclosure provides Form A of the monofumarate salt of the compound of formula (I). [[Chemical formula]]

[0009] [

[0009] ] In another aspect, the present disclosure provides Form B of the monofumarate salt of the compound of formula (I). [[Chemical formula]]

[0010] [

[0010] ] In another aspect, the present disclosure provides Form C of the monofumarate salt of the compound of formula (I). [[Chemical formula]]

[0011]

[0011] In another embodiment, the present disclosure provides crystalline hemifumarates of compounds of formula (I). [ka]

[0012]

[0012] In another embodiment, the present disclosure provides form A of the hemifumarate of the compound of formula (I). [ka]

[0013]

[0013] In another aspect, the present disclosure provides form B of the hemifumarate of the compound of formula (I). [ka]

[0014]

[0014] In another aspect, the present disclosure provides pharmaceutical compositions generally comprising a salt form (e.g., a crystalline salt form) of a compound of formula (I) described herein and pharmaceutically acceptable excipients.

[0015]

[0015] In another aspect, the present disclosure provides dosage forms (e.g., capsules) that generally include the pharmaceutical compositions described herein.

[0016]

[0016] In another aspect, the present disclosure provides a method for treating cancer in a subject of interest, which generally comprises administering an effective amount of a salt form (e.g., crystalline salt form) or pharmaceutical composition of a compound of formula (I) described herein. [Brief explanation of the drawing]

[0017] Brief explanation of the drawing [Figure 1]

[0017] This is an exemplary X-ray powder diffraction (XRPD) pattern of form A of the monofumarate of the compound of formula (I), prepared according to Example 3. [Figure 2]

[0018] This is an overlay of differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) thermograms of form A of the monofumarate of the compound of formula (I), prepared according to Example 3. [Figure 3]

[0019] This is an exemplary XRPD pattern of form B of the monofumarate of the compound of formula (I), prepared according to Example 8. [Figure 4]

[0020] This is an overlay of DSC and TGA thermograms of form B of the monofumarate of the compound of formula (I), prepared according to Example 8. [Figure 5]

[0021] This is an exemplary XRPD pattern of form C of the monofumarate of the compound of formula (I), prepared according to Example 9. [Figure 6]

[0022] This is an overlay of DSC and TGA thermograms of form C of the monofumarate of compound (I), prepared according to Example 9. [Figure 7]

[0023] This is an exemplary XRPD pattern of a crystalline fumarate of the compound of formula (I) obtained according to Example 10, crystallized from 0.5 to 1.1 equivalents of 0.1 M fumaric acid in methanol solution at room temperature. [Figure 8]

[0024] This is an exemplary XRPD pattern of form A of the hemifumarate of the compound of formula (I), prepared according to Example 11. [Figure 9]

[0025] This is an overlay of DSC and TGA thermograms of form A of the hemi-fumarate of compound (I), prepared according to Example 11. [Figure 10]

[0026] This is an exemplary dynamic water vapor adsorption (DVS) isotherm plot of form A of the hemifumarate of compound (I), prepared according to Example 11. [Figure 11]

[0027] This is a stack plot of the XRPD pattern of form A of the hemifumarate of the compound of formula (I), obtained by slurring form A and form B of the hemifumarate of the compound of formula (I) in isopropanol, as performed according to Example 14. [Figure 12]

[0028] This is a stack plot of the XRPD patterns of the solid obtained after adding form A of the hemi-fumarate of compound (I), prepared according to Example 15, to water, FaSSIF, and FaSSIF solution. Solid sampling was performed over 24 hours. [Figure 13]

[0029] This is an exemplary XRPD pattern of form B of the hemifumarate of the compound of formula (I), prepared according to Example 16. [Figure 14]

[0030] DSC and TGA thermogram overlays of form B of the hemi-fumarate of compound (I), prepared according to Example 16. [Figure 15]

[0031] This is a stack plot of XRPD patterns from competitive slurries of form A and form B of the hemi-fumarate of compound (I) in isopropanol at room temperature and 50°C, carried out according to Example 17. Solid sampling was performed after 3 days. [Figure 16]

[0032] This is an exemplary XRPD pattern of the L-tartrate of the compound of formula (I), prepared according to Example 19. [Figure 17]

[0033] Overlays of DSC and TGA thermograms of the L-tartrate of the compound of formula (I), prepared according to Example 19. [Figure 18]

[0034] This is an exemplary XRPD pattern of form A of the tosylate of the compound of formula (I), prepared according to Example 20. [Figure 19]

[0035] This is an overlay of DSC and TGA thermograms of form A of the tosylate of the compound of formula (I), prepared according to Example 20. [Figure 20]

[0036] This is an exemplary XRPD pattern of a solid material containing a tosylate of the compound of formula (I) crystallized from 1.1 equivalents of 0.1 M p-toluenesulfonic acid in MeOH, prepared according to Example 21. [Figure 21]

[0037] This is an exemplary XRPD pattern of a solid material containing a tosylate of the compound of formula (I), crystallized from seed crystals of the tosylate of the compound of formula (I) isolated from a salt screening experiment (Example 18) using 14V butyl as a poor solvent, prepared according to Example 22. [Figure 22]

[0038] This is an exemplary XRPD pattern of form A of the succinate of the compound of formula (I), prepared according to Example 23. [Figure 23]

[0039] This is an overlay of DSC and TGA thermograms of form A of the succinate of the compound of formula (I), prepared according to Example 23. [Figure 24]

[0040] This is an exemplary XRPD pattern of a solid material containing the succinate of the compound of formula (I), crystallized from a 1.1 equivalent 0.1 M succinic acid solution in MeOH, prepared according to Example 24. [Figure 25]

[0041] This is an exemplary XRPD pattern of a solid material containing a succinate of the compound of formula (I) crystallized from a 1.05 equivalent MeOH solution of 0.1 M succinic acid and succinate seed crystals from a salt screening experiment (Example 18), prepared according to Example 25. [Figure 26A]

[0042] This is an exemplary XRPD pattern of form A of the compound of formula (I), prepared according to Example 27. [Figure 26B]

[0043] This is the XRPD pattern of morphology A of the compound of formula (I), calculated from single-crystal X-ray diffraction data prepared according to Example 27. [Figure 27]

[0044] This is an exemplary DSC thermogram of form A of the compound of formula (I), prepared according to Example 27. [Figure 28]

[0045] This is an atomic displacement ellipsoid diagram of morphology A of the compound of formula (I). [Figure 29A]

[0046] This is an exemplary XRPD pattern of form A of compound (I), prepared by storing form A in a water / acetone mixture (80:20 v / v) under ambient conditions for 4 days, as carried out according to Example 29. [Figure 29B]

[0047] This is an exemplary XRPD pattern of form C of compound (I), which was prepared by storing form A of compound (I) in an acetonitrile / water mixture (92:8v / v) under ambient conditions for 4 days, as carried out according to Example 29. [Figure 29C]

[0048] This is an exemplary XRPD pattern of form H of compound (I), which was prepared by storing form A of compound (I) in an isopropanol / water mixture (90:10 v / v) under ambient conditions for 27 days, as carried out according to Example 29. [Figure 29D]

[0049] This is an exemplary XRPD pattern of a mixture of forms A and H of the compound of formula (I), prepared by storing form A in an isopropanol / water mixture (94:6v / v) under ambient conditions for 4 days, as carried out according to Example 29. [Figure 30]

[0050] This is an exemplary XRPD pattern of form B of the compound of formula (I), prepared according to Example 30. [Figure 31]

[0051] This is an exemplary DSC thermogram of form B of the compound of formula (I), prepared according to Example 30. [Figure 32]

[0052] This is an exemplary thermogravimetric analysis (TGA) thermogram of form B of the compound of formula (I), prepared according to Example 30. [Figure 33]

[0053] This is a periodic DSC thermogram (multiple heating + cooling cycles) of the compound of formula (I) (starting material form B of the compound of formula (I)) carried out according to Example 31. [Figure 34]

[0054] This is a stack plot of XRPD patterns from a variable temperature XRPD test of the compound of formula (I) (starting material form B of the compound of formula (I)) performed according to Example 31. [Figure 35]

[0055] This is an exemplary XRPD pattern of form C of the compound of formula (I), prepared according to Example 32. [Figure 36]

[0056] This is an exemplary DSC thermogram of form C of the compound of formula (I), prepared according to Example 32. [Figure 37]

[0057] This is an exemplary TGA thermogram of form C of the compound of formula (I), prepared according to Example 32. [Figure 38A]

[0058] As further described in Example 33, this is the XRPD pattern of a mixture of forms B and C of the compound of formula (I) obtained from acetone. [Figure 38B]

[0059] As further described in Example 33, this is the XRPD pattern of form B of compound (I) obtained after storing a mixture of forms B and C of compound (I) under ambient conditions for 13 days. [Figure 38C]

[0060] As further described in Example 33, this is the XRPD pattern of form C of the compound of formula (I) obtained from acetonitrile. [Figure 38D]

[0061] As further described in Example 33, this is the XRPD pattern of form B of the compound of formula (I), obtained after storing form C of the compound of formula (I) under ambient conditions for 25 days. [Figure 38E]

[0062] As further described in Example 33, this is the XRPD pattern of form C of the compound of formula (I) obtained from a mixture of acetonitrile and water. [Figure 38F]

[0063] As further described in Example 33, this is the XRPD pattern of a mixture of forms B and C of the compound of formula (I), obtained after storing form C of the compound of formula (I) under ambient conditions for 9 days. [Figure 39]

[0064] This is an exemplary XRPD pattern of form D of the compound of formula (I), prepared according to Example 34. [Figure 40]

[0065] This is an exemplary DSC thermogram of form D of the compound of formula (I), prepared according to Example 34. [Figure 41]

[0066] This is an exemplary TGA thermogram of form D of the compound of formula (I), prepared according to Example 34. [Figure 42]

[0067] This is an exemplary DVS isotherm plot of form D of the compound of formula (I), prepared according to Example 34. [Figure 43]

[0068] This is an exemplary XRPD pattern of form E of the compound of formula (I), prepared according to Example 35. [Figure 44]

[0069] This is an exemplary DSC thermogram of form E of the compound of formula (I), prepared according to Example 35. [Figure 45]

[0070] This is an exemplary TGA thermogram of form E of the compound of formula (I), prepared according to Example 35. [Figure 46]

[0071] This is an exemplary XRPD pattern of form H of the compound of formula (I), prepared according to Example 36. [Figure 47]

[0072] This is an exemplary DSC thermogram of form H of the compound of formula (I), prepared according to Example 36. [Figure 48]

[0073] This is an exemplary XRPD pattern of material F of compound (I), prepared according to Example 37. [Figure 49]

[0074] This is an exemplary XRPD pattern of material G of compound (I), prepared according to Example 38. [Figure 50]

[0075] This is an exemplary DSC thermogram of material G of compound (I), prepared according to Example 38. [Figure 51]

[0076] This is an exemplary TGA thermogram of material G of compound (I), prepared according to Example 38. [Figure 52]

[0077] This is the XRPD pattern of a mixture of form H and form A of the compound of formula (I), obtained after storing the mixture of form A and form H in a heptane / ethanol mixture (67:33, v / v) at ambient temperature for 21 days, as performed according to Example 39. [Figure 53]

[0078] These are the XRPD patterns of forms A and H of the compound of formula (I) obtained after storing a mixture of forms A and H in an isopropanol / water mixture (98:2, v / v) at ambient temperature for 11 days, as carried out according to Example 39. [Figure 54]

[0079] This is the XRPD pattern of form E of compound (I), obtained after storing a mixture of forms A and H of compound (I) in ethyl acetate at ambient temperature for 11 days, as performed according to Example 39. [Figure 55]

[0080] This is the XRPD pattern of a mixture of form E, material G, and form A of the compound of formula (I), obtained after storing the mixture of form E and material G in ethyl acetate at ambient temperature for 3 days, as carried out according to Example 39. [Figure 56]

[0081] This is the XRPD pattern of a mixture of forms A and H of the compound of formula (I), obtained after storing forms A and B of the compound of formula (I) in ethanol at 21°C for 4 days, as performed according to Example 39. [Figure 57]

[0082] This is the XRPD pattern of a mixture of form H and form A of the compound of formula (I), obtained after storing forms A and B of the compound of formula (I) in ethyl acetate for 4 days at 21°C, as performed according to Example 39. [Figure 58]

[0083] This is an exemplary XRPD pattern of crystalline cansylate form A of the compound of formula (I), prepared according to Example 40. [Figure 59]

[0084] This is an exemplary DSC thermogram of crystalline cansylate form A of the compound of formula (I), prepared according to Example 40. [Figure 60]

[0085] This is an exemplary TGA thermogram of crystalline cansylate form A of the compound of formula (I), prepared according to Example 40. [Figure 61]

[0086] This is an exemplary XRPD pattern of phosphate material A of compound (I), prepared according to Example 41. [Figure 62]

[0087] This is an exemplary XRPD pattern of phosphate material B of compound (I), prepared according to Example 42. [Figure 63]

[0088] This is an exemplary DSC thermogram of phosphate material B of compound (I), prepared according to Example 42. [Figure 64]

[0089] This is an exemplary TGA thermogram of phosphate material B of compound (I), prepared according to Example 42. [Modes for carrying out the invention]

[0018] Detailed explanation

[0090] As generally described herein, this disclosure provides salt forms (e.g., fumarate, L-tartrate, tosylate, and succinate) of the compound of formula (I), including crystalline salt and crystalline base forms. This disclosure also provides pharmaceutical compositions comprising the crystalline forms (e.g., crystalline salt or crystalline free base forms) of the compound of formula (I) described herein and pharmaceutically acceptable excipients, as well as methods of using the crystalline forms (e.g., crystalline salt and crystalline free base forms) and the pharmaceutical compositions described herein to treat the conditions, diseases, or disorders disclosed herein (e.g., cancer).

[0019] definition

[0091] To facilitate understanding of the present invention, several terms and phrases are defined below.

[0020]

[0092] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which this invention pertains. Abbreviations used herein have their conventional meanings in chemical and biological art. Chemical structures and formulas described herein are constructed in accordance with the standard rules of chemical valence known in the chemical art.

[0021]

[0093] Throughout this specification, where compositions and kits are described as having, encompassing, or containing certain components, or where processes and methods are described as having, encompassing, or containing certain steps, it is understood that there are compositions and kits of the present invention that are essentially composed of or consist of the listed components, and processes and methods of the present invention that are essentially composed of or consist of the listed processing steps.

[0022]

[0094] In this application, when an element or component is said to be included in the enumerated list of elements or components and / or selected from the enumerated list of elements or components, it should be understood that the element or component may be any one of the enumerated elements or components, or the element or component may be selected from a group consisting of two or more of the enumerated elements or components.

[0023]

[0095] Furthermore, it should be understood that the elements and / or features of the compositions or methods described herein, whether express or implied herein, can be combined in various ways without departing from the spirit and scope of the invention. For example, where a particular compound is referred to, that compound may be used in various embodiments of the compositions and / or methods of the invention unless otherwise understood from the context. In other words, while embodiments within this application have been described and shown in a manner that enables a clear and concise application to be described and depicted, it will be understood that embodiments can be combined or separated in various ways without departing from the teachings and the invention. For example, it will be understood that all features described and shown herein may be applicable to all embodiments of the invention described and shown herein.

[0024]

[0096] The articles “a” and “an” are used in this disclosure to refer to one or more (i.e., at least one) grammatical objects of the article, unless the context makes it inappropriate. For example, “an element” means one or more elements.

[0025]

[0097] In this disclosure, the terms "and / or" are used to mean either "and" or "or" unless otherwise indicated.

[0026]

[0098] The expression "at least one of ~" should be understood to include each of the enumerated objects that follow this phrase, and any various combinations of two or more of the enumerated objects, unless otherwise understood from the context and usage. The expression "and / or" relating to three or more enumerated objects should be understood to have the same meaning unless otherwise understood from the context.

[0027]

[0099] The use of the terms “include,” “includes,” “including,” “has,” “having,” “contains,” or “containing” (including their grammatical equivalents) should generally be understood to be open-ended and non-restrictive, for example, not excluding further unlisted elements or processes, unless specifically indicated or understood from the context.

[0028]

[0100] Where the term “about” is used before a quantitative value, the present invention also includes the specific quantitative value itself unless otherwise specified. As used herein, the term “about” refers to a variation of ±10%, ±5%, ±3%, ±2%, or ±1% from the nominal value, unless otherwise indicated or suggested by the context.

[0029]

[0101] Due to causes of experimental variability well known to those skilled in the art, the value of each XRPD peak is typically preceded by the term “approximately” or followed by an appropriate range that defines the experimental variability. For the data reported herein, the value is ±0.3°²θ unless otherwise specified. XRPD peaks cited herein are generally reported with this variability of ±0.3°²θ unless otherwise specified, and are intended to be reported with such variability whenever disclosed herein, whether or not the term “approximately” is present, unless otherwise indicated in the context.

[0030]

[0102] Due to causes of experimental variability well known to those skilled in the art, each differential scanning calorimetry (DSC) endothermic or exothermic value is typically preceded by the term “approximately” or followed by an appropriate range that defines the experimental variability. For the data reported herein, the value is ±10°C unless otherwise specified. DSC endothermic / exothermic values ​​cited herein are generally reported with this variability of ±10°C unless otherwise specified, and are intended to be reported with such variability whenever disclosed herein, whether or not the term “approximately” is present, unless otherwise indicated in the context.

[0031]

[0103] In various parts of this specification, variables or parameters are disclosed in groups or ranges. The description is particularly intended to include any individual partial combination of the components of such groups and ranges. For example, the integers in the range of 0 to 40 are particularly intended to be disclosed individually as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, and 40, and the integers in the range of 1 to 20 are particularly intended to be disclosed individually as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.

[0032]

[0104] Any use of any example or illustrative term herein, such as “etc.” or “including,” is intended merely to better illustrate the invention and, unless otherwise claimed, does not impose any limitation on the scope of the invention. No term herein should be construed as indicating that any unclaimed element is essential to the practice of the invention.

[0033]

[0105] As a general rule, percentages in compositions are based on weight unless otherwise specified. Furthermore, if a variable is not defined, the previous definition of the variable takes precedence.

[0034]

[0106] As used herein, “pharmaceutical composition” or “pharmaceutical preparation” refers to a combination of an active agent and an inert or active carrier that makes the composition particularly suitable for in vivo or ex vivo diagnostic or therapeutic use.

[0035]

[0107] "Pharmacologically acceptable" means that it has been approved or is eligible for approval by a federal or state regulatory agency or a corresponding agency in a country other than the United States for use in animals, more specifically in humans, or that it is listed in the United States Pharmacopoeia or other generally accepted pharmacopoeias.

[0036]

[0108] For therapeutic use, salts of the compounds of the present invention (e.g., compounds of formula (I)) are considered pharmaceutically acceptable. However, salts of pharmaceutically unacceptable acids and bases may also be used, for example, in the preparation or purification of pharmaceutically acceptable compounds.

[0037]

[0109] As used herein, “pharmaceutically acceptable excipients” means substances that may be included in the compositions of the present invention to assist the administration and / or absorption of the active agent to a subject without causing any significant adverse toxicological effects to the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, salines such as phosphate-buffered saline, emulsions (e.g., oil / water or water / oil emulsions), Ringer's lactate solution, ordinary sucrose, ordinary glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavorings, salt solutions (e.g., Ringer's solution), alcohols, oils, gelatin, carbohydrates, fatty acid esters, and colorants. Such preparations may be sterilized and, if necessary, mixed with adjuvants such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts to affect osmotic pressure, buffers, colorants, and / or aromatics, which do not react adversely with the compounds of the present invention. For examples of excipients, see Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA (1975).

[0038]

[0110] Possible "targets" for administration include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or non-human animals, e.g., primates (e.g., cynomolgus macaques, rhesus macaques), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the target is human. In certain embodiments, the target is adult. In certain embodiments, the target is non-human animal.

[0039]

[0111] As used herein, “solid dosage form” means a solid form, such as tablets, capsules, granules, powders, sachets, reconstituteable powders, dry powder inhalants, and chewables.

[0040]

[0112] As used herein, “administer” means to a subject by oral administration, suppository administration, topical contact, intravenous administration, parenteral administration, intraperitoneal administration, intramuscular administration, intralesional administration, intrathecal administration, intracranial administration, intranasal or subcutaneous administration, or implantation of a sustained-release device, such as a mini osmotic pump. Administration is by any route, including parenteral and transmucosal (e.g., oral cavity, sublingual, palate, gingiva, nose, vagina, rectum, or percutaneous). Parenteral administrations include, for example, intravenous, intramuscular, intra-arterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other delivery methods include, but are not limited to, the use of liposomal formulations, intravenous infusion, and transdermal patches. “Concurrent administration” means that the compositions described herein are administered simultaneously with, immediately before, or immediately after the administration of one or more additional treatments (e.g., anticancer agents, chemotherapeutic agents, or immunotherapies). The compound of formula (I), or a pharmaceutically acceptable salt thereof, may be administered alone or concurrently to a patient. Concurrent administration means simultaneous or sequential administration of the compound individually or in combination (two or more compounds or drugs). Therefore, the preparation may also be combined with other active substances as needed (e.g., to reduce metabolic degradation).

[0041]

[0113] As used herein, “fasting state” means at least one hour before a meal or at least two hours after a meal has been consumed by the subject.

[0042]

[0114] The terms "disease," "disorder," and "pathological condition" are used synonymously in this specification.

[0043]

[0115] As used herein, and unless otherwise specified, the terms “to treat,” “to treat,” and “treatment” are intended to describe any action taken while an object is suffering from a particular disease, disorder, or condition that reduces the severity of the disease, disorder, or condition, or delays or slows the progression of the disease, disorder, or condition (e.g., “therapeutic action”).

[0044]

[0116] Generally, the “effective amount” of a compound or composition (e.g., the compound of formula (I), the crystalline form of the compound of formula (I) described herein, or the pharmaceutical composition described herein) refers to an amount sufficient to induce a desired biological response, for example, to treat the cancer described herein. As those skilled in the art will understand, the effective amount of the compounds, crystalline forms, or pharmaceutical compositions of this disclosure may vary depending on the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the method of administration, and factors such as the age, weight, health, and condition of the subject.

[0045] Salt form of the compound of formula (I)

[0117] The compound of formula (I) shown below is a selective PERK inhibitor, also known as (R)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamide)-2-methylphenyl)-N-isopropylnicotinamide: [ka]

[0046]

[0118] The compound of formula (I) may also be referred to as HC-5404 throughout this disclosure. A method for chemically synthesizing the compound of formula (I) is described in Example 2.

[0047]

[0119] In one embodiment, a salt form of the compound of formula (I) is provided herein. [ka]

[0048]

[0120] In various embodiments, the salt form of the compound of formula (I) is the fumarate of the compound of formula (I). In certain embodiments, the fumarate of the compound of formula (I) is a monofumarate. In certain embodiments, the fumarate of the compound of formula (I) is a hemifumarate.

[0049]

[0121] In various embodiments, the salt form of the compound of formula (I) is the L-tartrate of the compound of formula (I).

[0050]

[0122] In various embodiments, the salt form of the compound of formula (I) is the tosylate of the compound of formula (I).

[0051]

[0123] In various embodiments, the salt form of the compound of formula (I) is the succinate salt of the compound of formula (I).

[0052]

[0124] In another embodiment, crystalline salt forms of the compound of formula (I) are provided herein.

[0053]

[0125] In various embodiments, the crystalline salt form of the compound of formula (I) is the crystalline fumarate of the compound of formula (I). In certain embodiments, the crystalline fumarate of the compound of formula (I) is the crystalline monofumarate. In certain embodiments, the crystalline fumarate of the compound of formula (I) is the crystalline monofumarate. In certain embodiments, the crystalline fumarate of the compound of formula (I) is the crystalline hemifumarate. In certain embodiments, the crystalline salt form is the crystalline cansylate form. In certain embodiments, the crystalline salt form is the crystalline phosphate form. In certain embodiments, the crystalline cansylate form is the crystalline cansylate form A of the compound of formula (I).

[0054]

[0126] In certain embodiments, the crystalline salt form of the compound of formula (I) is form A of the monofumarate of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is form B of the monofumarate of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is form C of the monofumarate of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is form A of the hemifumarate of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is form B of the hemifumarate of the compound of formula (I).

[0055]

[0127] In certain embodiments, the crystalline salt form of the compound of formula (I) is the crystalline L-tartrate of the compound of formula (I).

[0056]

[0128] In certain embodiments, the crystalline salt form of the compound of formula (I) is the crystalline tosylate of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is form A of the tosylate of the compound of formula (I).

[0057]

[0129] In certain embodiments, the crystalline salt form of the compound of formula (I) is the crystalline succinate of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is form A of the succinate of the compound of formula (I).

[0058] (1) Fumarate form

[0130] In one embodiment, a fumarate of the compound of formula (I) is provided herein. [ka]

[0059]

[0131] In certain embodiments, the fumarate of the compound of formula (I) is a monofumarate. In certain embodiments, the fumarate of the compound of formula (I) is a hemifumarate.

[0060]

[0132] In another embodiment, crystalline fumarates of the compound of formula (I) are provided herein. [ka]

[0061]

[0133] In certain embodiments, the crystalline fumarate has an X-ray powder diffraction (XRPD) pattern that includes one or more peaks at approximately 16.9°, approximately 17.9°, and approximately 24.1°²θ.

[0062]

[0134] In certain embodiments, the crystalline fumarate is a crystalline monofumarate. In certain embodiments, the crystalline fumarate has substantially the same XRPD pattern as shown in Figure 1. In certain embodiments, the crystalline fumarate has substantially the same XRPD pattern as shown in Figure 3. In certain embodiments, the crystalline fumarate has substantially the same XRPD pattern as shown in Figure 5. In certain embodiments, the crystalline fumarate has substantially the same XRPD pattern as shown in Figure 7.

[0063]

[0135] In certain embodiments, the crystalline fumarate is a crystalline hemifumarate. In certain embodiments, the crystalline fumarate has substantially the same XRPD pattern as shown in Figure 8. In certain embodiments, the crystalline fumarate has substantially the same XRPD pattern as shown in Figure 13.

[0064]

[0136] In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 1. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 8. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 9. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 10. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 11. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 19.

[0065]

[0137] In certain embodiments, the crystalline fumarate of the compound of formula (I) is an anhydrous crystalline fumarate.

[0066]

[0138] In certain embodiments, the crystalline fumarate of the compound of formula (I) is a crystalline hydrate. In certain embodiments, the crystalline hydrate is a crystalline monohydrate.

[0067] (A) Crystal form of monofumarate

[0139] In various embodiments, crystalline monofumarates of the compound of formula (I) are provided herein. [ka]

[0068]

[0140] In certain embodiments, the crystalline monofumarate has an XRPD pattern that includes one or more peaks at approximately 5.2°²θ.

[0069]

[0141] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 7.6° and approximately 14.4°²θ.

[0070]

[0142] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.8°, approximately 21.2°, approximately 24.5°, and approximately 25°²θ.

[0071]

[0143] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.1°, 16.7°, 17.3°, 17.9°, 19.4°, 19.9°, 20.6°, and 22.7°²θ.

[0072]

[0144] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 30.4° and approximately 31.4°²θ.

[0073]

[0145] In certain embodiments, the crystalline monofumarate has an XRPD pattern that includes one or more peaks at approximately 5.2°, 7.6°, 14.4°, 15.1°, 15.8°, 16.7°, 17.3°, 17.9°, 19.4°, 19.9°, 20.6°, 21.2°, 22.7°, 24.5°, 25.0°, 30.4°, and 31.4°²θ.

[0074]

[0146] In certain embodiments, the crystalline monofumarate has an XRPD pattern that includes peaks at approximately 5.2°, 7.6°, 14.4°, 15.1°, 15.8°, 16.7°, 17.3°, 17.9°, 19.4°, 19.9°, 20.6°, 21.2°, 22.7°, 24.5°, 25.0°, 30.4°, and 31.4°²θ.

[0075]

[0147] In certain embodiments, the crystalline monofumarate has an XRPD pattern containing one or more peaks at 5.2°±0.3°2θ.

[0076]

[0148] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.6°±0.3° and 14.4°±0.3°²θ.

[0077]

[0149] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.8°±0.3°, 21.2°±0.3°, 24.5°±0.3°, and 25°±0.3°2θ.

[0078]

[0150] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.3°, 16.7°±0.3°, 17.3°±0.3°, 17.9°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.6°±0.3°, and 22.7°±0.3°²θ.

[0079]

[0151] In certain embodiments, the XRPD pattern further includes one or more peaks at 30.4°±0.3° and 31.4°±0.3°2θ.

[0080]

[0152] In certain embodiments, the crystalline monofumarate has an XRPD pattern that includes one or more peaks at 5.2°±0.3°, 7.6°±0.3°, 14.4°±0.3°, 15.1°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 17.3°±0.3°, 17.9°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.6°±0.3°, 21.2°±0.3°, 22.7°±0.3°, 24.5°±0.3°, 25.0°±0.3°, 30.4°±0.3°, and 31.4°±0.3°2θ.

[0081]

[0153] In certain embodiments, the crystalline monofumarate has an XRPD pattern that includes peaks at 5.2°±0.3°, 7.6°±0.3°, 14.4°±0.3°, 15.1°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 17.3°±0.3°, 17.9°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.6°±0.3°, 21.2°±0.3°, 22.7°±0.3°, 24.5°±0.3°, 25.0°±0.3°, 30.4°±0.3°, and 31.4°±0.3°2θ.

[0082]

[0154] In certain embodiments, the crystalline monofumarate has an XRPD pattern containing one or more peaks at 5.2°±0.2°2θ.

[0083]

[0155] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.6°±0.2° and 14.4°±0.2°2θ.

[0084]

[0156] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.8°±0.2°, 21.2°±0.2°, 24.5°±0.2°, and 25°±0.2°2θ.

[0085]

[0157] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.2°, 16.7°±0.2°, 17.3°±0.2°, 17.9°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.6°±0.2°, and 22.7°±0.2°²θ.

[0086]

[0158] In certain embodiments, the XRPD pattern further includes one or more peaks at 30.4°±0.2° and 31.4°±0.2°2θ.

[0087]

[0159] In certain embodiments, the crystalline monofumarate has an XRPD pattern that includes one or more peaks at 5.2°±0.2°, 7.6°±0.2°, 14.4°±0.2°, 15.1°±0.2°, 15.8°±0.2°, 16.7°±0.2°, 17.3°±0.2°, 17.9°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.6°±0.2°, 21.2°±0.2°, 22.7°±0.2°, 24.5°±0.2°, 25.0°±0.2°, 30.4°±0.2°, and 31.4°±0.2°²θ.

[0088]

[0160] In certain embodiments, the crystalline monofumarate has an XRPD pattern that includes peaks at 5.2°±0.2°, 7.6°±0.2°, 14.4°±0.2°, 15.1°±0.2°, 15.8°±0.2°, 16.7°±0.2°, 17.3°±0.2°, 17.9°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.6°±0.2°, 21.2°±0.2°, 22.7°±0.2°, 24.5°±0.2°, 25.0°±0.2°, 30.4°±0.2°, and 31.4°±0.2°2θ.

[0089]

[0161] In certain embodiments, the crystalline monofumarate of the compound of formula (I) is form A of the monofumarate of the compound of formula (I). In certain embodiments, the crystalline monofumarate of the compound of formula (I) is form B of the monofumarate of the compound of formula (I). In certain embodiments, the crystalline monofumarate of the compound of formula (I) is form C of the monofumarate of the compound of formula (I).

[0090]

[0162] In certain embodiments, the crystalline monofumarate of the compound of formula (I) is in an anhydrous crystalline form.

[0091]

[0163] In certain embodiments, the crystalline monofumarate of the compound of formula (I) is a crystalline hydrate. In certain embodiments, the crystalline hydrate is a monohydrate.

[0092] (i) Form A of monofumarate

[0164] In various embodiments, form A of the monofumarate of the compound of formula (I) is provided herein. [ka]

[0093]

[0165] In certain embodiments, form A of the monofumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes one or more peaks at about 5.0°, about 7.4°, and about 8.2°²θ.

[0094]

[0166] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 9.7°, 10.1°, 10.7°, 11.4°, 11.9°, 13.2°, 14.7°, and 14.8°²θ.

[0095]

[0167] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.2°, 16.1°, 16.6°, 17.5°, 19.5°, 20.2°, 21.1°, 23.9°, and 24.2°²θ.

[0096]

[0168] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 17.9°, 18.4°, 19.2°, 19.9°, 20.8°, 21.9°, 22.9°, 23.1°, and 24.8°²θ.

[0097]

[0169] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.1°, 25.4°, 27.4°, and 27.8°²θ.

[0098]

[0170] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 28.9°, 30.1°, 30.4°, 31.3°, 31.5°, 32.8°, and 33.6°²θ.

[0099]

[0171] In certain embodiments, form A of the monofumarate of the compound of formula (I) is approximately 5.0°, approximately 7.4°, approximately 8.2°, approximately 9.7°, approximately 10.1°, approximately 10.7°, approximately 11.4°, approximately 11.9°, approximately 13.2°, approximately 14.7°, approximately 14.8°, approximately 15.2°, approximately 16.1°, approximately 16.6°, approximately 17.5°, approximately 17.9°, approximately 18.4°, approximately 19.2°, approximately 19 The XRPD pattern has one or more peaks at 0.5°, approximately 19.9°, approximately 20.2°, approximately 20.8°, approximately 21.1°, approximately 21.9°, approximately 22.9°, approximately 23.1°, approximately 23.5°, approximately 23.9°, approximately 24.2°, approximately 24.8°, approximately 28.9°, approximately 30.1°, approximately 30.4°, approximately 31.3°, approximately 31.5°, approximately 32.8°, and approximately 33.6°²θ.

[0100]

[0172] In certain embodiments, form A of the monofumarate of the compound of formula (I) is approximately 5.0°, approximately 7.4°, approximately 8.2°, approximately 9.7°, approximately 10.1°, approximately 10.7°, approximately 11.4°, approximately 11.9°, approximately 13.2°, approximately 14.7°, approximately 14.8°, approximately 15.2°, approximately 16.1°, approximately 16.6°, approximately 17.5°, approximately 17.9°, approximately 18.4°, approximately 19.2°, approximately The XRPD pattern has peaks at 19.5°, approximately 19.9°, approximately 20.2°, approximately 20.8°, approximately 21.1°, approximately 21.9°, approximately 22.9°, approximately 23.1°, approximately 23.5°, approximately 23.9°, approximately 24.2°, approximately 24.8°, approximately 28.9°, approximately 30.1°, approximately 30.4°, approximately 31.3°, approximately 31.5°, approximately 32.8°, and approximately 33.6°²θ.

[0101]

[0173] In certain embodiments, form A of the monofumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes one or more peaks at 5.0°±0.3°, 7.4°±0.3°, and 8.2°±0.3°²θ.

[0102]

[0174] In certain embodiments, the XRPD pattern further includes one or more peaks at 9.7°±0.3°, 10.1°±0.3°, 10.7°±0.3°, 11.4°±0.3°, 11.9°±0.3°, 13.2°±0.3°, 14.7°±0.3°, and 14.8°±0.3°²θ.

[0103]

[0175] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.2°±0.3°, 16.1°±0.3°, 16.6°±0.3°, 17.5°±0.3°, 19.5°±0.3°, 20.2°±0.3°, 21.1°±0.3°, 23.9°±0.3°, and 24.2°±0.3°2θ.

[0104]

[0176] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.9°±0.3°, 18.4°±0.3°, 19.2°±0.3°, 19.9°±0.3°, 20.8°±0.3°, 21.9°±0.3°, 22.9°±0.3°, 23.1°±0.3°, 23.5°±0.3°, and 24.8°±0.3°2θ.

[0105]

[0177] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.3°, 25.4°±0.3°, 27.4°±0.3°, and 27.8°±0.3°2θ.

[0106]

[0178] In certain embodiments, the XRPD pattern further includes one or more peaks at 28.9°±0.3°, 30.1°±0.3°, 30.4°±0.3°, 31.3°±0.3°, 31.5°±0.3°, 32.8°±0.3°, and 33.6°±0.3°2θ.

[0107]

[0179] In certain embodiments, form A of the monofumarate of the compound of formula (I) is 5.0°±0.3°, 7.4°±0.3°, 8.2°±0.3°, 9.7°±0.3°, 10.1°±0.3°, 10.7°±0.3°, 11.4°±0.3°, 11.9°±0.3°, 13.2°±0.3°, 14.7°±0.3°, 14.8°±0.3°, 15.2°±0.3°, 16.1°±0.3°, 16.6°±0.3°, 17.5°±0.3°, 17.9°±0.3°, 18.4°±0.3°, 19.2°±0.3°, 19.5° The XRPD pattern has one or more peaks at ±0.3°, 19.9°±0.3°, 20.2°±0.3°, 20.8°±0.3°, 21.1°±0.3°, 21.9°±0.3°, 22.9°±0.3°, 23.1°±0.3°, 23.5°±0.3°, 23.9°±0.3°, 24.2°±0.3°, 24.8°±0.3°, 28.9°±0.3°, 30.1°±0.3°, 30.4°±0.3°, 31.3°±0.3°, 31.5°±0.3°, 32.8°±0.3°, and 33.6°±0.3°2θ.

[0108]

[0180] In certain embodiments, form A of the monofumarate of the compound of formula (I) is 5.0°±0.3°, 7.4°±0.3°, 8.2°±0.3°, 9.7°±0.3°, 10.1°±0.3°, 10.7°±0.3°, 11.4°±0.3°, 11.9°±0.3°, 13.2°±0.3°, 14.7°±0.3°, 14.8°±0.3°, 15.2°±0.3°, 16.1°±0.3°, 16.6°±0.3°, 17.5°±0.3°, 17.9°±0.3°, 18.4°±0.3°, 19.2°±0.3°, 19. The XRPD pattern has peaks at 5°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 20.8°±0.3°, 21.1°±0.3°, 21.9°±0.3°, 22.9°±0.3°, 23.1°±0.3°, 23.5°±0.3°, 23.9°±0.3°, 24.2°±0.3°, 24.8°±0.3°, 28.9°±0.3°, 30.1°±0.3°, 30.4°±0.3°, 31.3°±0.3°, 31.5°±0.3°, 32.8°±0.3°, and 33.6°±0.3°2θ.

[0109]

[0181] In certain embodiments, form A of the monofumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes one or more peaks at 5.0°±0.2°, 7.4°±0.2°, and 8.2°±0.2°²θ.

[0110]

[0182] In certain embodiments, the XRPD pattern further includes one or more peaks at 9.7°±0.2°, 10.1°±0.2°, 10.7°±0.2°, 11.4°±0.2°, 11.9°±0.2°, 13.2°±0.2°, 14.7°±0.2°, and 14.8°±0.2°²θ.

[0111]

[0183] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.2°±0.2°, 16.1°±0.2°, 16.6°±0.2°, 17.5°±0.2°, 19.5°±0.2°, 20.2°±0.2°, 21.1°±0.2°, 23.9°±0.2°, and 24.2°±0.2°²θ.

[0112]

[0184] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.9°±0.2°, 18.4°±0.2°, 19.2°±0.2°, 19.9°±0.2°, 20.8°±0.2°, 21.9°±0.2°, 22.9°±0.2°, 23.1°±0.2°, 23.5°±0.2°, and 24.8°±0.2°²θ.

[0113]

[0185] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.2°, 25.4°±0.2°, 27.4°±0.2°, and 27.8°±0.2°²θ.

[0114]

[0186] In certain embodiments, the XRPD pattern further includes one or more peaks at 28.9°±0.2°, 30.1°±0.2°, 30.4°±0.2°, 31.3°±0.2°, 31.5°±0.2°, 32.8°±0.2°, and 33.6°±0.2°²θ.

[0115]

[0187] In certain embodiments, form A of the monofumarate of the compound of formula (I) is 5.0°±0.2°, 7.4°±0.2°, 8.2°±0.2°, 9.7°±0.2°, 10.1°±0.2°, 10.7°±0.2°, 11.4°±0.2°, 11.9°±0.2°, 13.2°±0.2°, 14.7°±0.2°, 14.8°±0.2°, 15.2°±0.2°, 16.1°±0.2°, 16.6°±0.2°, 17.5°±0.2°, 17.9°±0.2°, 18.4°±0.2°, 19.2°±0.2°, 19.5° The XRPD pattern has one or more peaks at ±0.2°, 19.9°±0.2°, 20.2°±0.2°, 20.8°±0.2°, 21.1°±0.2°, 21.9°±0.2°, 22.9°±0.2°, 23.1°±0.2°, 23.5°±0.2°, 23.9°±0.2°, 24.2°±0.2°, 24.8°±0.2°, 28.9°±0.2°, 30.1°±0.2°, 30.4°±0.2°, 31.3°±0.2°, 31.5°±0.2°, 32.8°±0.2°, and 33.6°±0.2°2θ.

[0116]

[0188] In certain embodiments, form A of the monofumarate of the compound of formula (I) is 5.0°±0.2°, 7.4°±0.2°, 8.2°±0.2°, 9.7°±0.2°, 10.1°±0.2°, 10.7°±0.2°, 11.4°±0.2°, 11.9°±0.2°, 13.2°±0.2°, 14.7°±0.2°, 14.8°±0.2°, 15.2°±0.2°, 16.1°±0.2°, 16.6°±0.2°, 17.5°±0.2°, 17.9°±0.2°, 18.4°±0.2°, 19.2°±0.2°, 19. The XRPD pattern has peaks at 5°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 20.8°±0.2°, 21.1°±0.2°, 21.9°±0.2°, 22.9°±0.2°, 23.1°±0.2°, 23.5°±0.2°, 23.9°±0.2°, 24.2°±0.2°, 24.8°±0.2°, 28.9°±0.2°, 30.1°±0.2°, 30.4°±0.2°, 31.3°±0.2°, 31.5°±0.2°, 32.8°±0.2°, and 33.6°±0.2°2θ.

[0117]

[0189] In certain embodiments, form A of the monofumarate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 1. In certain embodiments, form A of the monofumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 1.

[0118]

[0190] In certain embodiments, form A of the monofumarate of compound (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 32°C. In certain embodiments, form A of the monofumarate of compound (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 133°C. In certain embodiments, form A of the monofumarate of compound (I) has a differential scanning calorimetry (DSC) thermogram that includes one or more endothermic activity with peak onset at approximately 32°C and approximately 133°C. In certain embodiments, form A of the monofumarate of compound (I) has a DSC thermogram that is substantially the same as that shown in Figure 2.

[0119]

[0191] In certain embodiments, form A of the monofumarate of the compound of formula (I) exhibits a weight loss of about 1.2% by weight or less when form A is heated from about 25°C to about 100°C. The weight loss exhibited by the crystalline form (e.g., form A of the monofumarate of the compound of formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form A of the monofumarate of the compound of formula (I) has a TGA thermogram substantially the same as that shown in Figure 2.

[0120]

[0192] In certain embodiments, form A of the monofumarate of the compound of formula (I) is a crystalline hydrate.

[0121] (ii) Form B of monofumarate

[0193] In various embodiments, form B of the monofumarate of the compound of formula (I) is provided herein. [ka]

[0122]

[0194] In certain embodiments, form B of the monofumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes a peak at approximately 7.5°2θ.

[0123]

[0195] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 4.7°, 9.7°, 13.3°, 13.8°, 14.0°, 14.2°, and 15.0°²θ.

[0124]

[0196] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 17.4°, 21.5°, 22.2°, 22.6°, 23.1°, 23.4°, 24.4°, and 24.7°²θ.

[0125]

[0197] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.4°, 15.8°, 16.6°, 17.0°, 17.8°, 18.5°, 18.8°, 19.5°, 19.8°, 20.3°, 20.6°, and 24.1°²θ.

[0126]

[0198] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.4°, 15.8°, 16.6°, 17.0°, 17.4°, 17.8°, 18.5°, 18.8°, 19.5°, 19.8°, 20.3°, 20.6°, 21.5°, 22.2°, 22.6°, 23.1°, 23.4°, 24.4°, 24.1°, and 24.7°²θ.

[0127]

[0199] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.8°, approximately 28.1°, and approximately 29.7°²θ.

[0128]

[0200] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.3°, 26.0°, 27.6°, 30.2°, 30.8°, 31.5°, and 33.5°²θ.

[0129]

[0201] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.3°, 26.0°, 26.8°, 27.6°, 28.1°, and 29.7°, 30.2°, 30.8°, 31.5°, and 33.5°²θ.

[0130]

[0202] In certain embodiments, form B of the monofumarate of the compound of formula (I) is approximately 4.7°, approximately 7.5°, approximately 9.7°, approximately 13.3°, approximately 13.8°, approximately 14.0°, approximately 14.2°, and approximately 15.0°, approximately 15.4°, approximately 15.8°, approximately 16.6°, approximately 17.0°, approximately 17.4°, approximately 17.8°, approximately 18.5°, approximately 18.8°, approximately 19.5°, approximately 19.8°, and approximately 20.3°. The XRPD pattern has one or more peaks at approximately 20.6°, 21.5°, 22.2°, 22.6°, 23.1°, 23.4°, 24.1°, 24.4°, 24.7°, 25.3°, 26.0°, 26.8°, 27.6°, 28.1°, 29.7°, 30.2°, 30.8°, 31.5°, and 33.5°²θ.

[0131]

[0203] In certain embodiments, form B of the monofumarate of the compound of formula (I) is approximately 4.7°, approximately 7.5°, approximately 9.7°, approximately 13.3°, approximately 13.8°, approximately 14.0°, approximately 14.2°, and approximately 15.0°, approximately 15.4°, approximately 15.8°, approximately 16.6°, approximately 17.0°, approximately 17.4°, approximately 17.8°, approximately 18.5°, approximately 18.8°, approximately 19.5°, approximately 19.8°, and approximately 20 The XRPD pattern has peaks at approximately 0.3°, 20.6°, 21.5°, 22.2°, 22.6°, 23.1°, 23.4°, 24.1°, 24.4°, 24.7°, 25.3°, 26.0°, 26.8°, 27.6°, 28.1°, 29.7°, 30.2°, 30.8°, 31.5°, and 33.5°²θ.

[0132]

[0204] In certain embodiments, form B of the monofumarate of the compound of formula (I) has an XRPD pattern containing a peak at 7.5°±0.3°2θ.

[0133]

[0205] In certain embodiments, the XRPD pattern further includes one or more peaks at 4.7°±0.3°, 9.7°±0.3°, 13.3°±0.3°, 13.8°±0.3°, 14.0°±0.3°, 14.2°±0.3°, and 15.0°±0.3°2θ.

[0134]

[0206] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.4°±0.3°, 21.5°±0.3°, 22.2°±0.3°, 22.6°±0.3°, 23.1°±0.3°, 23.4°±0.3°, 24.4°±0.3°, and 24.7°±0.3°²θ.

[0135]

[0207] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.3°, 15.8°±0.3°, 16.6°±0.3°, 17.0°±0.3°, 17.8°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.5°±0.3°, 19.8°±0.3°, 20.3°±0.3°, 20.6°±0.3°, and 24.1°±0.3°²θ.

[0136]

[0208] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.3°, 15.8°±0.3°, 16.6°±0.3°, 17.0°±0.3°, 17.4°±0.3°, 17.8°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.5°±0.3°, 19.8°±0.3°, 20.3°±0.3°, 20.6°±0.3°, 21.5°±0.3°, 22.2°±0.3°, 22.6°±0.3°, 23.1°±0.3°, 23.4°±0.3°, 24.4°±0.3°, 24.1°±0.3°, and 24.7°±0.3°²θ.

[0137]

[0209] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.8°±0.3°, 28.1°±0.3°, and 29.7°±0.3°2θ.

[0138]

[0210] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.3°, 26.0°±0.3°, 27.6°±0.3°, 30.2°±0.3°, 30.8°±0.3°, 31.5°±0.3°, and 33.5°±0.3°²θ.

[0139]

[0211] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.3°, 26.0°±0.3°, 26.8°±0.3°, 27.6°±0.3°, 28.1°±0.3°, 29.7°±0.3°, 30.2°±0.3°, 30.8°±0.3°, 31.5°±0.3°, and 33.5°±0.3°²θ.

[0140]

[0212] In certain embodiments, form B of the monofumarate of the compound of formula (I) is 4.7°±0.3°, 7.5°±0.3°, 9.7°±0.3°, 13.3°±0.3°, 13.8°±0.3°, 14.0°±0.3°, 14.2°±0.3°, 15.0°±0.3°, 15.4°±0.3°, 15.8°±0.3°, 16.6°±0.3°, 17.0°±0.3°, 17.4°±0.3°, 17.8°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.5°±0.3°, 19.8°±0.3°, 20.3°±0.3° The XRPD pattern has one or more peaks at 20.6°±0.3°, 21.5°±0.3°, 22.2°±0.3°, 22.6°±0.3°, 23.1°±0.3°, 23.4°±0.3°, 24.1°±0.3°, 24.4°±0.3°, 24.7°±0.3°, 25.3°±0.3°, 26.0°±0.3°, 26.8°±0.3°, 27.6°±0.3°, 28.1°±0.3°, 29.7°±0.3°, 30.2°±0.3°, 30.8°±0.3°, 31.5°±0.3°, and 33.5°±0.3°2θ.

[0141]

[0213] In certain embodiments, form B of the monofumarate of the compound of formula (I) is 4.7°±0.3°, 7.5°±0.3°, 9.7°±0.3°, 13.3°±0.3°, 13.8°±0.3°, 14.0°±0.3°, 14.2°±0.3°, 15.0°±0.3°, 15.4°±0.3°, 15.8°±0.3°, 16.6°±0.3°, 17.0°±0.3°, 17.4°±0.3°, 17.8°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.5°±0.3°, 19.8°±0.3°, 20.3°±0. The XRPD pattern has peaks at 3°, 20.6°±0.3°, 21.5°±0.3°, 22.2°±0.3°, 22.6°±0.3°, 23.1°±0.3°, 23.4°±0.3°, 24.1°±0.3°, 24.4°±0.3°, 24.7°±0.3°, 25.3°±0.3°, 26.0°±0.3°, 26.8°±0.3°, 27.6°±0.3°, 28.1°±0.3°, 29.7°±0.3°, 30.2°±0.3°, 30.8°±0.3°, 31.5°±0.3°, and 33.5°±0.3°2θ.

[0142]

[0214] In certain embodiments, form B of the monofumarate of the compound of formula (I) has an XRPD pattern containing a peak at 7.5°±0.2°2θ.

[0143]

[0215] In certain embodiments, the XRPD pattern further includes one or more peaks at 4.7°±0.2°, 9.7°±0.2°, 13.3°±0.2°, 13.8°±0.2°, 14.0°±0.2°, 14.2°±0.2°, and 15.0°±0.2°²θ.

[0144]

[0216] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.4°±0.2°, 21.5°±0.2°, 22.2°±0.2°, 22.6°±0.2°, 23.1°±0.2°, 23.4°±0.2°, 24.4°±0.2°, and 24.7°±0.2°²θ.

[0145]

[0217] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.2°, 15.8°±0.2°, 16.6°±0.2°, 17.0°±0.2°, 17.8°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.5°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 20.6°±0.2°, and 24.1°±0.2°²θ.

[0146]

[0218] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.2°, 15.8°±0.2°, 16.6°±0.2°, 17.0°±0.2°, 17.4°±0.2°, 17.8°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.5°±0.2°, 19.8°±0.2°, 20.3°±0.2°, 20.6°±0.2°, 21.5°±0.2°, 22.2°±0.2°, 22.6°±0.2°, 23.1°±0.2°, 23.4°±0.2°, 24.1°±0.2°, 24.4°±0.2°, and 24.7°±0.2°²θ.

[0147]

[0219] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.8°±0.2°, 28.1°±0.2°, and 29.7°±0.2°²θ.

[0148]

[0220] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.2°, 26.0°±0.2°, 27.6°±0.2°, 30.2°±0.2°, 30.8°±0.2°, 31.5°±0.2°, and 33.5°±0.2°²θ.

[0149]

[0221] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.2°, 26.0°±0.2°, 26.8°±0.2°, 27.6°±0.2°, 28.1°±0.2°, 29.7°±0.2°, 30.2°±0.2°, 30.8°±0.2°, 31.5°±0.2°, and 33.5°±0.2°²θ.

[0150]

[0222] In certain embodiments, form B of the monofumarate of the compound of formula (I) is 4.7°±0.2°, 7.5°±0.2°, 9.7°±0.2°, 13.3°±0.2°, 13.8°±0.2°, 14.0°±0.2°, 14.2°±0.2°, 15.0°±0.2°, 15.4°±0.2°, 15.8°±0.2°, 16.6°±0.2°, 17.0°±0.2°, 17.4°±0.2°, 17.8°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.5°±0.2°, 19.8°±0.2°, 20.3°±0.2° The XRPD pattern has one or more peaks at 20.6°±0.2°, 21.5°±0.2°, 22.2°±0.2°, 22.6°±0.2°, 23.1°±0.2°, 23.4°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.3°±0.2°, 26.0°±0.2°, 26.8°±0.2°, 27.6°±0.2°, 28.1°±0.2°, 29.7°±0.2°, 30.2°±0.2°, 30.8°±0.2°, 31.5°±0.2°, and 33.5°±0.2°2θ.

[0151]

[0223] In certain embodiments, form B of the monofumarate of the compound of formula (I) is 4.7°±0.2°, 7.5°±0.2°, 9.7°±0.2°, 13.3°±0.2°, 13.8°±0.2°, 14.0°±0.2°, 14.2°±0.2°, 15.0°±0.2°, 15.4°±0.2°, 15.8°±0.2°, 16.6°±0.2°, 17.0°±0.2°, 17.4°±0.2°, 17.8°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.5°±0.2°, 19.8°±0.2°, 20.3°±0. The XRPD pattern has peaks at 2°, 20.6°±0.2°, 21.5°±0.2°, 22.2°±0.2°, 22.6°±0.2°, 23.1°±0.2°, 23.4°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.3°±0.2°, 26.0°±0.2°, 26.8°±0.2°, 27.6°±0.2°, 28.1°±0.2°, 29.7°±0.2°, 30.2°±0.2°, 30.8°±0.2°, 31.5°±0.2°, and 33.5°±0.2°2θ.

[0152]

[0224] In certain embodiments, form B of the monofumarate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 3. In certain embodiments, form B of the monofumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 8.

[0153]

[0225] In certain embodiments, form B of the monofumarate of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 41°C. In certain embodiments, form B of the monofumarate of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 112°C. In certain embodiments, form B of the monofumarate of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 122°C. In certain embodiments, form B of the monofumarate of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activity with peak onset at approximately 41°C, approximately 112°C, and approximately 122°C. In certain embodiments, form B of the monofumarate of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 4.

[0154]

[0226] In certain embodiments, form B of the monofumarate of compound (I) exhibits a weight loss of about 4.6% by weight or less when form B is heated from about 25°C to about 155°C. The weight loss exhibited by the crystalline form (e.g., form B of the monofumarate of compound (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form B of the monofumarate of compound (I) has a TGA thermogram substantially the same as that shown in Figure 4.

[0155]

[0227] In certain embodiments, form B of the monofumarate of the compound of formula (I) is a crystalline hydrate.

[0156] (iii) Form C of monofumarate

[0228] In various embodiments, form C of the monofumarate of the compound of formula (I) is provided herein. [ka]

[0157]

[0229] In certain embodiments, form C of the monofumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes a peak at approximately 5.2°2θ.

[0158]

[0230] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 7.6°, 10.6°, 13.8°, and 14.4°²θ.

[0159]

[0231] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.8°, 21.2°, 24.5°, and 25.0°²θ.

[0160]

[0232] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.1°, 16.7°, 17.3°, 17.9°, 19.4°, 19.9°, 20.6°, and 22.7°²θ.

[0161]

[0233] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.1°, 15.8°, 16.7°, 17.3°, 17.9°, 19.4°, 19.9°, 20.6°, 21.2°, 22.7°, 24.5°, and 25.0°²θ.

[0162]

[0234] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.7°, 26.6°, 28.9°, 30.4°, 31.4°, and 32.0°²θ.

[0163]

[0235] In certain embodiments, form C of the monofumarate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 5.2°, approximately 7.6°, approximately 10.6°, approximately 13.8°, approximately 14.4°, approximately 15.1°, approximately 15.8°, approximately 16.7°, approximately 17.3°, approximately 17.9°, approximately 19.4°, approximately 19.9°, approximately 20.6°, approximately 21.2°, approximately 22.7°, approximately 24.5°, approximately 25.0°, approximately 25.7°, approximately 26.6°, approximately 28.9°, approximately 30.4°, approximately 31.4°, and approximately 32.0°²θ.

[0164]

[0236] In certain embodiments, form C of the monofumarate of the compound of formula (I) has an XRPD pattern with peaks at approximately 5.2°, 7.6°, 10.6°, 13.8°, 14.4°, 15.1°, 15.8°, 16.7°, 17.3°, 17.9°, 19.4°, 19.9°, 20.6°, 21.2°, 22.7°, 24.5°, 25.0°, 25.7°, 26.6°, 28.9°, 30.4°, 31.4°, and 32.0°²θ.

[0165]

[0237] In certain embodiments, form C of the monofumarate of the compound of formula (I) has an XRPD pattern containing a peak at 5.2°±0.3°2θ.

[0166]

[0238] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.6°±0.3°, 10.6°±0.3°, 13.8°±0.3°, and 14.4°±0.3°²θ.

[0167]

[0239] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.8°±0.3°, 21.2°±0.3°, 24.5°±0.3°, and 25.0°±0.3°2θ.

[0168]

[0240] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.3°, 16.7°±0.3°, 17.3°±0.3°, 17.9°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.6°±0.3°, and 22.7°±0.3°²θ.

[0169]

[0241] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 17.3°±0.3°, 17.9°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.6°±0.3°, 21.2°±0.3°, 22.7°±0.3°, 24.5°±0.3°, and 25.0°±0.3°²θ.

[0170]

[0242] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.7°±0.3°, 26.6°±0.3°, 28.9°±0.3°, 30.4°±0.3°, 31.4°±0.3°, and 32.0°±0.3°²θ.

[0171]

[0243] In certain embodiments, form C of the monofumarate of the compound of formula (I) is 5.2°±0.3°, 7.6°±0.3°, 10.6°±0.3°, 13.8°±0.3°, 14.4°±0.3°, 15.1°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 17.3°±0.3°, 17.9°±0.3°, 19.4°±0.3°, 19.9° The XRPD pattern has one or more peaks at 2θ ± 0.3°, 20.6° ± 0.3°, 21.2° ± 0.3°, 22.7° ± 0.3°, 24.5° ± 0.3°, 25.0° ± 0.3°, 25.7° ± 0.3°, 26.6° ± 0.3°, 28.9° ± 0.3°, 30.4° ± 0.3°, 31.4° ± 0.3°, and 32.0° ± 0.3°.

[0172]

[0244] In certain embodiments, form C of the monofumarate of the compound of formula (I) is 5.2°±0.3°, 7.6°±0.3°, 10.6°±0.3°, 13.8°±0.3°, 14.4°±0.3°, 15.1°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 17.3°±0.3°, 17.9°±0.3°, 19.4°±0.3°, 19 The XRPD pattern has peaks at 0.9°±0.3°, 20.6°±0.3°, 21.2°±0.3°, 22.7°±0.3°, 24.5°±0.3°, 25.0°±0.3°, 25.7°±0.3°, 26.6°±0.3°, 28.9°±0.3°, 30.4°±0.3°, 31.4°±0.3°, and 32.0°±0.3°2θ.

[0173]

[0245] In certain embodiments, form C of the monofumarate of the compound of formula (I) has an XRPD pattern containing a peak at 5.2°±0.2°2θ.

[0174]

[0246] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.6°±0.2°, 10.6°±0.2°, 13.8°±0.2°, and 14.4°±0.2°²θ.

[0175]

[0247] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.8°±0.2°, 21.2°±0.2°, 24.5°±0.2°, and 25.0°±0.2°²θ.

[0176]

[0248] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.2°, 16.7°±0.2°, 17.3°±0.2°, 17.9°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.6°±0.2°, and 22.7°±0.2°²θ.

[0177]

[0249] In certain embodiments, the XRPD pattern further comprises one or more peaks at 15.1° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.2° ± 0.2°, 19.2° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2°, 21.2° ± 0.2°, 22.7° ± 0.2°, 24.5° ± 0.2°, and 25.0° ± 0.2° 2θ.

[0178]

[0250] In certain embodiments, the XRPD pattern further comprises one or more peaks at 25.7° ± 0.2°, 26.6° ± 0.2°, 28.9° ± 0.2°, 30.4° ± 0.2°, 31.4° ± 0.2°, and 32.0° ± 0.2° 2θ.

[0179]

[0251] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.2°, 7.6° ± 0.2°, 10.6° ± 0.2°, 13.8° ± 0.2°, 14.4° ± 0.2°, 15.1° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.9° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2°, 21.2° ± 0.2°, 22.7° ± 0.2°, 24.5° ± 0.2°, 25.0° ± 0.2°, 25.7° ± 0.2°, 26.6° ± 0.2°, 28.9° ± 0.2°, 30.4° ± 0.2°, 31.4° ± 0.2°, and 32.0° 2θ.

[0180]

[0252] In certain embodiments, form C of the monofumarate of the compound of formula (I) is 5.2°±0.2°, 7.6°±0.2°, 10.6°±0.2°, 13.8°±0.2°, 14.4°±0.2°, 15.1°±0.2°, 15.8°±0.2°, 16.7°±0.2°, 17.3°±0.2°, 17.9°±0.2°, 19.4°±0.2°, 19 The XRPD pattern has peaks at 0.9°±0.2°, 20.6°±0.2°, 21.2°±0.2°, 22.7°±0.2°, 24.5°±0.2°, 25.0°±0.2°, 25.7°±0.2°, 26.6°±0.2°, 28.9°±0.2°, 30.4°±0.2°, 31.4°±0.2°, and 32.0°±0.2°2θ.

[0181]

[0253] In certain embodiments, form C of the monofumarate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 5. In certain embodiments, form C of the monofumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 9.

[0182]

[0254] In certain embodiments, form C of the monofumarate of compound (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 30°C. In certain embodiments, form C of the monofumarate of compound (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 125°C. In certain embodiments, form C of the monofumarate of compound (I) has a DSC thermogram that includes one or more endothermic activity with peak onset at approximately 30°C and approximately 125°C. In certain embodiments, form C of the monofumarate of compound (I) has a DSC thermogram that is substantially the same as that shown in Figure 6.

[0183]

[0255] In certain embodiments, form C of the monofumarate of compound (I) exhibits a weight loss of about 0.9% by weight or less when form C is heated from about 25°C to about 80°C. The weight loss exhibited by the crystalline form (e.g., form C of the monofumarate of compound (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form C of the monofumarate of compound (I) has a TGA thermogram substantially the same as that shown in Figure 6.

[0184] (B) Crystallographic form of hemifumarate

[0256] In another embodiment, crystalline hemifumarates of compounds of formula (I) are provided herein. [ka]

[0185]

[0257] In certain embodiments, the crystalline hemifumarate has an XRPD pattern that includes one or more peaks at approximately 8.5°, approximately 11.0°, and approximately 12.0°²θ.

[0186]

[0258] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.9°, approximately 17.9°, and approximately 24.1°²θ.

[0187]

[0259] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.7°, approximately 27.7°, and approximately 34.1°²θ.

[0188]

[0260] In certain embodiments, the crystalline hemifumarate has an XRPD pattern that includes one or more peaks at approximately 8.5°, 11.0°, 12.0°, 16.9°, 17.9°, 24.1°, 25.7°, 27.7°, and 34.1°²θ.

[0189]

[0261] In certain embodiments, the crystalline hemifumarate has an XRPD pattern that includes peaks at approximately 8.5°, 11.0°, 12.0°, 16.9°, 17.9°, 24.1°, 25.7°, 27.7°, and 34.1°²θ.

[0190]

[0262] In certain embodiments, the crystalline hemifumarate has an XRPD pattern that includes one or more peaks at 8.5°±0.3°, 11.0°±0.3°, and 12.0°±0.3°²θ.

[0191]

[0263] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.9°±0.3°, 17.9°±0.3°, and 24.1°±0.3°2θ.

[0192]

[0264] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.7°±0.3°, 27.7°±0.3°, and 34.1°±0.3°²θ.

[0193]

[0265] In certain embodiments, the crystalline hemifumarate has an XRPD pattern that includes one or more peaks at 8.5°±0.3°, 11.0°±0.3°, 12.0°±0.3°, 16.9°±0.3°, 17.9°±0.3°, 24.1°±0.3°, 25.7°±0.3°, 27.7°±0.3°, and 34.1°±0.3°²θ.

[0194]

[0266] In certain embodiments, the crystalline hemifumarate has an XRPD pattern that includes peaks at 8.5°±0.3°, 11.0°±0.3°, 12.0°±0.3°, 16.9°±0.3°, 17.9°±0.3°, 24.1°±0.3°, 25.7°±0.3°, 27.7°±0.3°, and 34.1°±0.3°2θ.

[0195]

[0267] In certain embodiments, the crystalline hemifumarate has an XRPD pattern that includes one or more peaks at 8.5°±0.2°, 11.0°±0.2°, and 12.0°±0.2°²θ.

[0196]

[0268] In certain embodiments, the XRPD pattern further comprises one or more peaks at 16.9° ± 0.2°, 17.9° ± 0.2°, and 24.1° ± 0.2° 2θ.

[0197]

[0269] In certain embodiments, the XRPD pattern further comprises one or more peaks at 25.7° ± 0.2°, 27.7° ± 0.2°, and 34.1° ± 0.2° 2θ.

[0198]

[0270] In certain embodiments, the crystalline hemifumarate has an XRPD pattern comprising one or more peaks at 8.5° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 16.9° ± 0.2°, 17.9° ± 0.2°, 24.1° ± 0.2°, 25.7° ± 0.2°, 27.7° ± 0.2°, and 34.1° ± 0.2° 2θ.

[0199]

[0271] In certain embodiments, the crystalline hemifumarate has an XRPD pattern comprising peaks at 8.5° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 16.9° ± 0.2°, 17.9° ± 0.2°, 24.1° ± 0.2°, 25.7° ± 0.2°, 27.7° ± 0.2°, and 34.1° ± 0.2° 2θ.

[0200]

[0272] In certain embodiments, the crystalline hemifumarate of the compound of formula (I) is Form A of the hemifumarate of the compound of formula (I). In certain embodiments, the crystalline hemifumarate has an XRPD pattern substantially the same as that shown in Figure 7. In certain embodiments, the crystalline hemifumarate is Form B of the hemifumarate of the compound of formula (I). In certain embodiments, the crystalline hemifumarate has an XRPD pattern substantially the same as that shown in Figure 10.

[0201]

[0273] In certain embodiments, the crystalline hemifumarate of the compound of formula (I) is an anhydrous crystalline form.

[0202]

[0274] In certain embodiments, the crystalline hemifumarate of the compound of formula (I) is a crystalline hydrate.

[0203] (i) Form A of hemifumarate

[0275] In various embodiments, form A of the hemifumarate of the compound of formula (I) is provided herein. [ka]

[0204]

[0276] In certain embodiments, form A of the hemifumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes one or more peaks at about 9.9° and about 11.0°²θ.

[0205]

[0277] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 6.4°, 8.3°, 12.1°, 13.2°, 14.3°, and 14.5°²θ.

[0206]

[0278] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.9°, 17.2°, 17.8°, 18.5°, 20.2°, 22.1°, and 22.5°²θ.

[0207]

[0279] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.1°, 16.1°, 19.5°, 19.8°, 21.2°, 21.5°, 23.3°, 24.3°, 24.5°, and 25.0°²θ.

[0208]

[0280] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.5°, 26.3°, 27.2°, 28.9°, and 31.1°²θ.

[0209]

[0281] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 27.8°, 28.0°, 28.3°, 29.5°, 31.9°, 32.5°, 32.7°, 33.6°, 34.1°, and 34.4°²θ.

[0210]

[0282] In certain embodiments, form A of the hemifumarate of the compound of formula (I) is approximately 6.4°, approximately 8.3°, approximately 9.9°, approximately 11.0°, approximately 12.1°, approximately 13.2°, approximately 14.3°, approximately 14.5°, approximately 15.1°, approximately 16.1°, approximately 16.9°, approximately 17.2°, approximately 17.8°, approximately 18.5°, approximately 19.5°, approximately 19.8°, approximately 20.2°, approximately 21.2°, approximately 21.5°, and approximately 22.1°. The XRPD pattern has one or more peaks at approximately 22.5°, 23.3°, 24.3°, 24.5°, 25.0°, 25.5°, 26.3°, 27.2°, 27.8°, 28.0°, 28.3°, 28.9°, 29.5°, 31.1°, 31.9°, 32.5°, 32.7°, 33.6°, 34.1°, and 34.4°²θ.

[0211]

[0283] In certain embodiments, form A of the hemifumarate of the compound of formula (I) is approximately 6.4°, approximately 8.3°, approximately 9.9°, approximately 11.0°, approximately 12.1°, approximately 13.2°, approximately 14.3°, approximately 14.5°, approximately 15.1°, approximately 16.1°, approximately 16.9°, approximately 17.2°, approximately 17.8°, approximately 18.5°, approximately 19.5°, approximately 19.8°, approximately 20.2°, approximately 21.2°, approximately 21.5°, and approximately 22°. The XRPD pattern has peaks at 1°, approximately 22.5°, approximately 23.3°, approximately 24.3°, approximately 24.5°, approximately 25.0°, approximately 25.5°, approximately 26.3°, approximately 27.2°, approximately 27.8°, approximately 28.0°, approximately 28.3°, approximately 28.9°, approximately 29.5°, approximately 31.1°, approximately 31.9°, approximately 32.5°, approximately 32.7°, approximately 33.6°, approximately 34.1°, and approximately 34.4°²θ.

[0212]

[0284] In certain embodiments, form A of the hemifumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes one or more peaks at 9.9°±0.3° and 11.0°±0.3°2θ.

[0213]

[0285] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.4°±0.3°, 8.3°±0.3°, 12.1°±0.3°, 13.2°±0.3°, 14.3°±0.3°, and 14.5°±0.3°2θ.

[0214]

[0286] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.9°±0.3°, 17.2°±0.3°, 17.8°±0.3°, 18.5°±0.3°, 20.2°±0.3°, 22.1°±0.3°, and 22.5°±0.3°2θ.

[0215]

[0287] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.3°, 16.1°±0.3°, 19.5°±0.3°, 19.8°±0.3°, 21.2°±0.3°, 21.5°±0.3°, 23.3°±0.3°, 24.3°±0.3°, 24.5°±0.3°, and 25.0°±0.3°²θ.

[0216]

[0288] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.5°±0.3°, 26.3°±0.3°, 27.2°±0.3°, 28.9°±0.3°, and 31.1°±0.3°²θ.

[0217]

[0289] In certain embodiments, the XRPD pattern further includes one or more peaks at 27.8°±0.3°, 28.0°±0.3°, 28.3°±0.3°, 29.5°±0.3°, 31.9°±0.3°, 32.5°±0.3°, 32.7°±0.3°, 33.6°±0.3°, 34.1°±0.3°, and 34.4°±0.3°²θ.

[0218]

[0290] In certain embodiments, form A of the hemifumarate of the compound of formula (I) is 6.4°±0.3°, 8.3°±0.3°, 9.9°±0.3°, 11.0°±0.3°, 12.1°±0.3°, 13.2°±0.3°, 14.3°±0.3°, 14.5°±0.3°, 15.1°±0.3°, 16.1°±0.3°, 16.9°±0.3°, 17.2°±0.3°, 17.8°±0.3°, 18.5°±0.3°, 19.5°±0.3°, 19.8°±0.3°, 20.2°±0.3°, 21.2°±0.3°, 21.5°±0.3°, 22.1°±0.3° The XRPD pattern has one or more peaks at 22.5°±0.3°, 23.3°±0.3°, 24.3°±0.3°, 24.5°±0.3°, 25.0°±0.3°, 25.5°±0.3°, 26.3°±0.3°, 27.2°±0.3°, 27.8°±0.3°, 28.0°±0.3°, 28.3°±0.3°, 28.9°±0.3°, 29.5°±0.3°, 31.1°±0.3°, 31.9°±0.3°, 32.5°±0.3°, 32.7°±0.3°, 33.6°±0.3°, 34.1°±0.3°, and 34.4°±0.3°2θ.

[0219]

[0291] In certain embodiments, form A of the hemifumarate of the compound of formula (I) is 6.4°±0.3°, 8.3°±0.3°, 9.9°±0.3°, 11.0°±0.3°, 12.1°±0.3°, 13.2°±0.3°, 14.3°±0.3°, 14.5°±0.3°, 15.1°±0.3°, 16.1°±0.3°, 16.9°±0.3°, 17.2°±0.3°, 17.8°±0.3°, 18.5°±0.3°, 19.5°±0.3°, 19.8°±0.3°, 20.2°±0.3°, 21.2°±0.3°, 21.5°±0.3°, 22.1°±0. The XRPD pattern has peaks at 3°, 22.5°±0.3°, 23.3°±0.3°, 24.3°±0.3°, 24.5°±0.3°, 25.0°±0.3°, 25.5°±0.3°, 26.3°±0.3°, 27.2°±0.3°, 27.8°±0.3°, 28.0°±0.3°, 28.3°±0.3°, 28.9°±0.3°, 29.5°±0.3°, 31.1°±0.3°, 31.9°±0.3°, 32.5°±0.3°, 32.7°±0.3°, 33.6°±0.3°, 34.1°±0.3°, and 34.4°±0.3°2θ.

[0220]

[0292] In certain embodiments, form A of the hemifumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes one or more peaks at 9.9°±0.2° and 11.0°±0.2°2θ.

[0221]

[0293] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.4°±0.2°, 8.3°±0.2°, 12.1°±0.2°, 13.2°±0.2°, 14.3°±0.2°, and 14.5°±0.2°²θ.

[0222]

[0294] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.9°±0.2°, 17.2°±0.2°, 17.8°±0.2°, 18.5°±0.2°, 20.2°±0.2°, 22.1°±0.2°, and 22.5°±0.2°²θ.

[0223]

[0295] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.2°, 16.1°±0.2°, 19.5°±0.2°, 19.8°±0.2°, 21.2°±0.2°, 21.5°±0.2°, 23.3°±0.2°, 24.3°±0.2°, 24.5°±0.2°, and 25.0°±0.2°²θ.

[0224]

[0296] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.5°±0.2°, 26.3°±0.2°, 27.2°±0.2°, 28.9°±0.2°, and 31.1°±0.2°²θ.

[0225]

[0297] In certain embodiments, the XRPD pattern further includes one or more peaks at 27.8°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 29.5°±0.2°, 31.9°±0.2°, 32.5°±0.2°, 32.7°±0.2°, 33.6°±0.2°, 34.1°±0.2°, and 34.4°±0.2°²θ.

[0226]

[0298] In certain embodiments, form A of the hemifumarate of the compound of formula (I) is 6.4°±0.2°, 8.3°±0.2°, 9.9°±0.2°, 11.0°±0.2°, 12.1°±0.2°, 13.2°±0.2°, 14.3°±0.2°, 14.5°±0.2°, 15.1°±0.2°, 16.1°±0.2°, 16.9°±0.2°, 17.2°±0.2°, 17.8°±0.2°, 18.5°±0.2°, 19.5°±0.2°, 19.8°±0.2°, 20.2°±0.2°, 21.2°±0.2°, 21.5°±0.2°, 22.1°±0.2° The XRPD pattern has one or more peaks at 22.5°±0.2°, 23.3°±0.2°, 24.3°±0.2°, 24.5°±0.2°, 25.0°±0.2°, 25.5°±0.2°, 26.3°±0.2°, 27.2°±0.2°, 27.8°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.9°±0.2°, 29.5°±0.2°, 31.1°±0.2°, 31.9°±0.2°, 32.5°±0.2°, 32.7°±0.2°, 33.6°±0.2°, 34.1°±0.2°, and 34.4°±0.2°2θ.

[0227]

[0299] In certain embodiments, form A of the hemifumarate of the compound of formula (I) is 6.4°±0.2°, 8.3°±0.2°, 9.9°±0.2°, 11.0°±0.2°, 12.1°±0.2°, 13.2°±0.2°, 14.3°±0.2°, 14.5°±0.2°, 15.1°±0.2°, 16.1°±0.2°, 16.9°±0.2°, 17.2°±0.2°, 17.8°±0.2°, 18.5°±0.2°, 19.5°±0.2°, 19.8°±0.2°, 20.2°±0.2°, 21.2°±0.2°, 21.5°±0.2°, 22.1°±0. The XRPD pattern has peaks at 2°, 22.5°±0.2°, 23.3°±0.2°, 24.3°±0.2°, 24.5°±0.2°, 25.0°±0.2°, 25.5°±0.2°, 26.3°±0.2°, 27.2°±0.2°, 27.8°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.9°±0.2°, 29.5°±0.2°, 31.1°±0.2°, 31.9°±0.2°, 32.5°±0.2°, 32.7°±0.2°, 33.6°±0.2°, 34.1°±0.2°, and 34.4°±0.2°2θ.

[0228]

[0300] In certain embodiments, form A of the hemi-fumarate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 8. In certain embodiments, form A of the hemi-fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 11.

[0229]

[0301] In certain embodiments, form A of the hemi-fumarate of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 206°C. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has a DSC thermogram substantially identical to that shown in Figure 9.

[0230]

[0302] In certain embodiments, form A of the hemi-fumarate of the compound of formula (I) exhibits a weight loss of about 0.5% by weight or less when form A is heated from about 25°C to about 150°C. The weight loss exhibited by the crystalline form (e.g., form A of the hemi-fumarate of the compound of formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form A of the hemi-fumarate of the compound of formula (I) has a TGA thermogram substantially the same as that shown in Figure 9.

[0231]

[0303] In certain embodiments, form A of the hemi-fumarate of the compound of formula (I) exhibits a mass change of less than or equal to about 0.7% by weight when measured at 25°C and the relative humidity is varied from 0% to about 80%. The weight change indicated by the crystalline form (e.g., form A of the hemi-fumarate of the compound of formula (I)) can be determined, for example, using DVS. In certain embodiments, form A of the hemi-fumarate of the compound of formula (I) has substantially the same moisture adsorption isotherm as shown in Figure 10.

[0232]

[0304] In certain embodiments, form A of the hemifumarate of the compound of formula (I) is in an anhydrous crystalline form.

[0233] (ii) Form B of hemifumarate

[0305] In various embodiments, form B of the hemifumarate of the compound of formula (I) is provided herein. [ka]

[0234]

[0306] In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern including a peak at about 5.4°2θ. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern including a peak at about 8.7°2θ. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern including one or more peaks at about 5.4° and 8.7°2θ.

[0235]

[0307] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 10.4°, approximately 11.0°, approximately 11.9°, and approximately 12.6°²θ.

[0236]

[0308] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.5°, 16.9°, 17.4°, 17.9°, and 23.9°²θ.

[0237]

[0309] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.7°, approximately 27.7°, and approximately 34.1°²θ.

[0238]

[0310] In certain embodiments, form B of the hemifumarate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 5.4°, approximately 8.7°, approximately 10.4°, approximately 11.0°, approximately 11.9°, approximately 12.6°, approximately 16.5°, approximately 16.9°, approximately 17.4°, approximately 17.9°, and approximately 23.9°, approximately 25.7°, approximately 27.7°, and approximately 34.1°²θ.

[0239]

[0311] In certain embodiments, form B of the hemifumarate of the compound of formula (I) has an XRPD pattern that includes peaks at approximately 5.4°, approximately 8.7°, approximately 10.4°, approximately 11.0°, approximately 11.9°, approximately 12.6°, approximately 16.5°, approximately 16.9°, approximately 17.4°, approximately 17.9°, and approximately 23.9°, approximately 25.7°, approximately 27.7°, and approximately 34.1°²θ.

[0240]

[0312] In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern with a peak at 5.4°±0.3°2θ. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern with a peak at approximately 8.7°±0.3°2θ. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern with one or more peaks at approximately 5.4°±0.3° and 8.7°±0.3°2θ.

[0241]

[0313] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 10.4°±0.3°, approximately 11.0°±0.3°, approximately 11.9°±0.3°, and approximately 12.6°±0.3°²θ.

[0242]

[0314] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.5°±0.3°, approximately 16.9°±0.3°, approximately 17.4°±0.3°, approximately 17.9°±0.3°, and approximately 23.9°±0.3°²θ.

[0243]

[0315] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.7°±0.3°, approximately 27.7°±0.3°, and approximately 34.1°±0.3°²θ.

[0244]

[0316] In certain embodiments, form B of the hemifumarate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 5.4°±0.3°, 8.7°±0.3°, 10.4°±0.3°, 11.0°±0.3°, 11.9°±0.3°, 12.6°±0.3°, 16.5°±0.3°, 16.9°±0.3°, 17.4°±0.3°, 17.9°±0.3°, 23.9°±0.3°, 25.7°±0.3°, 27.7°±0.3°, and 34.1°±0.3°²θ.

[0245]

[0317] In certain embodiments, form B of the hemifumarate of the compound of formula (I) has an XRPD pattern that includes peaks at 5.4°±0.3°, 8.7°±0.3°, 10.4°±0.3°, 11.0°±0.3°, 11.9°±0.3°, 12.6°±0.3°, 16.5°±0.3°, 16.9°±0.3°, 17.4°±0.3°, 17.9°±0.3°, 23.9°±0.3°, 25.7°±0.3°, 27.7°±0.3°, and 34.1°±0.3°2θ.

[0246]

[0318] In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern including a peak at 5.4°±0.2°2θ. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern including a peak at approximately 8.7°±0.2°2θ. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern including one or more peaks at approximately 5.4°±0.2° and 8.7°±0.2°2θ.

[0247]

[0319] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 10.4°±0.2°, approximately 11.0°±0.2°, approximately 11.9°±0.2°, and approximately 12.6°±0.2°²θ.

[0248]

[0320] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.5°±0.2°, approximately 16.9°±0.2°, approximately 17.4°±0.2°, approximately 17.9°±0.2°, and approximately 23.9°±0.2°²θ.

[0249]

[0321] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.7°±0.2°, approximately 27.7°±0.2°, and approximately 34.1°±0.2°²θ.

[0250]

[0322] In certain embodiments, form B of the hemifumarate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 5.4°±0.2°, 8.7°±0.2°, 10.4°±0.2°, 11.0°±0.2°, 11.9°±0.2°, 12.6°±0.2°, 16.5°±0.2°, 16.9°±0.2°, 17.4°±0.2°, 17.9°±0.2°, 23.9°±0.2°, 25.7°±0.2°, 27.7°±0.2°, and 34.1°±0.2°²θ.

[0251]

[0323] In certain embodiments, form B of the hemifumarate of the compound of formula (I) has an XRPD pattern that includes peaks at 5.4°±0.2°, 8.7°±0.2°, 10.4°±0.2°, 11.0°±0.2°, 11.9°±0.2°, 12.6°±0.2°, 16.5°±0.2°, 16.9°±0.2°, 17.4°±0.2°, 17.9°±0.2°, 23.9°±0.2°, 25.7°±0.2°, 27.7°±0.2°, and 34.1°±0.2°²θ.

[0252]

[0324] In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 13. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 19.

[0253]

[0325] In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 118°C. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 182°C. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 202°C. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activity with peak onset at approximately 118°C, approximately 182°C, and approximately 202°C. In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 14.

[0254]

[0326] In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) exhibits a weight loss of less than about 1.1% by weight when form B is heated from about 25°C to about 150°C. The weight loss exhibited by the crystalline form (e.g., form B of the hemi-fumarate of the compound of formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form B of the hemi-fumarate of the compound of formula (I) has substantially the same TGA thermogram as shown in Figure 14.

[0255]

[0327] In certain embodiments, form B of the hemifumarate of the compound of formula (I) is a crystalline hydrate.

[0256] (2) L-tartrate form

[0328] In various embodiments, L-tartrate salts of compounds of formula (I) are provided herein. [ka]

[0257]

[0329] In certain embodiments, the L-tartrate of the compound of formula (I) is in crystalline salt form.

[0258]

[0330] In various embodiments, crystalline L-tartrates of compounds of formula (I) are provided herein. [ka]

[0259]

[0331] In certain embodiments, the crystalline L-tartrate has substantially the same XRPD pattern as shown in Figure 16.

[0260]

[0332] In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern that includes one or more diffraction peaks (2θ) as disclosed in Table 21.

[0261]

[0333] In certain embodiments, the L-tartrate of the compound of formula (I) is in a solvated crystalline form. In certain embodiments, the L-tartrate of the compound of formula (I) is in a crystalline MTBE solvate form.

[0262]

[0334] In certain embodiments, the L-tartrate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern containing a peak at about 3.3°²θ. In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern containing a peak at about 7.9°²θ. In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern containing one or more peaks at about 3.3° and about 7.9°²θ.

[0263]

[0335] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 10.2°, 11.6°, 12.4°, 14.4°, and 14.8°²θ.

[0264]

[0336] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.4°, approximately 17.0°, approximately 20.6°, and approximately 23.4°²θ.

[0265]

[0337] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.1° and approximately 31.2°²θ.

[0266]

[0338] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 3.3°, approximately 7.9°, approximately 10.2°, approximately 11.6°, approximately 12.4°, approximately 14.4°, approximately 14.8°, approximately 15.4°, approximately 17.0°, approximately 20.6°, approximately 23.4°, approximately 25.1°, and approximately 31.2°²θ.

[0267]

[0339] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern that includes peaks at approximately 3.3°, 7.9°, 10.2°, 11.6°, 12.4°, 14.4°, 14.8°, 15.4°, 17.0°, 20.6°, 23.4°, 25.1°, and 31.2°²θ.

[0268]

[0340] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern including a peak at 3.3°±0.3°2θ. In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern including a peak at 7.9°±0.3°2θ. In certain embodiments, the L-tartrate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern including one or more peaks at 3.3°±0.3° and 7.9°±0.3°2θ.

[0269]

[0341] In certain embodiments, the XRPD pattern further includes one or more peaks at 10.2°±0.3°, 11.6°±0.3°, 12.4°±0.3°, 14.4°±0.3°, and 14.8°±0.3°2θ.

[0270]

[0342] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.3°, 17.0°±0.3°, 20.6°±0.3°, and 23.4°±0.3°²θ.

[0271]

[0343] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.3° and 31.2°±0.3°2θ.

[0272]

[0344] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 3.3°±0.3°, 7.9°±0.3°, 10.2°±0.3°, 11.6°±0.3°, 12.4°±0.3°, 14.4°±0.3°, 14.8°±0.3°, 15.4°±0.3°, 17.0°±0.3°, 20.6°±0.3°, 23.4°±0.3°, 25.1°±0.3°, and 31.2°±0.3°²θ.

[0273]

[0345] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern that includes peaks at 3.3°±0.3°, 7.9°±0.3°, 10.2°±0.3°, 11.6°±0.3°, 12.4°±0.3°, 14.4°±0.3°, 14.8°±0.3°, 15.4°±0.3°, 17.0°±0.3°, 20.6°±0.3°, 23.4°±0.3°, 25.1°±0.3°, and 31.2°±0.3°2θ.

[0274]

[0346] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern including a peak at 3.3°±0.2°2θ. In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern including a peak at 7.9°±0.2°2θ. In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern including one or more peaks at 3.3°±0.2° and 7.9°±0.2°2θ.

[0275]

[0347] In certain embodiments, the XRPD pattern further includes one or more peaks at 10.2°±0.2°, 11.6°±0.2°, 12.4°±0.2°, 14.4°±0.2°, and 14.8°±0.2°²θ.

[0276]

[0348] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.2°, 17.0°±0.2°, 20.6°±0.2°, and 23.4°±0.2°²θ.

[0277]

[0349] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.2° and 31.2°±0.2°2θ.

[0278]

[0350] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 3.3°±0.2°, 7.9°±0.2°, 10.2°±0.2°, 11.6°±0.2°, 12.4°±0.2°, 14.4°±0.2°, 14.8°±0.2°, 15.4°±0.2°, 17.0°±0.2°, 20.6°±0.2°, 23.4°±0.2°, 25.1°±0.2°, and 31.2°±0.2°²θ.

[0279]

[0351] In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern that includes peaks at 3.3°±0.2°, 7.9°±0.2°, 10.2°±0.2°, 11.6°±0.2°, 12.4°±0.2°, 14.4°±0.2°, 14.8°±0.2°, 15.4°±0.2°, 17.0°±0.2°, 20.6°±0.2°, 23.4°±0.2°, 25.1°±0.2°, and 31.2°±0.2°2θ.

[0280]

[0352] In certain embodiments, the L-tartrate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 16. In certain embodiments, the L-tartrate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 21.

[0281]

[0353] In certain embodiments, the L-tartrate of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 117°C. In certain embodiments, the L-tartrate of the compound of formula (I) has a DSC thermogram substantially identical to that shown in Figure 17.

[0282]

[0354] In certain embodiments, the L-tartrate of the compound of formula (I) exhibits a weight loss of about 2.4% by weight or less when the L-tartrate is heated from about 25°C to about 150°C. The weight loss indicated by the crystalline form (e.g., the L-tartrate of the compound of formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, the L-tartrate of the compound of formula (I) has a TGA thermogram substantially the same as that shown in Figure 17.

[0283] (3) Tosylate form

[0355] In various embodiments, tosylates of compounds of formula (I) are provided herein. [ka]

[0284]

[0356] In certain embodiments, the tosylate of the compound of formula (I) is in crystalline salt form.

[0285]

[0357] In various embodiments, crystalline tosylates of the compound of formula (I) are provided herein. [ka]

[0286]

[0358] In certain embodiments, the crystalline tosylate of the compound of formula (I) is form A of the tosylate of the compound of formula (I).

[0287]

[0359] In certain embodiments, the crystalline tosylate has substantially the same XRPD pattern as shown in Figure 18. In certain embodiments, the crystalline tosylate has substantially the same XRPD pattern as shown in Figure 20. In certain embodiments, the crystalline tosylate has substantially the same XRPD pattern as shown in Figure 21.

[0288]

[0360] In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 22. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 23. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 24.

[0289]

[0361] In certain embodiments, form A of the tosylate of the compound of formula (I) is in a solvated crystalline form. In certain embodiments, form A of the tosylate of the compound of formula (I) is in a crystalline IPAc solvate form.

[0290] (A) Form A of tosylate

[0362] In various embodiments, form A of the tosylate salt of the compound of formula (I) is provided herein. [ka]

[0291]

[0363] In certain embodiments, form A of the tosylate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern that includes a peak at approximately 5.1°2θ.

[0292]

[0364] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 6.1°, 6.6°, 7.3°, 8.9°, 10.2°, 11.2°, 11.8°, 12.0°, 12.6°, 13.1°, and 13.8°²θ.

[0293]

[0365] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.6°, 16.3°, 17.1°, 17.3°, 17.6°, 20.5°, 21.0°, and 21.8°²θ.

[0294]

[0366] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.4°, approximately 26.8°, and approximately 32.0°²θ.

[0295]

[0367] In certain embodiments, form A of the tosylate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 5.1°, 6.1°, 6.6°, 7.3°, 8.9°, 10.2°, 11.2°, 11.8°, 12.0°, 12.6°, 13.1°, 13.8°, 15.6°, 16.3°, 17.1°, 17.3°, 17.6°, 20.5°, 21.0°, 21.8°, 25.4°, 26.8°, and 32.0°²θ.

[0296]

[0368] In certain embodiments, form A of the tosylate of the compound of formula (I) has an XRPD pattern with peaks at approximately 5.1°, 6.1°, 6.6°, 7.3°, 8.9°, 10.2°, 11.2°, 11.8°, 12.0°, 12.6°, 13.1°, 13.8°, 15.6°, 16.3°, 17.1°, 17.3°, 17.6°, 20.5°, 21.0°, 21.8°, 25.4°, 26.8°, and 32.0°²θ.

[0297]

[0369] In certain embodiments, form A of the tosylate of the compound of formula (I) has an XRPD pattern containing a peak at 5.1°±0.3°2θ.

[0298]

[0370] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.1°±0.3°, 6.6°±0.3°, 7.3°±0.3°, 8.9°±0.3°, 10.2°±0.3°, 11.2°±0.3°, 11.8°±0.3°, 12.0°±0.3°, 12.6°±0.3°, 13.1°±0.3°, and 13.8°±0.3°²θ.

[0299]

[0371] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.3°, 16.3°±0.3°, 17.1°±0.3°, 17.3°±0.3°, 17.6°±0.3°, 20.5°±0.3°, 21.0°±0.3°, and 21.8°±0.3°2θ.

[0300]

[0372] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.4°±0.3°, 26.8°±0.3°, and 32.0°±0.3°²θ.

[0301]

[0373] In certain embodiments, form A of the tosylate of the compound of formula (I) is 5.1°±0.3°, 6.1°±0.3°, 6.6°±0.3°, 7.3°±0.3°, 8.9°±0.3°, 10.2°±0.3°, 11.2°±0.3°, 11.8°±0.3°, 12.0°±0.3°, 12.6°±0.3°, 13.1°±0.3°, 13.8°±0. The XRPD pattern has one or more peaks at 0.3°, 15.6°±0.3°, 16.3°±0.3°, 17.1°±0.3°, 17.3°±0.3°, 17.6°±0.3°, 20.5°±0.3°, 21.0±0.3°, 21.8°±0.3°, 25.4°±0.3°, 26.8°±0.3°, and 32.0°±0.3°2θ.

[0302]

[0374] In certain embodiments, form A of the tosylate of the compound of formula (I) is 5.1°±0.3°, 6.1°±0.3°, 6.6°±0.3°, 7.3°±0.3°, 8.9°±0.3°, 10.2°±0.3°, 11.2°±0.3°, 11.8°±0.3°, 12.0°±0.3°, 12.6°±0.3°, 13.1°±0.3°, 13. The XRPD pattern has peaks at 8±0.3°, 15.6°±0.3°, 16.3°±0.3°, 17.1°±0.3°, 17.3°±0.3°, 17.6°±0.3°, 20.5°±0.3°, 21.0±0.3°, 21.8°±0.3°, 25.4°±0.3°, 26.8°±0.3°, and 32.0°±0.3°2θ.

[0303]

[0375] In certain embodiments, form A of the tosylate of the compound of formula (I) has an XRPD pattern containing a peak at 5.1°±0.2°2θ.

[0304]

[0376] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.1°±0.2°, 6.6°±0.2°, 7.3°±0.2°, 8.9°±0.2°, 10.2°±0.2°, 11.2°±0.2°, 11.8°±0.2°, 12.0°±0.2°, 12.6°±0.2°, 13.1°±0.2°, and 13.8°±0.2°²θ.

[0305]

[0377] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.2°, 16.3°±0.2°, 17.1°±0.2°, 17.3°±0.2°, 17.6°±0.2°, 20.5°±0.2°, 21.0°±0.2°, and 21.8°±0.2°²θ.

[0306]

[0378] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.4°±0.2°, 26.8°±0.2°, and 32.0°±0.2°²θ.

[0307]

[0379] In certain embodiments, form A of the tosylate of the compound of formula (I) is 5.1°±0.2°, 6.1°±0.2°, 6.6°±0.2°, 7.3°±0.2°, 8.9°±0.2°, 10.2°±0.2°, 11.2°±0.2°, 11.8°±0.2°, 12.0°±0.2°, 12.6°±0.2°, 13.1°±0.2°, 13.8°±0. The XRPD pattern has one or more peaks at 0.2°, 15.6°±0.2°, 16.3°±0.2°, 17.1°±0.2°, 17.3°±0.2°, 17.6°±0.2°, 20.5°±0.2°, 21.0±0.2°, 21.8°±0.2°, 25.4°±0.2°, 26.8°±0.2°, and 32.0°±0.2°2θ.

[0308]

[0380] In certain embodiments, form A of the tosylate of the compound of formula (I) is 5.1°±0.2°, 6.1°±0.2°, 6.6°±0.2°, 7.3°±0.2°, 8.9°±0.2°, 10.2°±0.2°, 11.2°±0.2°, 11.8°±0.2°, 12.0°±0.2°, 12.6°±0.2°, 13.1°±0.2°, 13. The XRPD pattern has peaks at 8±0.2°, 15.6°±0.2°, 16.3°±0.2°, 17.1°±0.2°, 17.3°±0.2°, 17.6°±0.2°, 20.5°±0.2°, 21.0±0.2°, 21.8°±0.2°, 25.4°±0.2°, 26.8°±0.2°, and 32.0°±0.2°2θ.

[0309]

[0381] In certain embodiments, form A of the tosylate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 18. In certain embodiments, form A of the tosylate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 22.

[0310]

[0382] In certain embodiments, form A of the tosylate of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 126°C. In certain embodiments, form A of the tosylate of the compound of formula (I) has a DSC thermogram substantially identical to that shown in Figure 19.

[0311]

[0383] In certain embodiments, form A of the tosylate of compound (I) exhibits a weight loss of about 5.1% by weight or less when form A is heated from about 25°C to about 170°C. The weight loss exhibited by the crystalline form (e.g., form A of the tosylate of compound (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form A of the tosylate of compound (I) has a TGA thermogram substantially the same as that shown in Figure 19.

[0312] (4) Succinate form

[0384] In various embodiments, succinates of the compound of formula (I) are provided herein. [ka]

[0313]

[0385] In certain embodiments, the succinate of the compound of formula (I) is in crystalline salt form.

[0314]

[0386] In various embodiments, crystalline succinates of the compound of formula (I) are provided herein. [ka]

[0315]

[0387] In certain embodiments, the crystalline succinate of the compound of formula (I) is form A of the succinate of the compound of formula (I).

[0316]

[0388] In certain embodiments, the crystalline succinate has substantially the same XRPD pattern as shown in Figure 22. In certain embodiments, the crystalline tosylate has substantially the same XRPD pattern as shown in Figure 24. In certain embodiments, the crystalline tosylate has substantially the same XRPD pattern as shown in Figure 25.

[0317]

[0389] In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 25. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 26. In certain embodiments, the crystalline fumarate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 27.

[0318] (A) Form A

[0390] In various embodiments, form A of the succinate of the compound of formula (I) is provided herein. [ka]

[0319]

[0391] In certain embodiments, form A of the succinate of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern containing a peak at approximately 7.6°2θ.

[0320]

[0392] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 5.6°, 8.9°, 10.0°, 11.0°, 12.7°, and 13.1°²θ.

[0321]

[0393] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.4°, 16.2°, 16.4°, 17.2°, 17.6°, 18.3°, 19.1°, 21.2°, 21.8°, 22.1°, 22.3°, 22.6°, 22.9°, 23.4°, 24.2°, 24.5°, and 24.8°²θ.

[0322]

[0394] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.8°, 26.3°, 26.5°, 27.0°, 27.6°, 27.7°, 28.6°, 29.8°, 30.2°, 31.0°, 32.2°, 32.5°, 33.3°, and 34.9°²θ.

[0323]

[0395] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 35.8°, 36.5°, 37.1°, 37.9°, 38.8°, and 39.5°²θ.

[0324]

[0396] In certain embodiments, succinate form A of the compound of formula (I) is approximately 5.6°, approximately 7.6°, approximately 8.9°, approximately 10.0°, approximately 11.0°, approximately 12.7°, approximately 13.1°, approximately 15.4°, approximately 16.2°, approximately 16.4°, approximately 17.2°, approximately 17.6°, approximately 18.3°, approximately 19.1°, approximately 21.2°, approximately 21.8°, approximately 22.1°, approximately 22.3°, approximately 22.6°, approximately 22.9°, approximately 23.4°, approximately 24.2°, The XRPD pattern has one or more peaks at approximately 24.5°, 24.8°, 25.8°, 26.3°, 26.5°, 27.0°, 27.6°, 27.7°, 28.6°, 29.8°, 30.2°, 31.0°, 32.2°, 32.5°, 33.3°, 34.9°, 35.8°, 36.5°, 37.1°, 37.9°, 38.8°, and 39.5°²θ.

[0325]

[0397] In certain embodiments, succinate form A of the compound of formula (I) is approximately 5.6°, approximately 7.6°, approximately 8.9°, approximately 10.0°, approximately 11.0°, approximately 12.7°, approximately 13.1°, approximately 15.4°, approximately 16.2°, approximately 16.4°, approximately 17.2°, approximately 17.6°, approximately 18.3°, approximately 19.1°, approximately 21.2°, approximately 21.8°, approximately 22.1°, approximately 22.3°, approximately 22.6°, approximately 22.9°, approximately 23.4°, approximately 24.2° The XRPD pattern has peaks at approximately 24.5°, 24.8°, 25.8°, 26.3°, 26.5°, 27.0°, 27.6°, 27.7°, 28.6°, 29.8°, 30.2°, 31.0°, 32.2°, 32.5°, 33.3°, 34.9°, 35.8°, 36.5°, 37.1°, 37.9°, 38.8°, and 39.5°²θ.

[0326]

[0398] In certain embodiments, form A of the succinate of the compound of formula (I) has an XRPD pattern containing a peak at 7.6°±0.3°2θ.

[0327]

[0399] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.6°±0.3°, 8.9°±0.3°, 10.0°±0.3°, 11.0°±0.3°, 12.7°±0.3°, and 13.1°±0.3°²θ.

[0328]

[0400] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.3°, 16.2°±0.3°, 16.4°±0.3°, 17.2°±0.3°, 17.6°±0.3°, 18.3°±0.3°, 19.1°±0.3°, 21.2°±0.3°, 21.8°±0.3°, 22.1°±0.3°, 22.3°±0.3°, 22.6°±0.3°, 22.9°±0.3°, 23.4°±0.3°, 24.2°±0.3°, 24.5°±0.3°, and 24.8°±0.3°²θ.

[0329]

[0401] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.8°±0.3°, 26.3°±0.3°, 26.5°±0.3°, 27.0°±0.3°, 27.6°±0.3°, 27.7°±0.3°, 28.6°±0.3°, 29.8°±0.3°, 30.2°±0.3°, 31.0°±0.3°, 32.2°±0.3°, 32.5°±0.3°, 33.3°±0.3°, and 34.9°±0.3°²θ.

[0330]

[0402] In certain embodiments, the XRPD pattern further includes one or more peaks at 35.8°±0.3°, 36.5°, 37.1°±0.3°, 37.9°±0.3°, 38.8°±0.3°, and 39.5°±0.3°²θ.

[0331]

[0403] In certain embodiments, form A of the succinate of the compound of formula (I) is 5.6°±0.3°, 7.6°±0.3°, 8.9°±0.3°, 10.0°±0.3°, 11.0°±0.3°, 12.7°±0.3°, 13.1°±0.3°, 15.4°±0.3°, 16.2°±0.3°, 16.4°±0. 3°, 17.2°±0.3°, 17.6°±0.3°, 18.3°±0.3°, 19.1°±0.3°, 21.2°±0.3°, 21.8°±0.3°, 22.1°±0.3°, 22.3°±0.3°, 22.6°±0.3°, 22.9°±0.3°, 23.4°±0.3°, 24.2°±0.3°, 24.5°±0.3°, 24.8°±0.3°, 25.8°±0.3°, 26.3°±0.3°, 26.5°±0.3°, 27.0°±0.3°, 27.6°±0.3°, 27.7°±0.3°, 28.6°±0.3°, 29.8°±0.3°, 30.2°±0.3°, 31.0°±0.3°, 32. The XRPD pattern has one or more peaks at 2°±0.3°, 32.5°±0.3°, 33.3°±0.3°, 34.9°±0.3°, 35.8°±0.3°, 36.5°±0.3°, 37.1°±0.3°, 37.9°±0.3°, 38.8°±0.3°, and 39.5°±0.3°2θ.

[0332]

[0404] In certain embodiments, form A of the succinate of the compound of formula (I) is 5.6°±0.3°, 7.6°±0.3°, 8.9°±0.3°, 10.0°±0.3°, 11.0°±0.3°, 12.7°±0.3°, 13.1°±0.3°, 15.4°±0.3°, 16.2°±0.3°, 16.4°±0. 0.3°, 17.2°±0.3°, 17.6°±0.3°, 18.3°±0.3°, 19.1°±0.3°, 21.2°±0.3°, 21.8°±0.3°, 22.1°±0.3°, 22.3°±0.3°, 22.6°±0.3°, 22.9°±0.3°, 23.4°±0.3°, 24.2°±0.3 °, 24.5°±0.3°, 24.8°±0.3°, 25.8°±0.3°, 26.3°±0.3°, 26.5°±0.3°, 27.0°±0.3°, 27.6°±0.3°, 27.7°±0.3°, 28.6°±0.3°, 29.8°±0.3°, 30.2°±0.3°, 31.0°±0.3° The XRPD pattern has peaks at 32.2°±0.3°, 32.5°±0.3°, 33.3°±0.3°, 34.9°±0.3°, 35.8°±0.3°, 36.5°±0.3°, 37.1°±0.3°, 37.9°±0.3°, 38.8°±0.3°, and 39.5°±0.3°2θ.

[0333]

[0405] In certain embodiments, form A of the succinate of the compound of formula (I) has an XRPD pattern containing a peak at 7.6°±0.2°2θ.

[0334]

[0406] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.6°±0.2°, 8.9°±0.2°, 10.0°±0.2°, 11.0°±0.2°, 12.7°±0.2°, and 13.1°±0.2°²θ.

[0335]

[0407] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.2°, 16.2°±0.2°, 16.4°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.3°±0.2°, 19.1°±0.2°, 21.2°±0.2°, 21.8°±0.2°, 22.1°±0.2°, 22.3°±0.2°, 22.6°±0.2°, 22.9°±0.2°, 23.4°±0.2°, 24.2°±0.2°, 24.5°±0.2°, and 24.8°±0.2°²θ.

[0336]

[0408] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.8°±0.2°, 26.3°±0.2°, 26.5°±0.2°, 27.0°±0.2°, 27.6°±0.2°, 27.7°±0.2°, 28.6°±0.2°, 29.8°±0.2°, 30.2°±0.2°, 31.0°±0.2°, 32.2°±0.2°, 32.5°±0.2°, 33.3°±0.2°, and 34.9°±0.2°²θ.

[0337]

[0409] In certain embodiments, the XRPD pattern further includes one or more peaks at 35.8°±0.2°, 36.5°±0.2°, 37.1°±0.2°, 37.9°±0.2°, 38.8°±0.2°, and 39.5°±0.2°²θ.

[0338]

[0410] In certain embodiments, form A of the succinate of the compound of formula (I) is 5.6°±0.2°, 7.6°±0.2°, 8.9°±0.2°, 10.0°±0.2°, 11.0°±0.2°, 12.7°±0.2°, 13.1°±0.2°, 15.4°±0.2°, 16.2°±0.2°, 16.4°±0. 2°, 17.2°±0.2°, 17.6°±0.2°, 18.3°±0.2°, 19.1°±0.2°, 21.2°±0.2°, 21.8°±0.2°, 22.1°±0.2°, 22.3°±0.2°, 22.6°±0.2°, 22.9°±0.2°, 23.4°±0.2°, 24.2°±0.2°, 24.5°±0.2°, 24.8°±0.2°, 25.8°±0.2°, 26.3°±0.2°, 26.5°±0.2°, 27.0°±0.2°, 27.6°±0.2°, 27.7°±0.2°, 28.6°±0.2°, 29.8°±0.2°, 30.2°±0.2°, 31.0°±0.2°, 32. The XRPD pattern has one or more peaks at 2°±0.2°, 32.5°±0.2°, 33.3°±0.2°, 34.9°±0.2°, 35.8°±0.2°, 36.5°±0.2°, 37.1°±0.2°, 37.9°±0.2°, 38.8°±0.2°, and 39.5°±0.2°2θ.

[0339]

[0411] In certain embodiments, form A of the succinate of the compound of formula (I) is 5.6°±0.2°, 7.6°±0.2°, 8.9°±0.2°, 10.0°±0.2°, 11.0°±0.2°, 12.7°±0.2°, 13.1°±0.2°, 15.4°±0.2°, 16.2°±0.2°, 16.4°±0. 0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.3°±0.2°, 19.1°±0.2°, 21.2°±0.2°, 21.8°±0.2°, 22.1°±0.2°, 22.3°±0.2°, 22.6°±0.2°, 22.9°±0.2°, 23.4°±0.2°, 24.2°±0.2 °, 24.5°±0.2°, 24.8°±0.2°, 25.8°±0.2°, 26.3°±0.2°, 26.5°±0.2°, 27.0°±0.2°, 27.6°±0.2°, 27.7°±0.2°, 28.6°±0.2°, 29.8°±0.2°, 30.2°±0.2°, 31.0°±0.2° The XRPD pattern has peaks at 32.2°±0.2°, 32.5°±0.2°, 33.3°±0.2°, 34.9°±0.2°, 35.8°±0.2°, 36.5°±0.2°, 37.1°±0.2°, 37.9°±0.2°, 38.8°±0.2°, and 39.5°±0.2°2θ.

[0340]

[0412] In certain embodiments, form A of the succinate of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 22. In certain embodiments, form A of the succinate of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 25.

[0341]

[0413] In certain embodiments, form A of the succinate of compound (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 87°C. In certain embodiments, form A of the succinate of compound (I) has a DSC thermogram substantially identical to that shown in Figure 23.

[0342]

[0414] In certain embodiments, form A of the succinate of compound (I) exhibits a weight loss of about 0.8% by weight or less when form A is heated from about 25°C to about 80°C. The weight loss exhibited by the crystalline form (e.g., form A of the succinate of compound (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form A of the succinate of compound (I) has a TGA thermogram substantially the same as that shown in Figure 23.

[0343] (5) Cansylate form

[0415] In one embodiment, crystalline cansylates of the compound of formula (I) are provided herein. [ka]

[0344]

[0416] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern with a peak at approximately 5.2°²θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern with a peak at approximately 13.2°²θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern with a peak at approximately 14.7°²θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern with one or more peaks at approximately 5.2°, approximately 13.2°, and approximately 14.7°²θ.

[0345]

[0417] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.7°, 17.8°, 18.2°, 19.3°, and 21.8°²θ.

[0346]

[0418] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 5.2°, approximately 13.2°, approximately 14.7°, approximately 15.7°, approximately 17.8°, approximately 18.2°, approximately 19.3°, and approximately 21.8°²θ.

[0347]

[0419] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern with peaks at approximately 5.2°, 13.2°, 14.7°, 15.7°, 17.8°, 18.2°, 19.3°, and 21.8°²θ.

[0348]

[0420] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 5.2°, approximately 13.2°, and approximately 14.7°²θ.

[0349]

[0421] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 6.9°, 8.5°, 8.9°, 10.5°, 10.8°, 12.3°, 12.6°, 13.4°, 14.0°, 14.1°, and 14.7°²θ.

[0350]

[0422] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 17.8°, 18.2°, 21.8°, and 21.9°²θ.

[0351]

[0423] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.1°, 15.7°, 17.0°, 17.2°, 17.6°, 18.1°, 19.3°, 19.8°, 20.2°, 20.6°, 20.9°, 21.1°, 21.6°, 22.5°, 22.9°, 23.9°, and 24.9°²θ.

[0352]

[0424] In certain embodiments, the XRPD pattern further includes peaks at approximately 25.4°, 25.6°, and 25.9°²θ.

[0353]

[0425] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.3°, 26.6°, 27.1°, 27.5°, 28.5°, 28.9°, 29.4°, and 30.1°²θ.

[0354]

[0426] In certain embodiments, the crystalline cansylate of the compound of formula (I) is approximately 5.2°, approximately 6.9°, approximately 8.5°, approximately 8.9°, approximately 10.5°, approximately 10.8°, approximately 12.3°, approximately 12.6°, approximately 13.2°, approximately 13.4°, approximately 14.0°, approximately 14.1°, approximately 14.7°, approximately 15.1°, approximately 15.7°, approximately 17.0°, approximately 17.2°, approximately 17.6°, approximately 17.8°, approximately 18.1°, approximately 18.2°, approximately 19.3°, approximately The XRPD pattern has one or more peaks at 19.8°, approximately 20.2°, approximately 20.6°, approximately 20.9°, approximately 21.1°, approximately 21.6°, approximately 21.8°, approximately 22.5°, approximately 22.9°, approximately 23.9°, approximately 24.9°, approximately 25.4°, approximately 25.6°, approximately 25.9°, approximately 26.3°, approximately 26.6°, approximately 27.1°, approximately 27.5°, approximately 28.5°, approximately 28.9°, approximately 29.4°, and approximately 30.1°²θ.

[0355]

[0427] In certain embodiments, the crystalline cansylate of the compound of formula (I) is approximately 5.2°, approximately 6.9°, approximately 8.5°, approximately 8.9°, approximately 10.5°, approximately 10.8°, approximately 12.3°, approximately 12.6°, approximately 13.2°, approximately 13.4°, approximately 14.0°, approximately 14.1°, approximately 14.7°, approximately 15.1°, approximately 15.7°, approximately 17.0°, approximately 17.2°, approximately 17.6°, approximately 17.8°, approximately 18.1°, approximately 18.2°, and approximately 19.3°. The XRPD pattern has peaks at approximately 19.8°, 20.2°, 20.6°, 20.9°, 21.1°, 21.6°, 21.8°, 22.5°, 22.9°, 23.9°, 24.9°, 25.4°, 25.6°, 25.9°, 26.3°, 26.6°, 27.1°, 27.5°, 28.5°, 28.9°, 29.4°, and 30.1°²θ.

[0356]

[0428] In certain embodiments, the angles are approximately 5.2°, 6.9°, 8.5°, 8.9°, 10.5°, 10.8°, 12.3°, 12.6°, 13.2°, 13.4°, 14.0°, 14.1°, 14.7°, 15.1°, 15.7°, 17.0°, 17.2°, 17.6°, 17.8°, 18.1°, 18.2°, 19.3°, 19.8°, 20.2°, 20.6°, 20.9°, and 21.1°. Crystalline cansylates of compounds of formula (I) having an XRPD pattern with peaks at approximately 21.6°, 21.8°, 22.5°, 22.9°, 23.9°, 24.9°, 25.4°, 25.6°, 25.9°, 26.3°, 26.6°, 27.1°, 27.5°, 28.5°, 28.9°, 29.4°, and 30.1°²θ may be referred to herein as "crystalline cansylate form A".

[0357]

[0429] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including a peak at 5.2°±0.3°2θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including a peak at 13.2°±0.3°2θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including a peak at 14.7°±0.3°2θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including one or more peaks at 5.2°±0.3°, 13.2°±0.3°, and 14.7°±0.3°2θ.

[0358]

[0430] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.7°±0.3°, 17.8°±0.3°, 18.2°±0.3°, 19.3°±0.3°, and 21.8°±0.3°2θ.

[0359]

[0431] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 5.2°±0.3°, 13.2°±0.3°, 14.7°±0.3°, 15.7°±0.3°, 17.8°±0.3°, 18.2°±0.3°, 19.3°±0.3°, and 21.8°±0.3°2θ.

[0360]

[0432] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 5.2°±0.3°, 13.2°±0.3°, and 14.7°±0.3°²θ.

[0361]

[0433] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.9°±0.3°, 8.5°±0.3°, 8.9°±0.3°, 10.5°±0.3°, 10.8°±0.3°, 12.3°±0.3°, 12.6°±0.3°, 13.4°±0.3°, 14.0°±0.3°, 14.1°±0.3°, and 14.7°±0.3°²θ.

[0362]

[0434] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.8°±0.3°, 18.2°±0.3°, 21.8°±0.3°, and 21.9°±0.3°2θ.

[0363]

[0435] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.3°, 15.7°±0.3°, 17.0°±0.3°, 17.2°±0.3°, 17.6°±0.3°, 18.1°±0.3°, 19.3°±0.3°, 19.8°±0.3°, 20.2°±0.3°, 20.6°±0.3°, 20.9°±0.3°, 21.1°±0.3°, 21.6°±0.3°, 22.5°±0.3°, 22.9°±0.3°, 23.9°±0.3°, and 24.9°±0.3°²θ.

[0364]

[0436] In certain embodiments, the XRPD pattern further includes peaks at 25.4°±0.3°, 25.6°±0.3°, and 25.9°±0.3°2θ.

[0365]

[0437] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.3°±0.3°, 26.6°±0.3°, 27.1°±0.3°, 27.5°±0.3°, 28.5°±0.3°, 28.9°±0.3°, 29.4°±0.3°, and 30.1°±0.3°²θ.

[0366]

[0438] In certain embodiments, the crystalline cansylates of the compound of formula (I) are 5.2°±0.3°, 6.9°±0.3°, 8.5°±0.3°, 8.9°±0.3°, 10.5°±0.3°, 10.8°±0.3°, 12.3°±0.3°, 12.6°±0.3°, 13.2°±0.3°, and 13.4°±0.3°. °, 14.0°±0.3°, 14.1°±0.3°, 14.7°±0.3°, 15.1°±0.3°, 15.7°±0.3°, 17.0°±0.3°, 17.2°±0.3°, 17.6°±0.3°, 17.8°±0.3°, 18.1°±0.3°, 18.2°±0.3°, 19.3°±0.3°, 1 9.8°±0.3°, 20.2°±0.3°, 20.6°±0.3°, 20.9°±0.3°, 21.1°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 22.5°±0.3°, 22.9°±0.3°, 23.9°±0.3°, 24.9°±0.3°, 25.4°±0.3°, 25. The XRPD pattern has one or more peaks at 6°±0.3°, 25.9°±0.3°, 26.3°±0.3°, 26.6°±0.3°, 27.1°±0.3°, 27.5°±0.3°, 28.5°±0.3°, 28.9°±0.3°, 29.4°±0.3°, and 30.1°±0.3°2θ.

[0367]

[0439] In certain embodiments, the values ​​are 5.2°±0.3°, 6.9°±0.3°, 8.5°±0.3°, 8.9°±0.3°, 10.5°±0.3°, 10.8°±0.3°, 12.3°±0.3°, 12.6°±0.3°, 13.2°±0.3°, 13.4°±0.3°, 14.0°±0.3°, 14.1°±0.3°, and 14. 0.7°±0.3°, 15.1°±0.3°, 15.7°±0.3°, 17.0°±0.3°, 17.2°±0.3°, 17.6°±0.3°, 17.8°±0.3°, 18.1°±0.3°, 18.2°±0.3°, 19.3°±0.3°, 19.8°±0.3°, 20.2°±0.3°, 20.6°±0.3°, 20.9°±0.3°, 21.1°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 22.5°±0.3°, 22.9°±0.3°, 23.9°±0.3°, 24.9°±0.3°, 25.4°±0.3°, 25.6°±0.3°, 25.9°±0.3°, 26.3°±0.3°, 26.6°±0. Crystalline cansylates of compounds of formula (I) having an XRPD pattern with peaks at 3°, 27.1°±0.3°, 27.5°±0.3°, 28.5°±0.3°, 28.9°±0.3°, 29.4°±0.3°, and 30.1°±0.3°2θ may be referred to herein as "crystalline cansylate form A".

[0368]

[0440] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including a peak at 5.2°±0.2°2θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including a peak at 13.2°±0.2°2θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including a peak at 14.7°±0.2°2θ. In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern including one or more peaks at 5.2°±0.2°, 13.2°±0.2°, and 14.7°±0.2°2θ.

[0369]

[0441] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.7°±0.2°, 17.8°±0.2°, 18.2°±0.2°, 19.3°±0.2°, and 21.8°±0.2°²θ.

[0370]

[0442] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 5.2°±0.2°, 13.2°±0.2°, 14.7°±0.2°, 15.7°±0.2°, 17.8°±0.2°, 18.2°±0.2°, 19.3°±0.2°, and 21.8°±0.2°²θ.

[0371]

[0443] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern that includes peaks at 5.2°±0.2°, 13.2°±0.2°, 14.7°±0.2°, 15.7°±0.2°, 17.8°±0.2°, 18.2°±0.2°, 19.3°±0.2°, and 21.8°±0.2°2θ.

[0372]

[0444] In certain embodiments, the crystalline cansylate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 5.2°±0.2°, 13.2°±0.2°, and 14.7°±0.2°²θ.

[0373]

[0445] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.9°±0.2°, 8.5°±0.2°, 8.9°±0.2°, 10.5°±0.2°, 10.8°±0.2°, 12.3°±0.2°, 12.6°±0.2°, 13.4°±0.2°, 14.0°±0.2°, 14.1°±0.2°, and 14.7°±0.2°²θ.

[0374]

[0446] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.8°±0.2°, 18.2°±0.2°, 21.8°±0.2°, and 21.9°±0.2°²θ.

[0375]

[0447] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.2°, 15.7°±0.2°, 17.0°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.1°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.2°±0.2°, 20.6°±0.2°, 20.9°±0.2°, 21.1°±0.2°, 21.6°±0.2°, 22.5°±0.2°, 22.9°±0.2°, 23.9°±0.2°, and 24.9°±0.2°²θ.

[0376]

[0448] In certain embodiments, the XRPD pattern further includes peaks at 25.4°±0.2°, 25.6°±0.2°, and 25.9°±0.2°²θ.

[0377]

[0449] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.3°±0.2°, 26.6°±0.2°, 27.1°±0.2°, 27.5°±0.2°, 28.5°±0.2°, 28.9°±0.2°, 29.4°±0.2°, and 30.1°±0.2°²θ.

[0378]

[0450] In certain embodiments, the crystalline cansylate of the compound of formula (I) has a range of 5.2°±0.2°, 6.9°±0.2°, 8.5°±0.2°, 8.9°±0.2°, 10.5°±0.2°, 10.8°±0.2°, 12.3°±0.2°, 12.6°±0.2°, 13.2°±0.2°, and 13.4°±0.2°. °, 14.0°±0.2°, 14.1°±0.2°, 14.7°±0.2°, 15.1°±0.2°, 15.7°±0.2°, 17.0°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 17.8°±0.2°, 18.1°±0.2°, 18.2°±0.2°, 19.3°±0.2°, 1 9.8°±0.2°, 20.2°±0.2°, 20.6°±0.2°, 20.9°±0.2°, 21.1°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 22.5°±0.2°, 22.9°±0.2°, 23.9°±0.2°, 24.9°±0.2°, 25.4°±0.2°, 25. The XRPD pattern has one or more peaks at 6°±0.2°, 25.9°±0.2°, 26.3°±0.2°, 26.6°±0.2°, 27.1°±0.2°, 27.5°±0.2°, 28.5°±0.2°, 28.9°±0.2°, 29.4°±0.2°, and 30.1°±0.2°2θ.

[0379]

[0451] In certain embodiments, the values ​​are 5.2°±0.2°, 6.9°±0.2°, 8.5°±0.2°, 8.9°±0.2°, 10.5°±0.2°, 10.8°±0.2°, 12.3°±0.2°, 12.6°±0.2°, 13.2°±0.2°, 13.4°±0.2°, 14.0°±0.2°, 14.1°±0.2°, and 14. 0.7°±0.2°, 15.1°±0.2°, 15.7°±0.2°, 17.0°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 17.8°±0.2°, 18.1°±0.2°, 18.2°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.2°±0.2°, 20.6°±0.2°, 20.9°±0.2°, 21.1°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 22.5°±0.2°, 22.9°±0.2°, 23.9°±0.2°, 24.9°±0.2°, 25.4°±0.2°, 25.6°±0.2°, 25.9°±0.2°, 26.3°±0.2°, 26.6°±0. Crystalline cansylates of compounds of formula (I) having an XRPD pattern with peaks at 2°, 27.1°±0.2°, 27.5°±0.2°, 28.5°±0.2°, 28.9°±0.2°, 29.4°±0.2°, and 30.1°±0.2°2θ may be referred to herein as "crystalline cansylate form A".

[0380]

[0452] In certain embodiments, the crystalline cansylate of the compound of formula (I) (e.g., crystalline cansylate form A) has substantially the same XRPD pattern as shown in Figure 58. In certain embodiments, the crystalline cansylate of the compound of formula (I) (e.g., crystalline cansylate form A) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 43.

[0381]

[0453] In certain embodiments, the crystalline cansylate form A of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 54°C. In certain embodiments, the crystalline cansylate form A of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 133°C. In certain embodiments, the crystalline cansylate form A of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 174°C. In certain embodiments, the crystalline cansylate form A of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activity with peak onset at approximately 54°C, approximately 133°C, and approximately 174°C. In certain embodiments, the crystalline cansylate form A of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 59.

[0382]

[0454] In certain embodiments, the crystalline cansylate form A of the compound of formula (I) exhibits a weight loss of about 2.8% by weight or less when heated from about 36°C to about 189°C. The weight loss exhibited by the crystalline form (e.g., the crystalline cansylate form A of the compound of formula (I)) can be determined, for example, using TGA. In certain embodiments, the crystalline cansylate of the compound of formula (I) (e.g., the crystalline cansylate form A of the compound of formula (I)) has substantially the same TGA thermogram as shown in Figure 60.

[0383]

[0455] In certain embodiments, the crystalline cansylate form A of the compound of formula (I) is a crystalline hydrate.

[0384] (6) Phosphate Form

[0456] In one embodiment, a phosphate of the compound of formula (I) is provided herein. [ka]

[0385]

[0457] In certain embodiments, the phosphate of the compound of formula (I) is a crystalline phosphate. In certain embodiments, materials (e.g., pharmaceutical materials) comprising the crystalline phosphate of the compound of formula (I) are provided herein.

[0386] (A) Phosphate material A

[0458] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at approximately 3.9°²θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at approximately 7.7°²θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at approximately 13.7°²θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including one or more peaks at approximately 3.9°, approximately 7.7°, and approximately 13.7°²θ.

[0387]

[0459] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at approximately 3.9°, approximately 7.7°, and approximately 13.7°²θ.

[0388]

[0460] In certain embodiments, a material comprising a crystalline phosphate having XRPD peaks at approximately 3.9°, approximately 7.7°, and approximately 13.7°²θ may be referred to herein as “Phosphate Material A”.

[0389]

[0461] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 3.9°2θ.

[0390]

[0462] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 5.5°, approximately 7.0°, approximately 7.7°, approximately 13.7°, and approximately 14.0°²θ.

[0391]

[0463] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.0°, 16.3°, 17.2°, and 24.2°²θ.

[0392]

[0464] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 3.9°, 5.5°, 7.0°, 7.7°, 13.7°, 14.0°, 16.0°, 16.3°, 17.2°, and 24.2°²θ.

[0393]

[0465] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at approximately 3.9°, 5.5°, 7.0°, 7.7°, 13.7°, 14.0°, 16.0°, 16.3°, 17.2°, and 24.2°²θ.

[0394]

[0466] In certain embodiments, a material comprising a crystalline phosphate having XRPD peaks at approximately 3.9°, 5.5°, 7.0°, 7.7°, 13.7°, 14.0°, 16.0°, 16.3°, 17.2°, and 24.2°²θ may be referred to herein as “Phosphate Material A”.

[0395]

[0467] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at 3.9°±0.3°2θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at 7.7°±0.3°2θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at 13.7°±0.3°2θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including one or more peaks at 3.9°±0.3°, 7.7°±0.3°, and 13.7°±0.3°2θ.

[0396]

[0468] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at 3.9°±0.3°, 7.7°±0.3°, and 13.7°±0.3°2θ.

[0397]

[0469] In certain embodiments, a material comprising a crystalline phosphate having XRPD peaks at 3.9°±0.3°, 7.7°±0.3°, and 13.7°±0.3°2θ may be referred to herein as “Phosphate Material A”.

[0398]

[0470] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 3.9°±0.3°2θ.

[0399]

[0471] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.5°±0.3°, 7.0°±0.3°, 7.7°±0.3°, 13.7°±0.3°, and 14.0°±0.3°²θ.

[0400]

[0472] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.0°±0.3°, 16.3°±0.3°, 17.2°±0.3°, and 24.2°±0.3°2θ.

[0401]

[0473] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 3.9°±0.3°, 5.5°±0.3°, 7.0°±0.3°, 7.7°±0.3°, 13.7°±0.3°, 14.0°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 17.2°±0.3°, and 24.2°±0.3°2θ.

[0402]

[0474] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at 3.9°±0.3°, 5.5°±0.3°, 7.0°±0.3°, 7.7°±0.3°, 13.7°±0.3°, 14.0°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 17.2°±0.3°, and 24.2°±0.3°2θ.

[0403]

[0475] In certain embodiments, materials containing crystalline phosphates, specifically those containing crystalline phosphates with XRPD peaks at 3.9°±0.3°, 5.5°±0.3°, 7.0°±0.3°, 7.7°±0.3°, 13.7°±0.3°, 14.0°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 17.2°±0.3°, and 24.2°±0.3°²θ, may be referred to herein as "Phosphate Material A".

[0404]

[0476] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at 3.9°±0.2°2θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at 7.7°±0.2°2θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including a peak at 13.7°±0.2°2θ. In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern including one or more peaks at 3.9°±0.2°, 7.7°±0.2°, and 13.7°±0.2°2θ.

[0405]

[0477] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at 3.9°±0.2°, 7.7°±0.2°, and 13.7°±0.2°²θ.

[0406]

[0478] In certain embodiments, a material comprising a crystalline phosphate having XRPD peaks at 3.9°±0.2°, 7.7°±0.2°, and 13.7°±0.2°2θ may be referred to herein as “Phosphate Material A”.

[0407]

[0479] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 3.9°±0.2°2θ.

[0408]

[0480] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.5°±0.2°, 7.0°±0.2°, 7.7°±0.2°, 13.7°±0.2°, and 14.0°±0.2°²θ.

[0409]

[0481] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.0°±0.2°, 16.3°±0.2°, 17.2°±0.2°, and 24.2°±0.2°2θ.

[0410]

[0482] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 3.9°±0.2°, 5.5°±0.2°, 7.0°±0.2°, 7.7°±0.2°, 13.7°±0.2°, 14.0°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 17.2°±0.2°, and 24.2°±0.2°²θ.

[0411]

[0483] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at 3.9°±0.2°, 5.5°±0.2°, 7.0°±0.2°, 7.7°±0.2°, 13.7°±0.2°, 14.0°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 17.2°±0.2°, and 24.2°±0.2°2θ.

[0412]

[0484] In certain embodiments, materials containing crystalline phosphates, specifically those containing crystalline phosphates with XRPD peaks at 3.9°±0.2°, 5.5°±0.2°, 7.0°±0.2°, 7.7°±0.2°, 13.7°±0.2°, 14.0°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 17.2°±0.2°, and 24.2°±0.2°²θ, may be referred to herein as "Phosphate Material A".

[0413]

[0485] In certain embodiments, the phosphate material A of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 61. In certain embodiments, the phosphate material A of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 44.

[0414] (B) Phosphate material B

[0486] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern containing peaks at approximately 4.1°, 6.9°, 10.8°, and 11.4°²θ.

[0415]

[0487] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 7.8°, 8.3°, 8.5°, 9.1°, 9.3°, 10.6°, 12.3°, 13.4°, and 14.6°²θ.

[0416]

[0488] In certain embodiments, the XRPD pattern further includes peaks at approximately 18.0°, 20.0°, 21.4°, and 21.7°²θ.

[0417]

[0489] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.8°, 16.2°, 16.4°, 16.6°, 16.7°, 17.1°, 18.4°, 18.8°, 19.8°, 20.8°, 22.0°, 22.5°, 22.9°, 23.2°, and 24.0°²θ.

[0418]

[0490] In certain embodiments, the XRPD pattern further includes peaks at approximately 25.1°, 26.1°, and 28.0°²θ.

[0419]

[0491] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.7°, 27.3°, 28.5°, and 28.7°²θ.

[0420]

[0492] In certain embodiments, the crystalline phosphate of the compound of formula (I) has a range of approximately 4.1°, approximately 6.9°, approximately 7.8°, approximately 8.3°, approximately 8.5°, approximately 9.1°, approximately 9.3°, approximately 10.6°, approximately 10.8°, approximately 11.4°, approximately 12.3°, approximately 13.4°, approximately 14.6°, approximately 15.8°, approximately 16.2°, approximately 16.4°, approximately 16.6°, approximately 16.7°, approximately 17.1°, and approximately 18.0°. The XRPD pattern has one or more peaks at approximately 18.4°, 18.8°, 19.8°, 20.0°, 20.8°, 21.4°, 21.7°, 22.0°, 22.5°, 22.9°, 23.2°, 24.0°, 25.1°, 26.1°, 26.7°, 27.3°, 28.0°, 28.5°, and 28.7°²θ.

[0421]

[0493] In certain embodiments, the crystalline phosphate of the compound of formula (I) is approximately 4.1°, approximately 6.9°, approximately 7.8°, approximately 8.3°, approximately 8.5°, approximately 9.1°, approximately 9.3°, approximately 10.6°, approximately 10.8°, approximately 11.4°, approximately 12.3°, approximately 13.4°, approximately 14.6°, approximately 15.8°, approximately 16.2°, approximately 16.4°, approximately 16.6°, approximately 16.7°, approximately 17.1°, and approximately 18. The XRPD pattern has peaks at 0°, approximately 18.4°, approximately 18.8°, approximately 19.8°, approximately 20.0°, approximately 20.8°, approximately 21.4°, approximately 21.7°, approximately 22.0°, approximately 22.5°, approximately 22.9°, approximately 23.2°, approximately 24.0°, approximately 25.1°, approximately 26.1°, approximately 26.7°, approximately 27.3°, approximately 28.0°, approximately 28.5°, and approximately 28.7°²θ.

[0422]

[0494] In certain embodiments, the angles are approximately 4.1°, 6.9°, 7.8°, 8.3°, 8.5°, 9.1°, 9.3°, 10.6°, 10.8°, 11.4°, 12.3°, 13.4°, 14.6°, 15.8°, 16.2°, 16.4°, 16.6°, 16.7°, 17.1°, 18.0°, 18.4°, 18.8°, and 19.8°. Materials containing crystalline phosphates with XRPD peaks at approximately 20.0°, 20.8°, 21.4°, 21.7°, 22.0°, 22.5°, 22.9°, 23.2°, 24.0°, 25.1°, 26.1°, 26.7°, 27.3°, 28.0°, 28.5°, and 28.7°²θ may be referred to herein as “Phosphate Material B”.

[0423]

[0495] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at 4.1°±0.3°, 6.9°±0.3°, 10.8°±0.3°, and 11.4°±0.3°2θ.

[0424]

[0496] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.8°±0.3°, 8.3°±0.3°, 8.5°±0.3°, 9.1°±0.3°, 9.3°±0.3°, 10.6°±0.3°, 12.3°±0.3°, 13.4°±0.3°, and 14.6°±0.3°²θ.

[0425]

[0497] In certain embodiments, the XRPD pattern further includes peaks at 18.0°±0.3°, 20.0°±0.3°, 21.4°±0.3°, and 21.7°±0.3°2θ.

[0426]

[0498] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.8°±0.3°, 16.2°±0.3°, 16.4°±0.3°, 16.6°±0.3°, 16.7°±0.3°, 17.1°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.8°±0.3°, 20.8°±0.3°, 22.0°±0.3°, 22.5°±0.3°, 22.9°±0.3°, 23.2°±0.3°, and 24.0°±0.3°²θ.

[0427]

[0499] In certain embodiments, the XRPD pattern further includes peaks at 25.1°±0.3°, 26.1°±0.3°, and 28.0°±0.3°2θ.

[0428]

[0500] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.7°±0.3°, 27.3°±0.3°, 28.5°±0.3°, and 28.7°±0.3°2θ.

[0429]

[0501] In certain embodiments, the crystalline phosphate of the compound of formula (I) is 4.1°±0.3°, 6.9°±0.3°, 7.8°±0.3°, 8.3°±0.3°, 8.5°±0.3°, 9.1°±0.3°, 9.3°±0.3°, 10.6°±0.3°, 10.8°±0.3°, 11.4°±0.3°, 12.3°±0.3°, 13.4°±0.3°, 14.6°±0.3°, 15.8°±0.3°, 16.2°±0.3°, 16.4°±0.3°, 16.6°±0.3°, 16.7°±0.3°, 17.1°±0.3°, 18.0°±0.3° The XRPD pattern has one or more peaks at 2θ, 18.4°±0.3°, 18.8°±0.3°, 19.8°±0.3°, 20.0°±0.3°, 20.8°±0.3°, 21.4°±0.3°, 21.7°±0.3°, 22.0°±0.3°, 22.5°±0.3°, 22.9°±0.3°, 23.2°±0.3°, 24.0°±0.3°, 25.1°±0.3°, 26.1°±0.3°, 26.7°±0.3°, 27.3°±0.3°, 28.0°±0.3°, 28.5°±0.3°, and 28.7°±0.3°2θ.

[0430]

[0502] In certain embodiments, the crystalline phosphate of the compound of formula (I) is 4.1°±0.3°, 6.9°±0.3°, 7.8°±0.3°, 8.3°±0.3°, 8.5°±0.3°, 9.1°±0.3°, 9.3°±0.3°, 10.6°±0.3°, 10.8°±0.3°, 11.4°±0.3°, 12.3°±0.3°, 13.4°±0.3°, 14.6°±0.3°, 15.8°±0.3°, 16.2°±0.3°, 16.4°±0.3°, 16.6°±0.3°, 16.7°±0.3°, 17.1°±0.3°, 18.0°± The XRPD pattern has peaks at 0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.8°±0.3°, 20.0°±0.3°, 20.8°±0.3°, 21.4°±0.3°, 21.7°±0.3°, 22.0°±0.3°, 22.5°±0.3°, 22.9°±0.3°, 23.2°±0.3°, 24.0°±0.3°, 25.1°±0.3°, 26.1°±0.3°, 26.7°±0.3°, 27.3°±0.3°, 28.0°±0.3°, 28.5°±0.3°, and 28.7°±0.3°2θ.

[0431]

[0503] In certain embodiments, the values ​​are 4.1°±0.3°, 6.9°±0.3°, 7.8°±0.3°, 8.3°±0.3°, 8.5°±0.3°, 9.1°±0.3°, 9.3°±0.3°, 10.6°±0.3°, 10.8°±0.3°, 11.4°±0.3°, 12.3°±0.3°, 13.4°±0.3°, 14.6°±0.3°, 15.8°±0.3°, 16.2°±0.3°, 16.4°±0.3°, 16.6°±0.3°, 16.7°±0.3°, 17.1°±0.3°, 18.0°±0.3°, 18.4°±0.3°, and 18.8°±0. Materials containing crystalline phosphates with XRPD peaks at 3°, 19.8°±0.3°, 20.0°±0.3°, 20.8°±0.3°, 21.4°±0.3°, 21.7°±0.3°, 22.0°±0.3°, 22.5°±0.3°, 22.9°±0.3°, 23.2°±0.3°, 24.0°±0.3°, 25.1°±0.3°, 26.1°±0.3°, 26.7°±0.3°, 27.3°±0.3°, 28.0°±0.3°, 28.5°±0.3°, and 28.7°±0.3°2θ may be referred to herein as “Phosphate Material B”.

[0432]

[0504] In certain embodiments, the crystalline phosphate of the compound of formula (I) has an XRPD pattern that includes peaks at 4.1°±0.2°, 6.9°±0.2°, 10.8°±0.2°, and 11.4°±0.2°²θ.

[0433]

[0505] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.8°±0.2°, 8.3°±0.2°, 8.5°±0.2°, 9.1°±0.2°, 9.3°±0.2°, 10.6°±0.2°, 12.3°±0.2°, 13.4°±0.2°, and 14.6°±0.2°²θ.

[0434]

[0506] In certain embodiments, the XRPD pattern further includes peaks at 18.0°±0.2°, 20.0°±0.2°, 21.4°±0.2°, and 21.7°±0.2°2θ.

[0435]

[0507] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.8°±0.2°, 16.2°±0.2°, 16.4°±0.2°, 16.6°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.8°±0.2°, 20.8°±0.2°, 22.0°±0.2°, 22.5°±0.2°, 22.9°±0.2°, 23.2°±0.2°, and 24.0°±0.2°²θ.

[0436]

[0508] In certain embodiments, the XRPD pattern further includes peaks at 25.1°±0.2°, 26.1°±0.2°, and 28.0°±0.2°2θ.

[0437]

[0509] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.7°±0.2°, 27.3°±0.2°, 28.5°±0.2°, and 28.7°±0.2°²θ.

[0438]

[0510] In certain embodiments, the crystalline phosphate of the compound of formula (I) is 4.1°±0.2°, 6.9°±0.2°, 7.8°±0.2°, 8.3°±0.2°, 8.5°±0.2°, 9.1°±0.2°, 9.3°±0.2°, 10.6°±0.2°, 10.8°±0.2°, 11.4°±0.2°, 12.3°±0.2°, 13.4°±0.2°, 14.6°±0.2°, 15.8°±0.2°, 16.2°±0.2°, 16.4°±0.2°, 16.6°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°±0.2° The XRPD pattern has one or more peaks at 2θ, 18.4°±0.2°, 18.8°±0.2°, 19.8°±0.2°, 20.0°±0.2°, 20.8°±0.2°, 21.4°±0.2°, 21.7°±0.2°, 22.0°±0.2°, 22.5°±0.2°, 22.9°±0.2°, 23.2°±0.2°, 24.0°±0.2°, 25.1°±0.2°, 26.1°±0.2°, 26.7°±0.2°, 27.3°±0.2°, 28.0°±0.2°, 28.5°±0.2°, and 28.7°±0.2°.

[0439]

[0511] In certain embodiments, the crystalline phosphate of the compound of formula (I) is 4.1°±0.2°, 6.9°±0.2°, 7.8°±0.2°, 8.3°±0.2°, 8.5°±0.2°, 9.1°±0.2°, 9.3°±0.2°, 10.6°±0.2°, 10.8°±0.2°, 11.4°±0.2°, 12.3°±0.2°, 13.4°±0.2°, 14.6°±0.2°, 15.8°±0.2°, 16.2°±0.2°, 16.4°±0.2°, 16.6°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°± The XRPD pattern has peaks at 0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.8°±0.2°, 20.0°±0.2°, 20.8°±0.2°, 21.4°±0.2°, 21.7°±0.2°, 22.0°±0.2°, 22.5°±0.2°, 22.9°±0.2°, 23.2°±0.2°, 24.0°±0.2°, 25.1°±0.2°, 26.1°±0.2°, 26.7°±0.2°, 27.3°±0.2°, 28.0°±0.2°, 28.5°±0.2°, and 28.7°±0.2°2θ.

[0440]

[0512] In certain embodiments, the values ​​are 4.1°±0.2°, 6.9°±0.2°, 7.8°±0.2°, 8.3°±0.2°, 8.5°±0.2°, 9.1°±0.2°, 9.3°±0.2°, 10.6°±0.2°, 10.8°±0.2°, 11.4°±0.2°, 12.3°±0.2°, 13.4°±0.2°, 14.6°±0.2°, 15.8°±0.2°, 16.2°±0.2°, 16.4°±0.2°, 16.6°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°±0.2°, 18.4°±0.2°, and 18.8°±0. Materials containing crystalline phosphates with XRPD peaks at 2°, 19.8°±0.2°, 20.0°±0.2°, 20.8°±0.2°, 21.4°±0.2°, 21.7°±0.2°, 22.0°±0.2°, 22.5°±0.2°, 22.9°±0.2°, 23.2°±0.2°, 24.0°±0.2°, 25.1°±0.2°, 26.1°±0.2°, 26.7°±0.2°, 27.3°±0.2°, 28.0°±0.2°, 28.5°±0.2°, and 28.7°±0.2°2θ may be referred to herein as “Phosphate Material B”.

[0441]

[0513] In certain embodiments, the phosphate material B of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 62. In certain embodiments, the phosphate material B of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 45.

[0442]

[0514] In certain embodiments, the phosphate material B of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 54°C. In certain embodiments, the phosphate material B of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 90°C. In certain embodiments, the phosphate material B of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activity with peak maximums at approximately 54°C and approximately 90°C. In certain embodiments, the phosphate material B of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 176°C. In certain embodiments, the phosphate material B of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 63.

[0443]

[0515] In certain embodiments, the phosphate material B of the compound of formula (I) exhibits a weight loss of about 3.3% by weight or less when heated from about 36°C to about 149°C. The weight loss exhibited by the crystalline form (e.g., the phosphate material B of the compound of formula (I)) can be determined, for example, using TGA. In certain embodiments, the phosphate material B of the compound of formula (I) has substantially the same TGA thermogram as shown in Figure 64.

[0444] Crystalline free base form of the compound of formula (I)

[0516] In one embodiment, the crystalline form of the compound of formula (I) is provided herein. [ka]

[0445]

[0517] In certain embodiments, the crystalline form of the compound of formula (I) is the crystalline free base form. In certain embodiments, the crystalline form of the compound of formula (I) is the anhydrous crystalline form.

[0446]

[0518] In a particular embodiment, the crystalline form of the compound of formula (I) is form A of the compound of formula (I). In a particular embodiment, the crystalline form of the compound of formula (I) is form B of the compound of formula (I). In a particular embodiment, the crystalline form of the compound of formula (I) is form C of the compound of formula (I). In a particular embodiment, the crystalline form of the compound of formula (I) is form D of the compound of formula (I). In a particular embodiment, the crystalline form of the compound of formula (I) is form E of the compound of formula (I). In a particular embodiment, the crystalline form of the compound of formula (I) is form H of the compound of formula (I).

[0447]

[0519] In certain embodiments, the crystalline form of the compound of formula (I) is a crystalline solvate. In certain embodiments, the crystalline solvate is a crystalline acetonitrile solvate. In certain embodiments, the crystalline solvate is a crystalline acetone solvate. In certain embodiments, the crystalline solvate is a crystalline ethyl acetate solvate.

[0448]

[0520] In certain embodiments, the crystalline form of the compound of formula (I) is a crystalline hydrate.

[0449] Crystalline free base form (1)Form A

[0521] In various embodiments, form A of the compound of formula (I) is provided herein. [ka]

[0450]

[0522] In certain embodiments, form A of the compound of formula (I) has an X-ray powder diffraction (XRPD) pattern containing a peak at approximately 8.1°²θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern containing a peak at approximately 9.4°²θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern containing a peak at approximately 9.8°²θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern containing one or more peaks at approximately 8.1°, approximately 9.4°, and approximately 9.8°²θ.

[0451]

[0523] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.6°, 16.0°, 16.3°, 16.9°, 17.1°, 18.4°, 18.8°, 20.0°, 20.1°, 20.3°, 20.6°, 21.4°, 21.6°, and 24.5°²θ.

[0452]

[0524] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 8.1°, 9.4°, 9.8°, 15.6°, 16.0°, 16.3°, 16.9°, 17.1°, 18.4°, 18.8°, 20.0°, 20.1°, 20.3°, 20.6°, 21.4°, 21.6°, and 24.5°²θ.

[0453]

[0525] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern with peaks at approximately 8.1°, 9.4°, 9.8°, 15.6°, 16.0°, 16.3°, 16.9°, 17.1°, 18.4°, 18.8°, 20.0°, 20.1°, 20.3°, 20.6°, 21.4°, 21.6°, and 24.5°²θ.

[0454]

[0526] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 8.1° and approximately 9.4°²θ.

[0455]

[0527] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 5.3°, 6.9°, 9.8°, 10.6°, 10.7°, 11.9°, 12.2°, 12.7°, 12.9°, 13.1°, 13.6°, 13.9°, 14.5°, and 14.8°²θ.

[0456]

[0528] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.3°, 17.1°, 18.8°, 20.0°, 20.1°, 20.6°, and 24.5° 2θ.

[0457]

[0529] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.6°, 16.0°, 16.9°, 17.6°, 18.4°, 19.1°, 19.3°, 19.6°, 20.3°, 20.8°, 21.0°, 21.1°, 21.4°, 21.6°, 21.8°, 22.0°, 22.3°, 22.7°, 22.9°, 23.3°, 23.8°, 24.1°, and 24.9°²θ.

[0458]

[0530] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.5°, 26.1°, 26.3°, 26.4°, 26.9°, 27.1°, and 29.1°²θ.

[0459]

[0531] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.6°, 27.7°, 27.8°, 28.3°, 28.8°, 29.8°, 30.8°, 31.2°, 31.5°, 31.7°, 32.3°, 33.1°, 33.6°, and 34.5°²θ.

[0460]

[0532] In certain embodiments, form A of the compound of formula (I) is approximately 5.3°, approximately 6.9°, approximately 8.1°, approximately 9.4°, approximately 9.8°, approximately 10.6°, approximately 10.7°, approximately 11.9°, approximately 12.2°, approximately 12.7°, approximately 12.9°, approximately 13.1°, approximately 13.6°, approximately 13.9°, approximately 14.5°, approximately 14.8° °, approximately 15.6°, approximately 16.0°, approximately 16.3°, approximately 16.9°, approximately 17.1°, approximately 17.6°, approximately 18.5°, approximately 18.8°, approximately 19.1°, approximately 19.3°, approximately 19.6°, approximately 20.0°, approximately 20.1°, approximately 20.3°, approximately 20.6°, approximately 20.8°, approximately 21.0°, approximately 21.1°, approximately The XRPD pattern has one or more peaks at 21.4°, approximately 21.6°, approximately 21.8°, approximately 22.0°, approximately 22.3°, approximately 22.7°, approximately 22.9°, approximately 23.3°, approximately 23.8°, approximately 24.1°, approximately 24.5°, approximately 24.9°, approximately 25.5°, approximately 26.1°, approximately 26.3°, approximately 26.4°, approximately 26.6°, approximately 26.9°, approximately 27.1°, approximately 27.7°, approximately 27.8°, approximately 28.3°, approximately 28.8°, approximately 29.1°, approximately 29.8°, approximately 30.8°, approximately 31.2°, approximately 31.5°, approximately 31.7°, approximately 32.3°, approximately 33.1°, approximately 33.6°, and approximately 34.5°²θ.

[0461]

[0533] In certain embodiments, form A of the compound of formula (I) is approximately 5.3°, approximately 6.9°, approximately 8.1°, approximately 9.4°, approximately 9.8°, approximately 10.6°, approximately 10.7°, approximately 11.9°, approximately 12.2°, approximately 12.7°, approximately 12.9°, approximately 13.1°, approximately 13.6°, approximately 13.9°, approximately 14.5°, approximately 14.8°, approximately 15.6°, approximately 16.0°, approximately 16.3°, approximately 16.9°, approximately 17.1°, approximately 17.6°, approximately 18.5°, approximately 18.8°, approximately 19.1°, approximately 19.3°, approximately 19.6°, approximately 20.0°, approximately 20.1°, approximately 20.3°, approximately 20.6°, approximately 20.8°, approximately 21.0°, approximately 21.1 The XRPD pattern has peaks at approximately 21.4°, 21.6°, 21.8°, 22.0°, 22.3°, 22.7°, 22.9°, 23.3°, 23.8°, 24.1°, 24.5°, 24.9°, 25.5°, 26.1°, 26.3°, 26.4°, 26.6°, 26.9°, 27.1°, 27.7°, 27.8°, 28.3°, 28.8°, 29.1°, 29.8°, 30.8°, 31.2°, 31.5°, 31.7°, 32.3°, 33.1°, 33.6°, and 34.5°²θ.

[0462]

[0534] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including a peak at 8.1°±0.3°2θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including a peak at 9.4°±0.3°2θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including a peak at 9.8°±0.3°2θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including one or more peaks at 8.1°±0.3°, 9.4°±0.3°, and 9.8°±0.3°2θ.

[0463]

[0535] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 20.0°±0.3°, 20.1°±0.3°, 20.3°±0.3°, 20.6°±0.3°, 21.4°±0.3°, 21.6°±0.3°, and 24.5°±0.3°²θ.

[0464]

[0536] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.3°, 9.4°±0.3°, 9.8°±0.3°, 15.6°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 20.0°±0.3°, 20.1°±0.3°, 20.3°±0.3°, 20.6°±0.3°, 21.4°±0.3°, 21.6°±0.3°, and 24.5°±0.3°2θ.

[0465]

[0537] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes peaks at 8.1°±0.3°, 9.4°±0.3°, 9.8°±0.3°, 15.6°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 20.0°±0.3°, 20.1°±0.3°, 20.3°±0.3°, 20.6°±0.3°, 21.4°±0.3°, 21.6°±0.3°, and 24.5°±0.3°2θ.

[0466]

[0538] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.3° and 9.4°±0.3°2θ.

[0467]

[0539] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.3°±0.3°, 6.9°±0.3°, 9.8°±0.3°, 10.6°±0.3°, 10.7°±0.3°, 11.9°±0.3°, 12.2°±0.3°, 12.7°±0.3°, 12.9°±0.3°, 13.1°±0.3°, 13.6°±0.3°, 13.9°±0.3°, 14.5°±0.3°, and 14.8°±0.3°²θ.

[0468]

[0540] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.3°±0.3°, 17.1°±0.3°, 18.8°±0.3°, 20.0°±0.3°, 20.1°±0.3°, 20.6°±0.3°, and 24.5°±0.3°2θ.

[0469]

[0541] In certain embodiments, the XRPD patterns are 15.6°±0.3°, 16.0°±0.3°, 16.9°±0.3°, 17.6°±0.3°, 18.4°±0.3°, 19.1°±0.3°, 19.3°±0.3°, 19.6°±0.3°, 20.3°±0.3°, 20.8°±0.3°, 21.0°±0.3°, and 21.1°. The data further includes one or more peaks at ±0.3°, 21.4°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 22.0°±0.3°, 22.3°±0.3°, 22.7°±0.3°, 22.9°±0.3°, 23.3°±0.3°, 23.8°±0.3°, 24.1°±0.3°, and 24.9°±0.3°²θ.

[0470]

[0542] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.5°±0.3°, 26.1°±0.3°, 26.3°±0.3°, 26.4°±0.3°, 26.9°±0.3°, 27.1°±0.3°, and 29.1°±0.3°2θ.

[0471]

[0543] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.6°±0.3°, 27.7°±0.3°, 27.8°±0.3°, 28.3°±0.3°, 28.8°±0.3°, 29.8°±0.3°, 30.8°±0.3°, 31.2°±0.3°, 31.5°±0.3°, 31.7°±0.3°, 32.3°±0.3°, 33.1°±0.3°, 33.6°±0.3°, and 34.5°±0.3°²θ.

[0472]

[0544] In a particular embodiment, form A of the compound of formula (I) is 5.3°±0.3°, 6.9°±0.3°, 8.1°±0.3°, 9.4°±0.3°, 9.8°±0.3°, 10.6°±0.3°, 10.7°±0.3°, 11.9°±0.3°, 12.2°±0.3°, 12.7°±0.3°, 12.9°±0.3°, 13.1°±0.3°, 13.6°±0.3°, 13.9°±0.3°, 14.5°±0.3°, 14.8°±0.3°, 1 5.6°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 17.6°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.1°±0.3°, 19.3°±0.3°, 19.6°±0.3°, 20.0°±0.3°, 20.1°±0.3°, 20.3°±0.3°, 20.6°±0.3°, 20.8°±0.3°, 21.0°±0.3°, 21.1°±0.3° , 21.4°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 22.0°±0.3°, 22.3°±0.3°, 22.7°±0.3°, 22.9°±0.3°, 23.3°±0.3°, 23.8°±0.3°, 24.1°±0.3°, 24.5°±0.3°, 24.9°±0.3°, 25.5°±0.3°, 26.1°±0.3°, 26.3°±0.3°, 26.4°±0.3°, 26.6°±0.3°, 26.9°±0. The XRPD pattern has one or more peaks at 3°, 27.1°±0.3°, 27.7°±0.3°, 27.8°±0.3°, 28.3°±0.3°, 28.8°±0.3°, 29.1°±0.3°, 29.8°±0.3°, 30.8°±0.3°, 31.2°±0.3°, 31.5°±0.3°, 31.7°±0.3°, 32.3°±0.3°, 33.1°±0.3°, 33.6°±0.3°, and 34.5°±0.3°2θ.

[0473]

[0545] In certain embodiments, form A of the compound of formula (I) is 5.3°±0.3°, 6.9°±0.3°, 8.1°±0.3°, 9.4°±0.3°, 9.8°±0.3°, 10.6°±0.3°, 10.7°±0.3°, 11.9°±0.3°, 12.2°±0.3°, 12.7°±0.3°, 12.9°±0.3°, 13.1°±0.3°, 13.6°±0.3°, 13.9°±0.3°, 14.5°±0.3°, 14.8°±0.3° 15.6°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 17.6°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.1°±0.3°, 19.3°±0.3°, 19.6°±0.3°, 20.0°±0.3°, 20.1°±0.3°, 20.3°±0.3°, 20.6°±0.3°, 20.8°±0.3°, 21.0°±0.3°, 21.1°±0 0.3°, 21.4°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 22.0°±0.3°, 22.3°±0.3°, 22.7°±0.3°, 22.9°±0.3°, 23.3°±0.3°, 23.8°±0.3°, 24.1°±0.3°, 24.5°±0.3°, 24.9°±0.3°, 25.5°±0.3°, 26.1°±0.3°, 26.3°±0.3°, 26.4°±0.3°, 26.6°±0.3°, 26.9 The XRPD pattern has peaks at °±0.3°, 27.1°±0.3°, 27.7°±0.3°, 27.8°±0.3°, 28.3°±0.3°, 28.8°±0.3°, 29.1°±0.3°, 29.8°±0.3°, 30.8°±0.3°, 31.2°±0.3°, 31.5°±0.3°, 31.7°±0.3°, 32.3°±0.3°, 33.1°±0.3°, 33.6°±0.3°, and 34.5°±0.3°2θ.

[0474]

[0546] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including a peak at 8.1°±0.2°2θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including a peak at 9.4°±0.2°2θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including a peak at 9.8°±0.2°2θ. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including one or more peaks at 8.1°±0.2°, 9.4°±0.2°, and 9.8°±0.2°2θ.

[0475]

[0547] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 20.0°±0.2°, 20.1°±0.2°, 20.3°±0.2°, 20.6°±0.2°, 21.4°±0.2°, 21.6°±0.2°, and 24.5°±0.2°²θ.

[0476]

[0548] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.2°, 9.4°±0.2°, 9.8°±0.2°, 15.6°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 20.0°±0.2°, 20.1°±0.2°, 20.3°±0.2°, 20.6°±0.2°, 21.4°±0.2°, 21.6°±0.2°, and 24.5°±0.2°²θ.

[0477]

[0549] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes peaks at 8.1°±0.2°, 9.4°±0.2°, 9.8°±0.2°, 15.6°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 20.0°±0.2°, 20.1°±0.2°, 20.3°±0.2°, 20.6°±0.2°, 21.4°±0.2°, 21.6°±0.2°, and 24.5°±0.2°2θ.

[0478]

[0550] In certain embodiments, form A of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.2° and 9.4°±0.2°²θ.

[0479]

[0551] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.3°±0.2°, 6.9°±0.2°, 9.8°±0.2°, 10.6°±0.2°, 10.7°±0.2°, 11.9°±0.2°, 12.2°±0.2°, 12.7°±0.2°, 12.9°±0.2°, 13.1°±0.2°, 13.6°±0.2°, 13.9°±0.2°, 14.5°±0.2°, and 14.8°±0.2°²θ.

[0480]

[0552] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.3°±0.2°, 17.1°±0.2°, 18.8°±0.2°, 20.0°±0.2°, 20.1°±0.2°, 20.6°±0.2°, and 24.5°±0.2°2θ.

[0481]

[0553] In certain embodiments, the XRPD pattern is 15.6°±0.2°, 16.0°±0.2°, 16.9°±0.2°, 17.6°±0.2°, 18.4°±0.2°, 19.1°±0.2°, 19.3°±0.2°, 19.6°±0.2°, 20.3°±0.2°, 20.8°±0.2°, 21.0°±0.2°, 21.1 The data further includes one or more peaks at 2θ, specifically at 21.4°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 22.0°±0.2°, 22.3°±0.2°, 22.7°±0.2°, 22.9°±0.2°, 23.3°±0.2°, 23.8°±0.2°, 24.1°±0.2°, and 24.9°±0.2°²θ.

[0482]

[0554] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.5°±0.2°, 26.1°±0.2°, 26.3°±0.2°, 26.4°±0.2°, 26.9°±0.2°, 27.1°±0.2°, and 29.1°±0.2°²θ.

[0483]

[0555] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.6°±0.2°, 27.7°±0.2°, 27.8°±0.2°, 28.3°±0.2°, 28.8°±0.2°, 29.8°±0.2°, 30.8°±0.2°, 31.2°±0.2°, 31.5°±0.2°, 31.7°±0.2°, 32.3°±0.2°, 33.1°±0.2°, 33.6°±0.2°, and 34.5°±0.2°²θ.

[0484]

[0556] In certain embodiments, form A of the compound of formula (I) is 5.3°±0.2°, 6.9°±0.2°, 8.1°±0.2°, 9.4°±0.2°, 9.8°±0.2°, 10.6°±0.2°, 10.7°±0.2°, 11.9°±0.2°, 12.2°±0.2°, 12.7°±0.2°, 12.9°±0.2°, 13.1°±0.2°, 13.6°±0.2°, 13.9°±0.2°, 14.5°±0.2°, 14.8°±0.2°, 1 5.6°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 17.6°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.1°±0.2°, 19.3°±0.2°, 19.6°±0.2°, 20.0°±0.2°, 20.1°±0.2°, 20.3°±0.2°, 20.6°±0.2°, 20.8°±0.2°, 21.0°±0.2°, 21.1°±0.2° 21.4°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 22.0°±0.2°, 22.3°±0.2°, 22.7°±0.2°, 22.9°±0.2°, 23.3°±0.2°, 23.8°±0.2°, 24.1°±0.2°, 24.5°±0.2°, 24.9°±0.2°, 25.5°±0.2°, 26.1°±0.2°, 26.3°±0.2°, 26.4°±0.2°, 26.6°±0.2°, 26.9°±0. The XRPD pattern has one or more peaks at 2°, 27.1°±0.2°, 27.7°±0.2°, 27.8°±0.2°, 28.3°±0.2°, 28.8°±0.2°, 29.1°±0.2°, 29.8°±0.2°, 30.8°±0.2°, 31.2°±0.2°, 31.5°±0.2°, 31.7°±0.2°, 32.3°±0.2°, 33.1°±0.2°, 33.6°±0.2°, and 34.5°±0.2°2θ.

[0485]

[0557] In certain embodiments, form A of the compound of formula (I) is 5.3°±0.2°, 6.9°±0.2°, 8.1°±0.2°, 9.4°±0.2°, 9.8°±0.2°, 10.6°±0.2°, 10.7°±0.2°, 11.9°±0.2°, 12.2°±0.2°, 12.7°±0.2°, 12.9°±0.2°, 13.1°±0.2°, 13.6°±0.2°, 13.9°±0.2°, 14.5°±0.2°, 14.8°±0.2° 15.6°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 17.6°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.1°±0.2°, 19.3°±0.2°, 19.6°±0.2°, 20.0°±0.2°, 20.1°±0.2°, 20.3°±0.2°, 20.6°±0.2°, 20.8°±0.2°, 21.0°±0.2°, 21.1°±0 0.2°, 21.4°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 22.0°±0.2°, 22.3°±0.2°, 22.7°±0.2°, 22.9°±0.2°, 23.3°±0.2°, 23.8°±0.2°, 24.1°±0.2°, 24.5°±0.2°, 24.9°±0.2°, 25.5°±0.2°, 26.1°±0.2°, 26.3°±0.2°, 26.4°±0.2°, 26.6°±0.2°, 26.9 The XRPD pattern has peaks at °±0.2°, 27.1°±0.2°, 27.7°±0.2°, 27.8°±0.2°, 28.3°±0.2°, 28.8°±0.2°, 29.1°±0.2°, 29.8°±0.2°, 30.8°±0.2°, 31.2°±0.2°, 31.5°±0.2°, 31.7°±0.2°, 32.3°±0.2°, 33.1°±0.2°, 33.6°±0.2°, and 34.5°±0.2°2θ.

[0486]

[0558] In certain embodiments, form A of the compound of formula (I) exists in a triclinic system and has a P1 space group. In certain embodiments, form A of the compound of formula (I) is characterized by crystallographic unit cell parameters as described below.

[0487] [Table 1]

[0488]

[0559] In certain embodiments, form A of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 26A. In certain embodiments, form A of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 28.

[0489]

[0560] In certain embodiments, form A of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with a peak onset at approximately 205°C. In certain embodiments, form A of the compound of formula (I) has a DSC thermogram substantially identical to that shown in Figure 27.

[0490]

[0561] In certain embodiments, form A of the compound of formula (I) is in an anhydrous crystalline form.

[0491] (2) Form B

[0562] In various embodiments, form B of the compound of formula (I) is provided herein. [ka]

[0492]

[0563] In certain embodiments, form B of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 4.0°, approximately 11.1°, and approximately 12.9°²θ.

[0493]

[0564] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 7.9°, 9.1°, 10.4°, and 11.9°²θ.

[0494]

[0565] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.9°, 18.8°, 22.4°, 23.1°, and 23.8°²θ.

[0495]

[0566] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 18.2°, 18.5°, 19.4°, 19.9°, 20.2°, 21.4°, 24.4°, and 24.7°²θ.

[0496]

[0567] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 28.8° and approximately 31.5°²θ.

[0497]

[0568] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.0°, 26.3°, 26.6°, 27.5°, 29.7°, 30.1°, 32.1°, 32.3°, 32.7°, 33.0°, 33.4°, 33.9°, and 33.4°²θ.

[0498]

[0569] In certain embodiments, form B of the compound of formula (I) is approximately 4.0°, approximately 7.9°, approximately 9.1°, approximately 10.4°, approximately 11.1°, approximately 11.9°, approximately 12.9°, approximately 15.9°, approximately 18.2°, approximately 18.5°, approximately 18.8°, approximately 19.4°, approximately 19.9°, approximately 20.2°, approximately 21.4°, approximately 22.4°, approximately 23.1°, approximately 23.8°, The XRPD pattern has one or more peaks at approximately 24.4°, 24.7°, 26.0°, 26.3°, 26.6°, 27.5°, 28.8°, 29.7°, 30.1°, 31.5°, 32.1°, 32.3°, 32.7°, 33.0°, 33.4°, 33.9°, and 33.4°²θ.

[0499]

[0570] In certain embodiments, form B of the compound of formula (I) is approximately 4.0°, approximately 7.9°, approximately 9.1°, approximately 10.4°, approximately 11.1°, approximately 11.9°, approximately 12.9°, approximately 15.9°, approximately 18.2°, approximately 18.5°, approximately 18.8°, approximately 19.4°, approximately 19.9°, approximately 20.2°, approximately 21.4°, approximately 22.4°, approximately 23.1°, and approximately 23. The XRPD pattern has peaks at 8°, approximately 24.4°, approximately 24.7°, approximately 26.0°, approximately 26.3°, approximately 26.6°, approximately 27.5°, approximately 28.8°, approximately 29.7°, approximately 30.1°, approximately 31.5°, approximately 32.1°, approximately 32.3°, approximately 32.7°, approximately 33.0°, approximately 33.4°, approximately 33.9°, and approximately 33.4°²θ.

[0500]

[0571] In certain embodiments, form B of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 4.0°±0.3°, 11.1°±0.3°, and 12.9°±0.3°²θ.

[0501]

[0572] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.9°±0.3°, 9.1°±0.3°, 10.4°±0.3°, and 11.9°±0.3°2θ.

[0502]

[0573] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.9°±0.3°, 18.8°±0.3°, 22.4°±0.3°, 23.1°±0.3°, and 23.8°±0.3°2θ.

[0503]

[0574] In certain embodiments, the XRPD pattern further includes one or more peaks at 18.2°±0.3°, 18.5°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 21.4°±0.3°, 24.4°±0.3°, and 24.7°±0.3°2θ.

[0504]

[0575] In certain embodiments, the XRPD pattern further includes one or more peaks at 28.8°±0.3° and 31.5°±0.3°2θ.

[0505]

[0576] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.0°±0.3°, 26.3°±0.3°, 26.6°±0.3°, 27.5°±0.3°, 29.7°±0.3°, 30.1°±0.3°, 32.1°±0.3°, 32.3°±0.3°, 32.7°±0.3°, 33.0°±0.3°, 33.4°±0.3°, 33.9°±0.3°, and 33.4°±0.3°²θ.

[0506]

[0577] In certain embodiments, form B of the compound of formula (I) is 4.0°±0.3°, 7.9°±0.3°, 9.1°±0.3°, 10.4°±0.3°, 11.1°±0.3°, 11.9°±0.3°, 12.9°±0.3°, 15.9°±0.3°, 18.2°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 21.4°±0.3°, 22.4°±0.3°, 23.1°±0.3°, 23.8°±0.3° The XRPD pattern has one or more peaks at 2θ, 24.4°±0.3°, 24.7°±0.3°, 26.0°±0.3°, 26.3°±0.3°, 26.6°±0.3°, 27.5°±0.3°, 28.8°±0.3°, 29.7°±0.3°, 30.1°±0.3°, 31.5°±0.3°, 32.1°±0.3°, 32.3°±0.3°, 32.7°±0.3°, 33.0°±0.3°, 33.4°±0.3°, 33.9°±0.3°, and 33.4°±0.3°2θ.

[0507]

[0578] In certain embodiments, form B of the compound of formula (I) is 4.0°±0.3°, 7.9°±0.3°, 9.1°±0.3°, 10.4°±0.3°, 11.1°±0.3°, 11.9°±0.3°, 12.9°±0.3°, 15.9°±0.3°, 18.2°±0.3°, 18.5°±0.3°, 18.8°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 21.4°±0.3°, 22.4°±0.3°, 23.1°±0.3°, 23.8°± The XRPD pattern has peaks at 0.3°, 24.4°±0.3°, 24.7°±0.3°, 26.0°±0.3°, 26.3°±0.3°, 26.6°±0.3°, 27.5°±0.3°, 28.8°±0.3°, 29.7°±0.3°, 30.1°±0.3°, 31.5°±0.3°, 32.1°±0.3°, 32.3°±0.3°, 32.7°±0.3°, 33.0°±0.3°, 33.4°±0.3°, 33.9°±0.3°, and 33.4°±0.3°2θ.

[0508]

[0579] In certain embodiments, form B of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 4.0°±0.2°, 11.1°±0.2°, and 12.9°±0.2°²θ.

[0509]

[0580] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.9°±0.2°, 9.1°±0.2°, 10.4°±0.2°, and 11.9°±0.2°²θ.

[0510]

[0581] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.9°±0.2°, 18.8°±0.2°, 22.4°±0.2°, 23.1°±0.2°, and 23.8°±0.2°2θ.

[0511]

[0582] In certain embodiments, the XRPD pattern further includes one or more peaks at 18.2°±0.2°, 18.5°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 21.4°±0.2°, 24.4°±0.2°, and 24.7°±0.2°²θ.

[0512]

[0583] In certain embodiments, the XRPD pattern further includes one or more peaks at 28.8°±0.2° and 31.5°±0.2°2θ.

[0513]

[0584] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.0°±0.2°, 26.3°±0.2°, 26.6°±0.2°, 27.5°±0.2°, 29.7°±0.2°, 30.1°±0.2°, 32.1°±0.2°, 32.3°±0.2°, 32.7°±0.2°, 33.0°±0.2°, 33.4°±0.2°, 33.9°±0.2°, and 33.4°±0.2°²θ.

[0514]

[0585] In certain embodiments, form B of the compound of formula (I) is 4.0°±0.2°, 7.9°±0.2°, 9.1°±0.2°, 10.4°±0.2°, 11.1°±0.2°, 11.9°±0.2°, 12.9°±0.2°, 15.9°±0.2°, 18.2°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 21.4°±0.2°, 22.4°±0.2°, 23.1°±0.2°, 23.8°±0.2° The XRPD pattern has one or more peaks at 2θ, 24.4°±0.2°, 24.7°±0.2°, 26.0°±0.2°, 26.3°±0.2°, 26.6°±0.2°, 27.5°±0.2°, 28.8°±0.2°, 29.7°±0.2°, 30.1°±0.2°, 31.5°±0.2°, 32.1°±0.2°, 32.3°±0.2°, 32.7°±0.2°, 33.0°±0.2°, 33.4°±0.2°, 33.9°±0.2°, and 33.4°±0.2°2θ.

[0515]

[0586] In certain embodiments, form B of the compound of formula (I) is 4.0°±0.2°, 7.9°±0.2°, 9.1°±0.2°, 10.4°±0.2°, 11.1°±0.2°, 11.9°±0.2°, 12.9°±0.2°, 15.9°±0.2°, 18.2°±0.2°, 18.5°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 21.4°±0.2°, 22.4°±0.2°, 23.1°±0.2°, 23.8°± The XRPD pattern has peaks at 0.2°, 24.4°±0.2°, 24.7°±0.2°, 26.0°±0.2°, 26.3°±0.2°, 26.6°±0.2°, 27.5°±0.2°, 28.8°±0.2°, 29.7°±0.2°, 30.1°±0.2°, 31.5°±0.2°, 32.1°±0.2°, 32.3°±0.2°, 32.7°±0.2°, 33.0°±0.2°, 33.4°±0.2°, 33.9°±0.2°, and 33.4°±0.2°2θ.

[0516]

[0587] In certain embodiments, form B of the compound of formula (I) has substantially the same XRPD pattern as that shown in Figure 30. In certain embodiments, form B of the compound of formula (I) has an XRPD pattern that includes one or more diffraction peaks (2θ) disclosed in Table 32.

[0517]

[0588] In certain embodiments, form B of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 89°C. In certain embodiments, form B of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 136°C. In certain embodiments, form B of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 197°C. In certain embodiments, form B of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activities with peak onset at approximately 89°C, approximately 136°C, and approximately 197°C. In certain embodiments, form B of the compound of formula (I) has a DSC thermogram that includes exothermic activity with a peak onset at approximately 164°C. In certain embodiments, form B of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 31.

[0518]

[0589] In certain embodiments, form B of the compound of formula (I) exhibits a weight loss of less than or equal to about 0.8% by weight when form B is heated from about 25°C to about 194°C. The weight loss exhibited by the crystalline form (e.g., form B of the compound of formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, form B of the compound of formula (I) has a TGA thermogram substantially identical to that shown in Figure 32.

[0519]

[0590] In certain embodiments, form B of the compound of formula (I) is an anhydrous crystalline form.

[0520] (3) Form C

[0591] In various embodiments, form C of the compound of formula (I) is provided herein. [ka]

[0521]

[0592] In certain embodiments, form C of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 6.7° and approximately 12.0°²θ.

[0522]

[0593] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 3.4°, 9.3°, 9.6°, 10.2°, 11.0°, 13.1°, 13.5°, and 14.4°²θ.

[0523]

[0594] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 18.9°, 19.3°, 22.6°, 22.8°, and 23.6°²θ.

[0524]

[0595] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.7°, 16.9°, 17.1°, 18.4°, 18.7°, 19.1°, 20.1°, 20.4°, 21.6°, 22.1°, 23.2°, 24.2°, 24.7°, and 25.0°²θ.

[0525]

[0596] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.9° and approximately 30.1°²θ.

[0526]

[0597] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.2°, 26.6°, 28.1°, 28.5°, 29.1°, 29.4°, 29.6°, and 30.7°²θ.

[0527]

[0598] In certain embodiments, form C of the compound of formula (I) is approximately 3.4°, approximately 6.7°, approximately 9.3°, approximately 9.6°, approximately 10.2°, approximately 11.0°, approximately 12.0°, approximately 13.1°, approximately 13.5°, approximately 14.4°, approximately 15.7°, approximately 16.9°, approximately 17.1°, approximately 18.4°, approximately 18.7°, approximately 18.9°, approximately 19.1°, approximately 19.3°, approximately 20.1°, approximately 20.4°, The XRPD pattern has one or more peaks at approximately 21.6°, 22.1°, 22.6°, 22.8°, 23.2°, 23.6°, 24.2°, 24.7°, 25.0°, 25.9°, 26.2°, 26.6°, 28.1°, 28.5°, 29.1°, 29.4°, 29.6°, 30.1°, and 30.7°²θ.

[0528]

[0599] In certain embodiments, form C of the compound of formula (I) is approximately 3.4°, approximately 6.7°, approximately 9.3°, approximately 9.6°, approximately 10.2°, approximately 11.0°, approximately 12.0°, approximately 13.1°, approximately 13.5°, approximately 14.4°, approximately 15.7°, approximately 16.9°, approximately 17.1°, approximately 18.4°, approximately 18.7°, approximately 18.9°, approximately 19.1°, approximately 19.3°, approximately 20.1°, approximately 20.4° The XRPD pattern has peaks at approximately 21.6°, 22.1°, 22.6°, 22.8°, 23.2°, 23.6°, 24.2°, 24.7°, 25.0°, 25.9°, 26.2°, 26.6°, 28.1°, 28.5°, 29.1°, 29.4°, 29.6°, 30.1°, and 30.7°²θ.

[0529]

[0600] In certain embodiments, form C of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 6.7°±0.3° and 12.0°±0.3°²θ.

[0530]

[0601] In certain embodiments, the XRPD pattern further includes one or more peaks at 3.4°±0.3°, 9.3°±0.3°, 9.6°±0.3°, 10.2°±0.3°, 11.0°±0.3°, 13.1°±0.3°, 13.5°±0.3°, and 14.4°±0.3°²θ.

[0531]

[0602] In certain embodiments, the XRPD pattern further includes one or more peaks at 18.9°±0.3°, 19.3°±0.3°, 22.6°±0.3°, 22.8°±0.3°, and 23.6°±0.3°2θ.

[0532]

[0603] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.7°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 18.4°±0.3°, 18.7°±0.3°, 19.1°±0.3°, 20.1°±0.3°, 20.4°±0.3°, 21.6°±0.3°, 22.1°±0.3°, 23.2°±0.3°, 24.2°±0.3°, 24.7°±0.3°, and 25.0°±0.3°²θ.

[0533]

[0604] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.9°±0.3° and 30.1°±0.3°2θ.

[0534]

[0605] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.2°±0.3°, 26.6°±0.3°, 28.1°±0.3°, 28.5°±0.3°, 29.1°±0.3°, 29.4°±0.3°, 29.6°±0.3°, and 30.7°±0.3°²θ.

[0535]

[0606] In certain embodiments, form C of the compound of formula (I) is 3.4°±0.3°, 6.7°±0.3°, 9.3°±0.3°, 9.6°±0.3°, 10.2°±0.3°, 11.0°±0.3°, 12.0°±0.3°, 13.1°±0.3°, 13.5°±0.3°, 14.4°±0.3°, 15.7°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 18.4°±0.3°, 18.7°±0.3°, 18.9°±0.3°, 19.1°±0.3°, 19.3°±0.3°, 20.1°±0.3°, 20.4°±0.3° The XRPD pattern has one or more peaks at 2θ, 21.6°±0.3°, 22.1°±0.3°, 22.6°±0.3°, 22.8°±0.3°, 23.2°±0.3°, 23.6°±0.3°, 24.2°±0.3°, 24.7°±0.3°, 25.0°±0.3°, 25.9°±0.3°, 26.2°±0.3°, 26.6°±0.3°, 28.1°±0.3°, 28.5°±0.3°, 29.1°±0.3°, 29.4°±0.3°, 29.6°±0.3°, 30.1°±0.3°, and 30.7°±0.3°2θ.

[0536]

[0607] In certain embodiments, form C of the compound of formula (I) is 3.4°±0.3°, 6.7°±0.3°, 9.3°±0.3°, 9.6°±0.3°, 10.2°±0.3°, 11.0°±0.3°, 12.0°±0.3°, 13.1°±0.3°, 13.5°±0.3°, 14.4°±0.3°, 15.7°±0.3°, 16.9°±0.3°, 17.1°±0.3°, 18.4°±0.3°, 18.7°±0.3°, 18.9°±0.3°, 19.1°±0.3°, 19.3°±0.3°, 20.1°±0.3°, 20.4°±0. The XRPD pattern has peaks at 0.3°, 21.6°±0.3°, 22.1°±0.3°, 22.6°±0.3°, 22.8°±0.3°, 23.2°±0.3°, 23.6°±0.3°, 24.2°±0.3°, 24.7°±0.3°, 25.0°±0.3°, 25.9°±0.3°, 26.2°±0.3°, 26.6°±0.3°, 28.1°±0.3°, 28.5°±0.3°, 29.1°±0.3°, 29.4°±0.3°, 29.6°±0.3°, 30.1°±0.3°, and 30.7°±0.3°2θ.

[0537]

[0608] In certain embodiments, form C of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 6.7°±0.2° and 12.0°±0.2°²θ.

[0538]

[0609] In certain embodiments, the XRPD pattern further includes one or more peaks at 3.4°±0.2°, 9.3°±0.2°, 9.6°±0.2°, 10.2°±0.2°, 11.0°±0.2°, 13.1°±0.2°, 13.5°±0.2°, and 14.4°±0.2°²θ.

[0539]

[0610] In certain embodiments, the XRPD pattern further includes one or more peaks at 18.9°±0.2°, 19.3°±0.2°, 22.6°±0.2°, 22.8°±0.2°, and 23.6°±0.2°²θ.

[0540]

[0611] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.7°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 18.4°±0.2°, 18.7°±0.2°, 19.1°±0.2°, 20.1°±0.2°, 20.4°±0.2°, 21.6°±0.2°, 22.1°±0.2°, 23.2°±0.2°, 24.2°±0.2°, 24.7°±0.2°, and 25.0°±0.2°²θ.

[0541]

[0612] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.9°±0.2° and 30.1°±0.2°2θ.

[0542]

[0613] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.2°±0.2°, 26.6°±0.2°, 28.1°±0.2°, 28.5°±0.2°, 29.1°±0.2°, 29.4°±0.2°, 29.6°±0.2°, and 30.7°±0.2°²θ.

[0543]

[0614] In certain embodiments, form C of the compound of formula (I) is 3.4°±0.2°, 6.7°±0.2°, 9.3°±0.2°, 9.6°±0.2°, 10.2°±0.2°, 11.0°±0.2°, 12.0°±0.2°, 13.1°±0.2°, 13.5°±0.2°, 14.4°±0.2°, 15.7°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 18.4°±0.2°, 18.7°±0.2°, 18.9°±0.2°, 19.1°±0.2°, 19.3°±0.2°, 20.1°±0.2°, 20.4°±0.2° The XRPD pattern has one or more peaks at 2θ, 21.6°±0.2°, 22.1°±0.2°, 22.6°±0.2°, 22.8°±0.2°, 23.2°±0.2°, 23.6°±0.2°, 24.2°±0.2°, 24.7°±0.2°, 25.0°±0.2°, 25.9°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 28.1°±0.2°, 28.5°±0.2°, 29.1°±0.2°, 29.4°±0.2°, 29.6°±0.2°, 30.1°±0.2°, and 30.7°±0.2°.

[0544]

[0615] In certain embodiments, form C of the compound of formula (I) is 3.4°±0.2°, 6.7°±0.2°, 9.3°±0.2°, 9.6°±0.2°, 10.2°±0.2°, 11.0°±0.2°, 12.0°±0.2°, 13.1°±0.2°, 13.5°±0.2°, 14.4°±0.2°, 15.7°±0.2°, 16.9°±0.2°, 17.1°±0.2°, 18.4°±0.2°, 18.7°±0.2°, 18.9°±0.2°, 19.1°±0.2°, 19.3°±0.2°, 20.1°±0.2°, 20.4°±0. The XRPD pattern has peaks at 0.2°, 21.6°±0.2°, 22.1°±0.2°, 22.6°±0.2°, 22.8°±0.2°, 23.2°±0.2°, 23.6°±0.2°, 24.2°±0.2°, 24.7°±0.2°, 25.0°±0.2°, 25.9°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 28.1°±0.2°, 28.5°±0.2°, 29.1°±0.2°, 29.4°±0.2°, 29.6°±0.2°, 30.1°±0.2°, and 30.7°±0.2°2θ.

[0545]

[0616] In certain embodiments, form C of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 35. In certain embodiments, form C of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 34.

[0546]

[0617] In certain embodiments, form C of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 91°C. In certain embodiments, form C of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 132°C. In certain embodiments, form C of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 203°C. In certain embodiments, form C of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activities with peak onset at approximately 91°C, approximately 132°C, and approximately 203°C. In certain embodiments, form C of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 65°C. In certain embodiments, form C of the compound of formula (I) has a DSC thermogram that includes exothermic activity with a peak onset at approximately 157°C. In certain embodiments, form C of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 36.

[0547]

[0618] In certain embodiments, form C of the compound of formula (I) exhibits a weight loss of less than about 2.7% by weight when form C is heated from about 25°C to about 199°C. The weight loss exhibited by the crystalline form (e.g., form C of the compound of formula (I)) can be determined, for example, using TGA. In certain embodiments, form C of the compound of formula (I) has substantially the same TGA thermogram as shown in Figure 37.

[0548]

[0619] In certain embodiments, form C of the compound of formula (I) is a crystalline solvate. In certain embodiments, form C of the compound of formula (I) is a crystalline acetonitrile solvate. In certain embodiments, form C of the compound of formula (I) is a crystalline ethyl acetate solvate.

[0549] (4) Form D

[0620] In various embodiments, form D of the compound of formula (I) is provided herein. [ka]

[0550]

[0621] In certain embodiments, form D of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 9.2°, approximately 10.3°, and approximately 10.6°²θ.

[0551]

[0622] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 7.4°, 7.6°, 11.0°, 12.0°, 12.2°, 12.8°, 13.0°, and 14.8°²θ.

[0552]

[0623] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.4°, 17.3°, 21.3°, and 22.6°²θ.

[0553]

[0624] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.1°, 16.0°, 16.9°, 17.6°, 18.1°, 18.5°, 19.0°, 19.5°, 19.7°, 20.3°, 21.8°, 22.0°, 22.2°, 22.9°, 23.3°, 23.6°, 24.0°, 24.4°, 24.6°, and 24.9°²θ.

[0554]

[0625] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.6°, 27.8°, 28.7°, and 32.2°²θ.

[0555]

[0626] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.1°, 25.8°, 26.2°, 26.7°, 27.0°, 27.6°, 28.2°, 29.0°, 29.2°, 30.2°, 30.9°, 31.5°, and 32.6°²θ.

[0556]

[0627] In certain embodiments, form D of the compound of formula (I) is approximately 7.4°, approximately 7.6°, approximately 9.2°, approximately 10.3°, approximately 10.6°, approximately 11.0°, approximately 12.0°, approximately 12.2°, approximately 12.8°, approximately 13.0°, approximately 14.8°, approximately 15.1°, approximately 16.0°, approximately 16.4°, approximately 16.9°, approximately 17.3°, approximately 17.6°, approximately 18.1°, approximately 18.5°, approximately 19.0°, approximately 19.5°, approximately 19.7°, approximately 20.3°, approximately 21.3°, approximately 21.8°, approximately 22.0°, approximately 22 The XRPD pattern has one or more peaks at 0.2°, approximately 22.6°, approximately 22.9°, approximately 23.3°, approximately 23.6°, approximately 24.0°, approximately 24.4°, approximately 24.6°, approximately 24.9°, approximately 25.1°, approximately 25.8°, approximately 26.2°, approximately 26.6°, approximately 26.7°, approximately 27.0°, approximately 27.6°, approximately 27.8°, approximately 28.2°, approximately 28.7°, approximately 29.0°, approximately 29.2°, approximately 30.2°, approximately 30.9°, approximately 31.5°, approximately 32.2°, and approximately 32.6°²θ.

[0557]

[0628] In certain embodiments, form D of the compound of formula (I) is approximately 7.4°, approximately 7.6°, approximately 9.2°, approximately 10.3°, approximately 10.6°, approximately 11.0°, approximately 12.0°, approximately 12.2°, approximately 12.8°, approximately 13.0°, approximately 14.8°, approximately 15.1°, approximately 16.0°, approximately 16.4°, approximately 16.9°, approximately 17.3°, approximately 17.6°, approximately 18.1°, approximately 18.5°, approximately 19.0°, approximately 19.5°, approximately 19.7°, approximately 20.3°, approximately 21.3°, approximately 21.8°, approximately 22.0°, approximately The XRPD pattern has peaks at 22.2°, approximately 22.6°, approximately 22.9°, approximately 23.3°, approximately 23.6°, approximately 24.0°, approximately 24.4°, approximately 24.6°, approximately 24.9°, approximately 25.1°, approximately 25.8°, approximately 26.2°, approximately 26.6°, approximately 26.7°, approximately 27.0°, approximately 27.6°, approximately 27.8°, approximately 28.2°, approximately 28.7°, approximately 29.0°, approximately 29.2°, approximately 30.2°, approximately 30.9°, approximately 31.5°, approximately 32.2°, and approximately 32.6°²θ.

[0558]

[0629] In certain embodiments, form D of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 9.2°±0.3°, 10.3°±0.3°, and 10.6°±0.3°2θ.

[0559]

[0630] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.4°±0.3°, 7.6°±0.3°, 11.0°±0.3°, 12.0°±0.3°, 12.2°±0.3°, 12.8°±0.3°, 13.0°±0.3°, and 14.8°±0.3°²θ.

[0560]

[0631] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.4°±0.3°, 17.3°±0.3°, 21.3°±0.3°, and 22.6°±0.3°²θ.

[0561]

[0632] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.3°, 16.0°±0.3°, 16.9°±0.3°, 17.6°±0.3°, 18.1°±0.3°, 18.5°±0.3°, 19.0°±0.3°, 19.5°±0.3°, 19.7°±0.3°, 20.3°±0.3°, 21.8°±0.3°, 22.0°±0.3°, 22.2°±0.3°, 22.9°±0.3°, 23.3°±0.3°, 23.6°±0.3°, 24.0°±0.3°, 24.4°±0.3°, 24.6°±0.3°, and 24.9°±0.3°²θ.

[0562]

[0633] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.6°±0.3°, 27.8°±0.3°, 28.7°±0.3°, and 32.2°±0.3°²θ.

[0563]

[0634] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.3°, 25.8°±0.3°, 26.2°±0.3°, 26.7°±0.3°, 27.0°±0.3°, 27.6°±0.3°, 28.2°±0.3°, 29.0°±0.3°, 29.2°±0.3°, 30.2°±0.3°, 30.9°±0.3°, 31.5°±0.3°, and 32.6°±0.3°²θ.

[0564]

[0635] In certain embodiments, form D of the compound of formula (I) is 7.4°±0.3°, 7.6°±0.3°, 9.2°±0.3°, 10.3°±0.3°, 10.6°±0.3°, 11.0°±0.3°, 12.0°±0.3°, 12.2°±0.3°, 12.8°±0.3°, 13.0°±0.3°, 14.8°±0.3°, 15.1°±0.3°, 16 0°±0.3°, 16.4°±0.3°, 16.9°±0.3°, 17.3°±0.3°, 17.6°±0.3°, 18.1°±0.3°, 18.5°±0.3°, 19.0°±0.3°, 19.5°±0.3°, 19.7°±0.3°, 20.3°±0.3°, 21.3°±0.3°, 21.8°±0.3°, 22.0°±0.3°, 22. 2°±0.3°, 22.6°±0.3°, 22.9°±0.3°, 23.3°±0.3°, 23.6°±0.3°, 24.0°±0.3°, 24.4°±0.3°, 24.6°±0.3°, 24.9°±0.3°, 25.1°±0.3°, 25.8°±0.3°, 26.2°±0.3°, 26.6°±0.3°, 26.7°±0.3°, 27.0 The XRPD pattern has one or more peaks at 2θ ± 0.3°, 27.6° ± 0.3°, 27.8° ± 0.3°, 28.2° ± 0.3°, 28.7° ± 0.3°, 29.0° ± 0.3°, 29.2° ± 0.3°, 30.2° ± 0.3°, 30.9° ± 0.3°, 31.5° ± 0.3°, 32.2° ± 0.3°, and 32.6° ± 0.3°.

[0565]

[0636] In certain embodiments, form D of the compound of formula (I) is 7.4°±0.3°, 7.6°±0.3°, 9.2°±0.3°, 10.3°±0.3°, 10.6°±0.3°, 11.0°±0.3°, 12.0°±0.3°, 12.2°±0.3°, 12.8°±0.3°, 13.0°±0.3°, 14.8°±0.3°, 15.1°±0.3°, 1 6.0°±0.3°, 16.4°±0.3°, 16.9°±0.3°, 17.3°±0.3°, 17.6°±0.3°, 18.1°±0.3°, 18.5°±0.3°, 19.0°±0.3°, 19.5°±0.3°, 19.7°±0.3°, 20.3°±0.3°, 21.3°±0.3°, 21.8°±0.3°, 22.0°±0.3°, 2 2.2°±0.3°, 22.6°±0.3°, 22.9°±0.3°, 23.3°±0.3°, 23.6°±0.3°, 24.0°±0.3°, 24.4°±0.3°, 24.6°±0.3°, 24.9°±0.3°, 25.1°±0.3°, 25.8°±0.3°, 26.2°±0.3°, 26.6°±0.3°, 26.7°±0.3°, 2 The XRPD pattern has peaks at 7.0°±0.3°, 27.6°±0.3°, 27.8°±0.3°, 28.2°±0.3°, 28.7°±0.3°, 29.0°±0.3°, 29.2°±0.3°, 30.2°±0.3°, 30.9°±0.3°, 31.5°±0.3°, 32.2°±0.3°, and 32.6°±0.3°2θ.

[0566]

[0637] In certain embodiments, form D of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 9.2°±0.2°, 10.3°±0.2°, and 10.6°±0.2°²θ.

[0567]

[0638] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.4°±0.2°, 7.6°±0.2°, 11.0°±0.2°, 12.0°±0.2°, 12.2°±0.2°, 12.8°±0.2°, 13.0°±0.2°, and 14.8°±0.2°²θ.

[0568]

[0639] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.4°±0.2°, 17.3°±0.2°, 21.3°±0.2°, and 22.6°±0.2°²θ.

[0569]

[0640] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.2°, 16.0°±0.2°, 16.9°±0.2°, 17.6°±0.2°, 18.1°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 19.5°±0.2°, 19.7°±0.2°, 20.3°±0.2°, 21.8°±0.2°, 22.0°±0.2°, 22.2°±0.2°, 22.9°±0.2°, 23.3°±0.2°, 23.6°±0.2°, 24.0°±0.2°, 24.4°±0.2°, 24.6°±0.2°, and 24.9°±0.2°²θ.

[0570]

[0641] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.6°±0.2°, 27.8°±0.2°, 28.7°±0.2°, and 32.2°±0.2°²θ.

[0571]

[0642] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.2°, 25.8°±0.2°, 26.2°±0.2°, 26.7°±0.2°, 27.0°±0.2°, 27.6°±0.2°, 28.2°±0.2°, 29.0°±0.2°, 29.2°±0.2°, 30.2°±0.2°, 30.9°±0.2°, 31.5°±0.2°, and 32.6°±0.2°²θ.

[0572]

[0643] In certain embodiments, form D of the compound of formula (I) is 7.4°±0.2°, 7.6°±0.2°, 9.2°±0.2°, 10.3°±0.2°, 10.6°±0.2°, 11.0°±0.2°, 12.0°±0.2°, 12.2°±0.2°, 12.8°±0.2°, 13.0°±0.2°, 14.8°±0.2°, 15.1°±0.2°, 16 0°±0.2°, 16.4°±0.2°, 16.9°±0.2°, 17.3°±0.2°, 17.6°±0.2°, 18.1°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 19.5°±0.2°, 19.7°±0.2°, 20.3°±0.2°, 21.3°±0.2°, 21.8°±0.2°, 22.0°±0.2°, 22. 2°±0.2°, 22.6°±0.2°, 22.9°±0.2°, 23.3°±0.2°, 23.6°±0.2°, 24.0°±0.2°, 24.4°±0.2°, 24.6°±0.2°, 24.9°±0.2°, 25.1°±0.2°, 25.8°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 26.7°±0.2°, 27.0 The XRPD pattern has one or more peaks at 2θ ± 0.2°, 27.6° ± 0.2°, 27.8° ± 0.2°, 28.2° ± 0.2°, 28.7° ± 0.2°, 29.0° ± 0.2°, 29.2° ± 0.2°, 30.2° ± 0.2°, 30.9° ± 0.2°, 31.5° ± 0.2°, 32.2° ± 0.2°, and 32.6° ± 0.2°.

[0573]

[0644] In certain embodiments, form D of the compound of formula (I) is 7.4°±0.2°, 7.6°±0.2°, 9.2°±0.2°, 10.3°±0.2°, 10.6°±0.2°, 11.0°±0.2°, 12.0°±0.2°, 12.2°±0.2°, 12.8°±0.2°, 13.0°±0.2°, 14.8°±0.2°, 15.1°±0.2°, 1 6.0°±0.2°, 16.4°±0.2°, 16.9°±0.2°, 17.3°±0.2°, 17.6°±0.2°, 18.1°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 19.5°±0.2°, 19.7°±0.2°, 20.3°±0.2°, 21.3°±0.2°, 21.8°±0.2°, 22.0°±0.2°, 2 2.2°±0.2°, 22.6°±0.2°, 22.9°±0.2°, 23.3°±0.2°, 23.6°±0.2°, 24.0°±0.2°, 24.4°±0.2°, 24.6°±0.2°, 24.9°±0.2°, 25.1°±0.2°, 25.8°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 26.7°±0.2°, 2 The XRPD pattern has peaks at 7.0°±0.2°, 27.6°±0.2°, 27.8°±0.2°, 28.2°±0.2°, 28.7°±0.2°, 29.0°±0.2°, 29.2°±0.2°, 30.2°±0.2°, 30.9°±0.2°, 31.5°±0.2°, 32.2°±0.2°, and 32.6°±0.2°2θ.

[0574]

[0645] In certain embodiments, form D of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 39. In certain embodiments, form D of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 36.

[0575]

[0646] In certain embodiments, form D of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 66°C. In certain embodiments, form D of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 138°C. In certain embodiments, form D of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activities with peak maximums at approximately 66°C and approximately 138°C. In certain embodiments, form D of the compound of formula (I) has a DSC thermogram that includes exothermic activity with a peak maximum at approximately 157°C. In certain embodiments, form D of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 40.

[0576]

[0647] In certain embodiments, form D of the compound of formula (I) exhibits a weight loss of less than about 1.0% by weight when form D is heated from about 25°C to about 108°C. The weight loss exhibited by the crystalline form (e.g., form D of the compound of formula (I)) can be determined, for example, using TGA. In certain embodiments, form D of the compound of formula (I) has substantially the same TGA thermogram as shown in Figure 41.

[0577]

[0648] In certain embodiments, form D of the compound of formula (I) is an anhydrous crystalline form.

[0578]

[0649] In certain embodiments, form D of the compound of formula (I) exhibits a mass change of less than about 1.9 wt% when measured at ambient temperature and with relative humidity varied between about 5% and about 95%. The weight change indicated by the crystalline form (e.g., form D of the compound of formula (I)) can be determined, for example, using dynamic water vapor adsorption / desorption (DVS). In certain embodiments, form D of the compound of formula (I) has substantially the same water adsorption isotherm as shown in Figure 42.

[0579] (5) Form E

[0650] In various embodiments, form E of the compound of formula (I) is provided herein. [ka]

[0580]

[0651] In certain embodiments, form E of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 6.7°, approximately 8.5°, approximately 8.8°, and approximately 10.2°²θ.

[0581]

[0652] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 7.2°, 11.1°, 11.4°, 12.2°, 13.5°, 14.2°, and 14.5°²θ.

[0582]

[0653] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.1°, 18.5°, 19.0°, 21.1°, 22.8°, and 23.4°²θ.

[0583]

[0654] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.1°, 16.0°, 16.8°, 17.0°, 17.6°, 17.7°, 19.2°, 19.7°, 20.5°, 21.0°, 21.7°, 22.2°, 24.1°, and 24.6°²θ.

[0584]

[0655] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.7°, approximately 26.1°, and approximately 27.2°²θ.

[0585]

[0656] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.1°, 26.6°, 27.7°, 28.2°, 29.2°, 29.5°, 30.1°, 30.4°, 30.9°, and 31.4°²θ.

[0586]

[0657] In certain embodiments, form E of the compound of formula (I) is approximately 6.7°, approximately 7.2°, approximately 8.5°, approximately 8.8°, approximately 10.2°, approximately 11.1°, approximately 11.4°, approximately 12.2°, approximately 13.5°, approximately 14.2°, approximately 14.5°, approximately 15.1°, approximately 16.0°, approximately 16.1°, approximately 16.8°, approximately 17.0°, approximately 17.6°, approximately 17.7°, approximately 18.5°, approximately 19.0°, approximately 19.2°, approximately 19.7°, and approximately 20. The XRPD pattern has one or more peaks at 5°, approximately 21.0°, approximately 21.1°, approximately 21.7°, approximately 22.2°, approximately 22.8°, approximately 23.4°, approximately 24.1°, approximately 24.6°, approximately 25.1°, approximately 25.7°, approximately 26.1°, approximately 26.6°, approximately 27.2°, approximately 27.7°, approximately 28.2°, approximately 29.2°, approximately 29.5°, approximately 30.1°, approximately 30.4°, approximately 30.9°, and approximately 31.4°²θ.

[0587]

[0658] In certain embodiments, form E of the compound of formula (I) is approximately 6.7°, approximately 7.2°, approximately 8.5°, approximately 8.8°, approximately 10.2°, approximately 11.1°, approximately 11.4°, approximately 12.2°, approximately 13.5°, approximately 14.2°, approximately 14.5°, approximately 15.1°, approximately 16.0°, approximately 16.1°, approximately 16.8°, approximately 17.0°, approximately 17.6°, approximately 17.7°, approximately 18.5°, approximately 19.0°, approximately 19.2°, approximately 19.7°, approximately The XRPD pattern has peaks at 20.5°, approximately 21.0°, approximately 21.1°, approximately 21.7°, approximately 22.2°, approximately 22.8°, approximately 23.4°, approximately 24.1°, approximately 24.6°, approximately 25.1°, approximately 25.7°, approximately 26.1°, approximately 26.6°, approximately 27.2°, approximately 27.7°, approximately 28.2°, approximately 29.2°, approximately 29.5°, approximately 30.1°, approximately 30.4°, approximately 30.9°, and approximately 31.4°²θ.

[0588]

[0659] In certain embodiments, form E of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 6.7°±0.3°, 8.5°±0.3°, 8.8°±0.3°, and 10.2°±0.3°²θ.

[0589]

[0660] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.2°±0.3°, 11.1°±0.3°, 11.4°±0.3°, 12.2°±0.3°, 13.5°±0.3°, 14.2°±0.3°, and 14.5°±0.3°2θ.

[0590]

[0661] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.1°±0.3°, 18.5°±0.3°, 19.0°±0.3°, 21.1°±0.3°, 22.8°±0.3°, and 23.4°±0.3°2θ.

[0591]

[0662] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.3°, 16.0°±0.3°, 16.8°±0.3°, 17.0°±0.3°, 17.6°±0.3°, 17.7°±0.3°, 19.2°±0.3°, 19.7°±0.3°, 20.5°±0.3°, 21.0°±0.3°, 21.7°±0.3°, 22.2°±0.3°, 24.1°±0.3°, and 24.6°±0.3°²θ.

[0592]

[0663] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.7°±0.3°, 26.1°±0.3°, and 27.2°±0.3°2θ.

[0593]

[0664] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.3°, 26.6°±0.3°, 27.7°±0.3°, 28.2°±0.3°, 29.2°±0.3°, 29.5°±0.3°, 30.1°±0.3°, 30.4°±0.3°, 30.9°±0.3°, and 31.4°±0.3°²θ.

[0594]

[0665] In certain embodiments, form E of the compound of formula (I) is 6.7°±0.3°, 7.2°±0.3°, 8.5°±0.3°, 8.8°±0.3°, 10.2°±0.3°, 11.1°±0.3°, 11.4°±0.3°, 12.2°±0.3°, 13.5°±0.3°, 14.2°±0.3°, 14. 5°±0.3°, 15.1°±0.3°, 16.0°±0.3°, 16.1°±0.3°, 16.8°±0.3°, 17.0°±0.3°, 17.6°±0.3°, 17.7°±0.3°, 18.5°±0.3°, 19.0°±0.3°, 19.2°±0.3°, 19.7°±0.3°, 20.5 °±0.3°, 21.0°±0.3°, 21.1°±0.3°, 21.7°±0.3°, 22.2°±0.3°, 22.8°±0.3°, 23.4°±0.3°, 24.1°±0.3°, 24.6°±0.3°, 25.1°±0.3°, 25.7°±0.3°, 26.1°±0.3°, 26.6° The XRPD pattern has one or more peaks at ±0.3°, 27.2°±0.3°, 27.7°±0.3°, 28.2°±0.3°, 29.2°±0.3°, 29.5°±0.3°, 30.1°±0.3°, 30.4°±0.3°, 30.9°±0.3°, and 31.4°±0.3°2θ.

[0595]

[0666] In certain embodiments, form E of the compound of formula (I) is 6.7°±0.3°, 7.2°±0.3°, 8.5°±0.3°, 8.8°±0.3°, 10.2°±0.3°, 11.1°±0.3°, 11.4°±0.3°, 12.2°±0.3°, 13.5°±0.3°, 14.2°±0.3°, 1 4.5°±0.3°, 15.1°±0.3°, 16.0°±0.3°, 16.1°±0.3°, 16.8°±0.3°, 17.0°±0.3°, 17.6°±0.3°, 17.7°±0.3°, 18.5°±0.3°, 19.0°±0.3°, 19.2°±0.3°, 19.7°±0.3°, 2 0.5°±0.3°, 21.0°±0.3°, 21.1°±0.3°, 21.7°±0.3°, 22.2°±0.3°, 22.8°±0.3°, 23.4°±0.3°, 24.1°±0.3°, 24.6°±0.3°, 25.1°±0.3°, 25.7°±0.3°, 26.1°±0.3°, 2 The XRPD pattern has peaks at 6.6°±0.3°, 27.2°±0.3°, 27.7°±0.3°, 28.2°±0.3°, 29.2°±0.3°, 29.5°±0.3°, 30.1°±0.3°, 30.4°±0.3°, 30.9°±0.3°, and 31.4°±0.3°2θ.

[0596]

[0667] In certain embodiments, form E of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 6.7°±0.2°, 8.5°±0.2°, 8.8°±0.2°, and 10.2°±0.2°²θ.

[0597]

[0668] In certain embodiments, the XRPD pattern further includes one or more peaks at 7.2°±0.2°, 11.1°±0.2°, 11.4°±0.2°, 12.2°±0.2°, 13.5°±0.2°, 14.2°±0.2°, and 14.5°±0.2°²θ.

[0598]

[0669] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.1°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 21.1°±0.2°, 22.8°±0.2°, and 23.4°±0.2°²θ.

[0599]

[0670] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.1°±0.2°, 16.0°±0.2°, 16.8°±0.2°, 17.0°±0.2°, 17.6°±0.2°, 17.7°±0.2°, 19.2°±0.2°, 19.7°±0.2°, 20.5°±0.2°, 21.0°±0.2°, 21.7°±0.2°, 22.2°±0.2°, 24.1°±0.2°, and 24.6°±0.2°²θ.

[0600]

[0671] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.7°±0.2°, 26.1°±0.2°, and 27.2°±0.2°²θ.

[0601]

[0672] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.1°±0.2°, 26.6°±0.2°, 27.7°±0.2°, 28.2°±0.2°, 29.2°±0.2°, 29.5°±0.2°, 30.1°±0.2°, 30.4°±0.2°, 30.9°±0.2°, and 31.4°±0.2°²θ.

[0602]

[0673] In certain embodiments, form E of the compound of formula (I) is 6.7°±0.2°, 7.2°±0.2°, 8.5°±0.2°, 8.8°±0.2°, 10.2°±0.2°, 11.1°±0.2°, 11.4°±0.2°, 12.2°±0.2°, 13.5°±0.2°, 14.2°±0.2°, 14. 5°±0.2°, 15.1°±0.2°, 16.0°±0.2°, 16.1°±0.2°, 16.8°±0.2°, 17.0°±0.2°, 17.6°±0.2°, 17.7°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 19.2°±0.2°, 19.7°±0.2°, 20.5 °±0.2°, 21.0°±0.2°, 21.1°±0.2°, 21.7°±0.2°, 22.2°±0.2°, 22.8°±0.2°, 23.4°±0.2°, 24.1°±0.2°, 24.6°±0.2°, 25.1°±0.2°, 25.7°±0.2°, 26.1°±0.2°, 26.6° The XRPD pattern has one or more peaks at ±0.2°, 27.2°±0.2°, 27.7°±0.2°, 28.2°±0.2°, 29.2°±0.2°, 29.5°±0.2°, 30.1°±0.2°, 30.4°±0.2°, 30.9°±0.2°, and 31.4°±0.2°2θ.

[0603]

[0674] In certain embodiments, form E of the compound of formula (I) is 6.7°±0.2°, 7.2°±0.2°, 8.5°±0.2°, 8.8°±0.2°, 10.2°±0.2°, 11.1°±0.2°, 11.4°±0.2°, 12.2°±0.2°, 13.5°±0.2°, 14.2°±0.2°, 1 4.5°±0.2°, 15.1°±0.2°, 16.0°±0.2°, 16.1°±0.2°, 16.8°±0.2°, 17.0°±0.2°, 17.6°±0.2°, 17.7°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 19.2°±0.2°, 19.7°±0.2°, 2 0.5°±0.2°, 21.0°±0.2°, 21.1°±0.2°, 21.7°±0.2°, 22.2°±0.2°, 22.8°±0.2°, 23.4°±0.2°, 24.1°±0.2°, 24.6°±0.2°, 25.1°±0.2°, 25.7°±0.2°, 26.1°±0.2°, 2 The XRPD pattern has peaks at 6.6°±0.2°, 27.2°±0.2°, 27.7°±0.2°, 28.2°±0.2°, 29.2°±0.2°, 29.5°±0.2°, 30.1°±0.2°, 30.4°±0.2°, 30.9°±0.2°, and 31.4°±0.2°2θ.

[0604]

[0675] In certain embodiments, form E of the compound of formula (I) has substantially the same XRPD pattern as that shown in Figure 43. In certain embodiments, form E of the compound of formula (I) has an XRPD pattern that includes one or more diffraction peaks (2θ) disclosed in Table 38.

[0605]

[0676] In certain embodiments, form E of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 40°C. In certain embodiments, form E of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 92°C. In certain embodiments, form E of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak maximum at approximately 137°C. In certain embodiments, form E of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activity with peak maximums at approximately 40°C, approximately 92°C, and approximately 137°C. In certain embodiments, form E of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 202°C. In certain embodiments, form E of the compound of formula (I) has a DSC thermogram that includes exothermic activity with a peak maximum at approximately 161°C. In certain embodiments, form E of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 44.

[0606]

[0677] In certain embodiments, form E of the compound of formula (I) exhibits a weight loss of about 9.0% by weight or less when form E is heated from about 25°C to about 219°C. The weight loss exhibited by the crystalline form (e.g., form E of the compound of formula (I)) can be determined, for example, using TGA. In certain embodiments, form E of the compound of formula (I) has substantially the same TGA thermogram as shown in Figure 45.

[0607]

[0678] In certain embodiments, form E of the compound of formula (I) is a crystalline solvate. In certain embodiments, form E of the compound of formula (I) is a crystalline ethyl acetate solvate.

[0608] (6) Form H

[0679] In various embodiments, form H of the compound of formula (I) is provided herein. [ka]

[0609]

[0680] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern with a peak at approximately 8.1°2θ. In certain embodiments, form H of the compound of formula (I) has an XRPD pattern with a peak at approximately 9.4°2θ. In certain embodiments, form H of the compound of formula (I) has an XRPD pattern with one or more peaks at approximately 8.1° and approximately 9.4°2θ.

[0610]

[0681] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.6°, 16.3°, 16.9°, 17.0°, 18.4°, 18.8°, 19.9°, 20.2°, 20.5°, 21.5°, 21.6°, 21.8°, 24.5°, and 26.3°²θ.

[0611]

[0682] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 8.1°, 9.4°, 15.6°, 16.3°, 16.9°, 17.0°, 18.4°, 18.8°, 19.9°, 20.2°, 20.5°, 21.5°, 21.6°, 21.8°, 24.5°, and 26.3°²θ.

[0612]

[0683] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern with peaks at approximately 8.1°, 9.4°, 15.6°, 16.3°, 16.9°, 17.0°, 18.4°, 18.8°, 19.9°, 20.2°, 20.5°, 21.5°, 21.6°, 21.8°, 24.5°, and 26.3°²θ.

[0613]

[0684] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 8.1° and approximately 9.4°²θ.

[0614]

[0685] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 5.3°, 6.9°, 8.1°, 9.4°, 9.7°, 10.7°, 11.6°, 12.3°, 12.4°, 13.5°, 13.8°, and 14.7°²θ.

[0615]

[0686] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.3°, 16.9°, 17.0°, 18.4°, 18.8°, 19.9°, 20.2°, 20.5°, 21.6°, and 24.5°²θ.

[0616]

[0687] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.6°, 17.7°, 19.4°, 20.8°, 21.2°, 21.5°, 21.8°, 22.4°, 22.8°, 23.1°, 24.3°, and 24.9°²θ.

[0617]

[0688] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.3°2θ.

[0618]

[0689] In certain embodiments, form H of the compound of formula (I) is approximately 5.3°, approximately 6.9°, approximately 8.1°, approximately 9.4°, approximately 9.7°, approximately 10.7°, approximately 11.6°, approximately 12.3°, approximately 12.4°, approximately 13.5°, approximately 13.8°, approximately 14.7°, approximately 15.6°, approximately 16.0°, approximately 16.3°, approximately 16.9°, approximately 17.0°, approximately 17.7°, approximately 18.4°, approximately 18.8°, approximately 19.4°, and approximately 19. The XRPD pattern has one or more peaks at 9°, approximately 20.2°, approximately 20.5°, approximately 20.8°, approximately 21.2°, approximately 21.5°, approximately 21.6°, approximately 21.8°, approximately 22.4°, approximately 22.8°, approximately 23.1°, approximately 24.3°, approximately 24.5°, approximately 24.9°, approximately 25.6°, approximately 26.3°, approximately 26.9°, approximately 28.2°, approximately 29.0°, approximately 29.3°, and approximately 30.0°²θ.

[0619]

[0690] In certain embodiments, form H of the compound of formula (I) is approximately 5.3°, approximately 6.9°, approximately 8.1°, approximately 9.4°, approximately 9.7°, approximately 10.7°, approximately 11.6°, approximately 12.3°, approximately 12.4°, approximately 13.5°, approximately 13.8°, approximately 14.7°, approximately 15.6°, approximately 16.0°, approximately 16.3°, approximately 16.9°, approximately 17.0°, approximately 17.7°, approximately 18.4°, approximately 18.8°, approximately 19.4°, approximately 1 The XRPD pattern has peaks at 9.9°, approximately 20.2°, approximately 20.5°, approximately 20.8°, approximately 21.2°, approximately 21.5°, approximately 21.6°, approximately 21.8°, approximately 22.4°, approximately 22.8°, approximately 23.1°, approximately 24.3°, approximately 24.5°, approximately 24.9°, approximately 25.6°, approximately 26.3°, approximately 26.9°, approximately 28.2°, approximately 29.0°, approximately 29.3°, and approximately 30.0°²θ.

[0620]

[0691] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern including a peak at 8.1°±0.3°2θ. In certain embodiments, form H of the compound of formula (I) has an XRPD pattern including a peak at 9.4°±0.3°2θ. In certain embodiments, form H of the compound of formula (I) has an XRPD pattern including one or more peaks at 8.1°±0.3° and 9.4°±0.3°2θ.

[0621]

[0692] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.0°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 20.5°±0.3°, 21.5°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 24.5°±0.3°, and 26.3°±0.3°²θ.

[0622]

[0693] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.3°, 9.4°±0.3°, 15.6°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.0°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 20.5°±0.3°, 21.5°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 24.5°±0.3°, and 26.3°±0.3°2θ.

[0623]

[0694] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes peaks at 8.1°±0.3°, 9.4°±0.3°, 15.6°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.0°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 20.5°±0.3°, 21.5°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 24.5°±0.3°, and 26.3°±0.3°2θ.

[0624]

[0695] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.3° and 9.4°±0.3°2θ.

[0625]

[0696] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.3°±0.3°, 6.9°±0.3°, 8.1°±0.3°, 9.4°±0.3°, 9.7°±0.3°, 10.7°±0.3°, 11.6°±0.3°, 12.3°±0.3°, 12.4°±0.3°, 13.5°±0.3°, 13.8°±0.3°, and 14.7°±0.3°²θ.

[0626]

[0697] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.3°±0.3°, 16.9°±0.3°, 17.0°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 20.5°±0.3°, 21.6°±0.3°, and 24.5°±0.3°²θ.

[0627]

[0698] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.3°, 17.7°±0.3°, 19.4°±0.3°, 20.8°±0.3°, 21.2°±0.3°, 21.5°±0.3°, 21.8°±0.3°, 22.4°±0.3°, 22.8°±0.3°, 23.1°±0.3°, 24.3°±0.3°, and 24.9°±0.3°2θ.

[0628]

[0699] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.3°±0.3°2θ.

[0629]

[0700] In certain embodiments, form H of the compound of formula (I) is 5.3°±0.3°, 6.9°±0.3°, 8.1°±0.3°, 9.4°±0.3°, 9.7°±0.3°, 10.7°±0.3°, 11.6°±0.3°, 12.3°±0.3°, 12.4°±0.3°, 13.5°±0.3°, 13.8°±0.3°, 14.7°±0.3°, 15.6°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.0°±0.3°, 17.7°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.4°±0.3°, 19.9° The XRPD pattern has one or more peaks at 2θ ± 0.3°, 20.2° ± 0.3°, 20.5° ± 0.3°, 20.8° ± 0.3°, 21.2° ± 0.3°, 21.5° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.4° ± 0.3°, 22.8° ± 0.3°, 23.1° ± 0.3°, 24.3° ± 0.3°, 24.5° ± 0.3°, 24.9° ± 0.3°, 25.6° ± 0.3°, 26.3° ± 0.3°, 26.9° ± 0.3°, 28.2° ± 0.3°, 29.0° ± 0.3°, 29.3° ± 0.3°, and 30.0° ± 0.3°.

[0630]

[0701] In certain embodiments, form H of the compound of formula (I) is 5.3°±0.3°, 6.9°±0.3°, 8.1°±0.3°, 9.4°±0.3°, 9.7°±0.3°, 10.7°±0.3°, 11.6°±0.3°, 12.3°±0.3°, 12.4°±0.3°, 13.5°±0.3°, 13.8°±0.3°, 14.7°±0.3°, 15.6°±0.3°, 16.0°±0.3°, 16.3°±0.3°, 16.9°±0.3°, 17.0°±0.3°, 17.7°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.4°±0.3°, 19 The XRPD pattern has peaks at 0.9°±0.3°, 20.2°±0.3°, 20.5°±0.3°, 20.8°±0.3°, 21.2°±0.3°, 21.5°±0.3°, 21.6°±0.3°, 21.8°±0.3°, 22.4°±0.3°, 22.8°±0.3°, 23.1°±0.3°, 24.3°±0.3°, 24.5°±0.3°, 24.9°±0.3°, 25.6°±0.3°, 26.3°±0.3°, 26.9°±0.3°, 28.2°±0.3°, 29.0°±0.3°, 29.3°±0.3°, and 30.0°±0.3°2θ.

[0631]

[0702] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern including a peak at 8.1°±0.2°2θ. In certain embodiments, form H of the compound of formula (I) has an XRPD pattern including a peak at 9.4°±0.2°2θ. In certain embodiments, form H of the compound of formula (I) has an XRPD pattern including one or more peaks at 8.1°±0.2° and 9.4°±0.2°2θ.

[0632]

[0703] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.0°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 20.5°±0.2°, 21.5°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 24.5°±0.2°, and 26.3°±0.2°²θ.

[0633]

[0704] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.2°, 9.4°±0.2°, 15.6°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.0°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 20.5°±0.2°, 21.5°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 24.5°±0.2°, and 26.3°±0.2°²θ.

[0634]

[0705] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes peaks at 8.1°±0.2°, 9.4°±0.2°, 15.6°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.0°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 20.5°±0.2°, 21.5°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 24.5°±0.2°, and 26.3°±0.2°2θ.

[0635]

[0706] In certain embodiments, form H of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.1°±0.2° and 9.4°±0.2°²θ.

[0636]

[0707] In certain embodiments, the XRPD pattern further includes one or more peaks at 5.3°±0.2°, 6.9°±0.2°, 8.1°±0.2°, 9.4°±0.2°, 9.7°±0.2°, 10.7°±0.2°, 11.6°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 13.5°±0.2°, 13.8°±0.2°, and 14.7°±0.2°²θ.

[0637]

[0708] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.3°±0.2°, 16.9°±0.2°, 17.0°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 20.5°±0.2°, 21.6°±0.2°, and 24.5°±0.2°²θ.

[0638]

[0709] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.6°±0.2°, 17.7°±0.2°, 19.4°±0.2°, 20.8°±0.2°, 21.2°±0.2°, 21.5°±0.2°, 21.8°±0.2°, 22.4°±0.2°, 22.8°±0.2°, 23.1°±0.2°, 24.3°±0.2°, and 24.9°±0.2°²θ.

[0639]

[0710] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.3°±0.2°2θ.

[0640]

[0711] In certain embodiments, form H of the compound of formula (I) is 5.3°±0.2°, 6.9°±0.2°, 8.1°±0.2°, 9.4°±0.2°, 9.7°±0.2°, 10.7°±0.2°, 11.6°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 13.5°±0.2°, 13.8°±0.2°, 14.7°±0.2°, 15.6°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.0°±0.2°, 17.7°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 19.9° The XRPD pattern has one or more peaks at 2θ ± 0.2°, 20.2° ± 0.2°, 20.5° ± 0.2°, 20.8° ± 0.2°, 21.2° ± 0.2°, 21.5° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 22.4° ± 0.2°, 22.8° ± 0.2°, 23.1° ± 0.2°, 24.3° ± 0.2°, 24.5° ± 0.2°, 24.9° ± 0.2°, 25.6° ± 0.2°, 26.3° ± 0.2°, 26.9° ± 0.2°, 28.2° ± 0.2°, 29.0° ± 0.2°, 29.3° ± 0.2°, and 30.0° ± 0.2°.

[0641]

[0712] In certain embodiments, form H of the compound of formula (I) is 5.3°±0.2°, 6.9°±0.2°, 8.1°±0.2°, 9.4°±0.2°, 9.7°±0.2°, 10.7°±0.2°, 11.6°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 13.5°±0.2°, 13.8°±0.2°, 14.7°±0.2°, 15.6°±0.2°, 16.0°±0.2°, 16.3°±0.2°, 16.9°±0.2°, 17.0°±0.2°, 17.7°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 19 The XRPD pattern has peaks at 0.9°±0.2°, 20.2°±0.2°, 20.5°±0.2°, 20.8°±0.2°, 21.2°±0.2°, 21.5°±0.2°, 21.6°±0.2°, 21.8°±0.2°, 22.4°±0.2°, 22.8°±0.2°, 23.1°±0.2°, 24.3°±0.2°, 24.5°±0.2°, 24.9°±0.2°, 25.6°±0.2°, 26.3°±0.2°, 26.9°±0.2°, 28.2°±0.2°, 29.0°±0.2°, 29.3°±0.2°, and 30.0°±0.2°2θ.

[0642]

[0713] In certain embodiments, form H of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 46. In certain embodiments, form H of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 39.

[0643]

[0714] In certain embodiments, form H of the compound of formula (I) has a DSC thermogram that includes endothermic properties with a peak onset at approximately 205°C. In certain embodiments, form H of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 47.

[0644]

[0715] In certain embodiments, the form H of the compound of formula (I) is in an anhydrous crystalline form.

[0645] (7) Material F

[0716] In various embodiments, materials (e.g., pharmaceutical materials) comprising crystalline forms of the compound of formula (I) are provided herein. [ka]

[0646]

[0717] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 12.9° and approximately 13.6°²θ.

[0647]

[0718] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 4.0°, 7.7°, 9.1°, 9.4°, 10.5°, 11.1°, and 11.9°²θ.

[0648]

[0719] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.4°, 15.8°, 18.4°, 18.8°, 22.4°, 23.1°, and 23.8°²θ.

[0649]

[0720] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 16.7°, 19.4°, 19.9°, 20.2°, 21.0°, 21.4°, 22.7°, and 24.7°²θ.

[0650]

[0721] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.8° and approximately 28.8°²θ.

[0651]

[0722] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.3°, 26.5°, 27.6°, and 29.6°²θ.

[0652]

[0723] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 4.0°, 7.7°, 9.1°, 9.4°, 10.5°, 11.1°, 11.9°, 12.9°, 13.6°, 15.4°, 15.8°, 16.7°, 18.4°, 18.8°, 19.4°, 19.9°, 20.2°, 21.0°, 21.4°, 22.4°, 22.7°, 23.1°, 23.8°, 24.7°, 25.3°, 25.8°, 26.5°, 27.6°, 28.8°, and 29.6°²θ.

[0653]

[0724] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern with peaks at approximately 4.0°, 7.7°, 9.1°, 9.4°, 10.5°, 11.1°, 11.9°, 12.9°, 13.6°, 15.4°, 15.8°, 16.7°, 18.4°, 18.8°, 19.4°, 19.9°, 20.2°, 21.0°, 21.4°, 22.4°, 22.7°, 23.1°, 23.8°, 24.7°, 25.3°, 25.8°, 26.5°, 27.6°, 28.8°, and 29.6°²θ.

[0654]

[0725] In certain embodiments, a material comprising a crystalline form of the compound of formula (I) having XRPD peaks at approximately 4.0°, 7.7°, 9.1°, 9.4°, 10.5°, 11.1°, 11.9°, 12.9°, 13.6°, 15.4°, 15.8°, 16.7°, 18.4°, 18.8°, 19.4°, 19.9°, 20.2°, 21.0°, 21.4°, 22.4°, 22.7°, 23.1°, 23.8°, 24.7°, 25.3°, 25.8°, 26.5°, 27.6°, 28.8°, and 29.6°²θ may be referred to herein as “Material F”.

[0655]

[0726] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 12.9°±0.3° and 13.6°±0.3°2θ.

[0656]

[0727] In certain embodiments, the XRPD pattern further includes one or more peaks at 4.0°±0.3°, 7.7°±0.3°, 9.1°±0.3°, 9.4°±0.3°, 10.5°±0.3°, 11.1°±0.3°, and 11.9°±0.3°²θ.

[0657]

[0728] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.3°, 15.8°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 22.4°±0.3°, 23.1°±0.3°, and 23.8°±0.3°2θ.

[0658]

[0729] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.7°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 21.0°±0.3°, 21.4°±0.3°, 22.7°±0.3°, and 24.7°±0.3°2θ.

[0659]

[0730] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.8°±0.3° and 28.8°±0.3°2θ.

[0660]

[0731] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.3°, 26.5°±0.3°, 27.6°±0.3°, and 29.6°±0.3°2θ.

[0661]

[0732] In certain embodiments, the crystalline forms of the compound of formula (I) are 4.0°±0.3°, 7.7°±0.3°, 9.1°±0.3°, 9.4°±0.3°, 10.5°±0.3°, 11.1°±0.3°, 11.9°±0.3°, 12.9°±0.3°, 13.6°±0.3°, 15.4°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.4°±0.3°, and 19. The XRPD pattern has one or more peaks at 9°±0.3°, 20.2°±0.3°, 21.0°±0.3°, 21.4°±0.3°, 22.4°±0.3°, 22.7°±0.3°, 23.1°±0.3°, 23.8°±0.3°, 24.7°±0.3°, 25.3°±0.3°, 25.8°±0.3°, 26.5°±0.3°, 27.6°±0.3°, 28.8°±0.3°, and 29.6°±0.3°2θ.

[0662]

[0733] In certain embodiments, the crystalline forms of the compound of formula (I) are 4.0°±0.3°, 7.7°±0.3°, 9.1°±0.3°, 9.4°±0.3°, 10.5°±0.3°, 11.1°±0.3°, 11.9°±0.3°, 12.9°±0.3°, 13.6°±0.3°, 15.4°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.4°±0.3°, 1 The XRPD pattern has peaks at 9.9°±0.3°, 20.2°±0.3°, 21.0°±0.3°, 21.4°±0.3°, 22.4°±0.3°, 22.7°±0.3°, 23.1°±0.3°, 23.8°±0.3°, 24.7°±0.3°, 25.3°±0.3°, 25.8°±0.3°, 26.5°±0.3°, 27.6°±0.3°, 28.8°±0.3°, and 29.6°±0.3°2θ.

[0663]

[0734] In certain embodiments, the values ​​are 4.0°±0.3°, 7.7°±0.3°, 9.1°±0.3°, 9.4°±0.3°, 10.5°±0.3°, 11.1°±0.3°, 11.9°±0.3°, 12.9°±0.3°, 13.6°±0.3°, 15.4°±0.3°, 15.8°±0.3°, 16.7°±0.3°, 18.4°±0.3°, 18.8°±0.3°, 19.4°±0.3°, 19.9°±0.3°, 20.2°±0.3°, 21 Materials containing crystalline forms of the compound of formula (I) with XRPD peaks at 0.0°±0.3°, 21.4°±0.3°, 22.4°±0.3°, 22.7°±0.3°, 23.1°±0.3°, 23.8°±0.3°, 24.7°±0.3°, 25.3°±0.3°, 25.8°±0.3°, 26.5°±0.3°, 27.6°±0.3°, 28.8°±0.3°, and 29.6°±0.3°2θ may be referred to herein as "material F".

[0664]

[0735] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 12.9°±0.2° and 13.6°±0.2°2θ.

[0665]

[0736] In certain embodiments, the XRPD pattern further includes one or more peaks at 4.0°±0.2°, 7.7°±0.2°, 9.1°±0.2°, 9.4°±0.2°, 10.5°±0.2°, 11.1°±0.2°, and 11.9°±0.2°²θ.

[0666]

[0737] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.4°±0.2°, 15.8°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 22.4°±0.2°, 23.1°±0.2°, and 23.8°±0.2°2θ.

[0667]

[0738] In certain embodiments, the XRPD pattern further includes one or more peaks at 16.7°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 21.0°±0.2°, 21.4°±0.2°, 22.7°±0.2°, and 24.7°±0.2°²θ.

[0668]

[0739] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.8°±0.2° and 28.8°±0.2°2θ.

[0669]

[0740] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.2°, 26.5°±0.2°, 27.6°±0.2°, and 29.6°±0.2°²θ.

[0670]

[0741] In certain embodiments, the crystalline forms of the compound of formula (I) are 4.0°±0.2°, 7.7°±0.2°, 9.1°±0.2°, 9.4°±0.2°, 10.5°±0.2°, 11.1°±0.2°, 11.9°±0.2°, 12.9°±0.2°, 13.6°±0.2°, 15.4°±0.2°, 15.8°±0.2°, 16.7°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.4°±0.2°, and 19. The XRPD pattern has one or more peaks at 9°±0.2°, 20.2°±0.2°, 21.0°±0.2°, 21.4°±0.2°, 22.4°±0.2°, 22.7°±0.2°, 23.1°±0.2°, 23.8°±0.2°, 24.7°±0.2°, 25.3°±0.2°, 25.8°±0.2°, 26.5°±0.2°, 27.6°±0.2°, 28.8°±0.2°, and 29.6°±0.2°2θ.

[0671]

[0742] In certain embodiments, the crystalline forms of the compound of formula (I) are 4.0°±0.2°, 7.7°±0.2°, 9.1°±0.2°, 9.4°±0.2°, 10.5°±0.2°, 11.1°±0.2°, 11.9°±0.2°, 12.9°±0.2°, 13.6°±0.2°, 15.4°±0.2°, 15.8°±0.2°, 16.7°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 1 The XRPD pattern has peaks at 9.9°±0.2°, 20.2°±0.2°, 21.0°±0.2°, 21.4°±0.2°, 22.4°±0.2°, 22.7°±0.2°, 23.1°±0.2°, 23.8°±0.2°, 24.7°±0.2°, 25.3°±0.2°, 25.8°±0.2°, 26.5°±0.2°, 27.6°±0.2°, 28.8°±0.2°, and 29.6°±0.2°2θ.

[0672]

[0743] In certain embodiments, the values ​​are 4.0°±0.2°, 7.7°±0.2°, 9.1°±0.2°, 9.4°±0.2°, 10.5°±0.2°, 11.1°±0.2°, 11.9°±0.2°, 12.9°±0.2°, 13.6°±0.2°, 15.4°±0.2°, 15.8°±0.2°, 16.7°±0.2°, 18.4°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 19.9°±0.2°, 20.2°±0.2°, 2 Materials containing crystalline forms of the compound of formula (I) with XRPD peaks at 1.0°±0.2°, 21.4°±0.2°, 22.4°±0.2°, 22.7°±0.2°, 23.1°±0.2°, 23.8°±0.2°, 24.7°±0.2°, 25.3°±0.2°, 25.8°±0.2°, 26.5°±0.2°, 27.6°±0.2°, 28.8°±0.2°, and 29.6°±0.2° may be referred to herein as "material F".

[0673]

[0744] In certain embodiments, material F of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 48. In certain embodiments, material F of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 40.

[0674]

[0745] In certain embodiments, the material F of the compound of formula (I) includes the anhydrous crystalline form of the compound of formula (I).

[0675] (8) Material G

[0746] In various embodiments, materials (e.g., pharmaceutical materials) comprising crystalline forms of the compound of formula (I) are provided herein. [ka]

[0676]

[0747] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern that includes one or more peaks at approximately 8.7°, approximately 9.9°, and approximately 10.7°²θ.

[0677]

[0748] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 6.9°, 7.3°, 8.9°, 9.5°, 9.9°, 10.4°, 11.0°, 11.3°, 11.5°, 11.7°, 12.3°, 12.8°, 13.8°, and 14.8°²θ.

[0678]

[0749] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 17.5°, 18.6°, 21.3°, 21.5°, 22.3°, and 22.6°²θ.

[0679]

[0750] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 15.2°, 15.3°, 15.7°, 16.5°, 16.8°, 17.8°, 19.0°, 19.4°, 19.8°, 20.5°, 20.8°, 22.1°, 23.7°, 24.1°, 24.4°, 24.7°, and 25.0°²θ.

[0680]

[0751] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 25.3°, approximately 25.6°, and approximately 26.1°²θ.

[0681]

[0752] In certain embodiments, the XRPD pattern further includes one or more peaks at approximately 26.7°, 27.0°, 27.5°, 27.9°, 28.3°, and 28.9°²θ.

[0682]

[0753] In certain embodiments, the crystalline forms of the compound of formula (I) are approximately 6.9°, 7.3°, 8.7°, 8.9°, 9.5°, 9.9°, 10.4°, 10.7°, 11.0°, 11.3°, 11.5°, 11.7°, 12.3°, 12.8°, 13.8°, 14.8°, 15.2°, 15.3°, 15.7°, 16.5°, 16.8°, 17.5°, 17.8°, 18.6°, and 19. The XRPD pattern has one or more peaks at 0°, approximately 19.4°, approximately 19.8°, approximately 20.5°, approximately 20.8°, approximately 21.3°, approximately 21.5°, approximately 22.1°, approximately 22.3°, approximately 22.6°, approximately 23.7°, approximately 24.1°, approximately 24.4°, approximately 24.7°, approximately 25.0°, approximately 25.3°, approximately 25.6°, approximately 26.1°, approximately 26.7°, approximately 27.0°, approximately 27.5°, approximately 27.9°, approximately 28.3°, and approximately 28.9°²θ.

[0683]

[0754] In certain embodiments, the crystalline form of the compound of formula (I) is approximately 6.9°, approximately 7.3°, approximately 8.7°, approximately 8.9°, approximately 9.5°, approximately 9.9°, approximately 10.4°, approximately 10.7°, approximately 11.0°, approximately 11.3°, approximately 11.5°, approximately 11.7°, approximately 12.3°, approximately 12.8°, approximately 13.8°, approximately 14.8°, approximately 15.2°, approximately 15.3°, approximately 15.7°, approximately 16.5°, approximately 16.8°, approximately 17.5°, approximately 17.8°, approximately 18.6°, approximately 1 The XRPD pattern has peaks at 9.0°, approximately 19.4°, approximately 19.8°, approximately 20.5°, approximately 20.8°, approximately 21.3°, approximately 21.5°, approximately 22.1°, approximately 22.3°, approximately 22.6°, approximately 23.7°, approximately 24.1°, approximately 24.4°, approximately 24.7°, approximately 25.0°, approximately 25.3°, approximately 25.6°, approximately 26.1°, approximately 26.7°, approximately 27.0°, approximately 27.5°, approximately 27.9°, approximately 28.3°, and approximately 28.9°²θ.

[0684]

[0755] In certain embodiments, the angles are approximately 6.9°, 7.3°, 8.7°, 8.9°, 9.5°, 9.9°, 10.4°, 10.7°, 11.0°, 11.3°, 11.5°, 11.7°, 12.3°, 12.8°, 13.8°, 14.8°, 15.2°, 15.3°, 15.7°, 16.5°, 16.8°, 17.5°, 17.8°, 18.6°, 19.0°, 19.4°, 19.8°, and 20. Materials containing crystalline forms of the compound of formula (I) with XRPD peaks at 5°, approximately 20.8°, approximately 21.3°, approximately 21.5°, approximately 22.1°, approximately 22.3°, approximately 22.6°, approximately 23.7°, approximately 24.1°, approximately 24.4°, approximately 24.7°, approximately 25.0°, approximately 25.3°, approximately 25.6°, approximately 26.1°, approximately 26.7°, approximately 27.0°, approximately 27.5°, approximately 27.9°, approximately 28.3°, and approximately 28.9°²θ may be referred to herein as "material G".

[0685]

[0756] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.7°±0.3°, 9.9°±0.3°, and 10.7°±0.3°2θ.

[0686]

[0757] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.9°±0.3°, 7.3°±0.3°, 8.9°±0.3°, 9.5°±0.3°, 9.9°±0.3°, 10.4°±0.3°, 11.0°±0.3°, 11.3°±0.3°, 11.5°±0.3°, 11.7°±0.3°, 12.3°±0.3°, 12.8°±0.3°, 13.8°±0.3°, and 14.8°±0.3°²θ.

[0687]

[0758] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.5°±0.3°, 18.6°±0.3°, 21.3°±0.3°, 21.5°±0.3°, 22.3°±0.3°, and 22.6°±0.3°2θ.

[0688]

[0759] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.2°±0.3°, 15.3°±0.3°, 15.7°±0.3°, 16.5°±0.3°, 16.8°±0.3°, 17.8°±0.3°, 19.0°±0.3°, 19.4°±0.3°, 19.8°±0.3°, 20.5°±0.3°, 20.8°±0.3°, 22.1°±0.3°, 23.7°±0.3°, 24.1°±0.3°, 24.4°±0.3°, 24.7°±0.3°, and 25.0°±0.3°²θ.

[0689]

[0760] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.3°, 25.6°±0.3°, and 26.1°±0.3°2θ.

[0690]

[0761] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.7°±0.3°, 27.0°±0.3°, 27.5°±0.3°, 27.9°±0.3°, 28.3°±0.3°, and 28.9°±0.3°2θ.

[0691]

[0762] In certain embodiments, the crystalline forms of the compound of formula (I) are 6.9°±0.3°, 7.3°±0.3°, 8.7°±0.3°, 8.9°±0.3°, 9.5°±0.3°, 9.9°±0.3°, 10.4°±0.3°, 10.7°±0.3°, 11.0°±0.3°, 11.3°±0.3°, 11.5°±0.3°, and 11. 7°±0.3°, 12.3°±0.3°, 12.8°±0.3°, 13.8°±0.3°, 14.8°±0.3°, 15.2°±0.3°, 15.3°±0.3°, 15.7°±0.3°, 16.5°±0.3°, 16.8°±0.3°, 17.5°±0.3°, 17.8°±0.3°, 18.6°±0.3°, 19.0 °±0.3°, 19.4°±0.3°, 19.8°±0.3°, 20.5°±0.3°, 20.8°±0.3°, 21.3°±0.3°, 21.5°±0.3°, 22.1°±0.3°, 22.3°±0.3°, 22.6°±0.3°, 23.7°±0.3°, 24.1°±0.3°, 24.4°±0.3°, 24.7° The XRPD pattern has one or more peaks at ±0.3°, 25.0°±0.3°, 25.3°±0.3°, 25.6°±0.3°, 26.1°±0.3°, 26.7°±0.3°, 27.0°±0.3°, 27.5°±0.3°, 27.9°±0.3°, 28.3°±0.3°, and 28.9°±0.3°2θ.

[0692]

[0763] In certain embodiments, the crystalline forms of the compound of formula (I) are 6.9°±0.3°, 7.3°±0.3°, 8.7°±0.3°, 8.9°±0.3°, 9.5°±0.3°, 9.9°±0.3°, 10.4°±0.3°, 10.7°±0.3°, 11.0°±0.3°, 11.3°±0.3°, 11.5°±0.3°, and 11. 0.7°±0.3°, 12.3°±0.3°, 12.8°±0.3°, 13.8°±0.3°, 14.8°±0.3°, 15.2°±0.3°, 15.3°±0.3°, 15.7°±0.3°, 16.5°±0.3°, 16.8°±0.3°, 17.5°±0.3°, 17.8°±0.3°, 18.6°±0.3°, 19 0°±0.3°, 19.4°±0.3°, 19.8°±0.3°, 20.5°±0.3°, 20.8°±0.3°, 21.3°±0.3°, 21.5°±0.3°, 22.1°±0.3°, 22.3°±0.3°, 22.6°±0.3°, 23.7°±0.3°, 24.1°±0.3°, 24.4°±0.3°, 2 The XRPD pattern has peaks at 4.7°±0.3°, 25.0°±0.3°, 25.3°±0.3°, 25.6°±0.3°, 26.1°±0.3°, 26.7°±0.3°, 27.0°±0.3°, 27.5°±0.3°, 27.9°±0.3°, 28.3°±0.3°, and 28.9°±0.3°2θ.

[0693]

[0764] In certain embodiments, the values ​​are 6.9°±0.3°, 7.3°±0.3°, 8.7°±0.3°, 8.9°±0.3°, 9.5°±0.3°, 9.9°±0.3°, 10.4°±0.3°, 10.7°±0.3°, 11.0°±0.3°, 11.3°±0.3°, 11.5°±0.3°, 11.7°±0.3°, and 12.3°±0.3°. , 12.8°±0.3°, 13.8°±0.3°, 14.8°±0.3°, 15.2°±0.3°, 15.3°±0.3°, 15.7°±0.3°, 16.5°±0.3°, 16.8°±0.3°, 17.5°±0.3°, 17.8°±0.3°, 18.6°±0.3°, 19.0°±0.3°, 19.4°±0.3°, 19. 8°±0.3°, 20.5°±0.3°, 20.8°±0.3°, 21.3°±0.3°, 21.5°±0.3°, 22.1°±0.3°, 22.3°±0.3°, 22.6°±0.3°, 23.7°±0.3°, 24.1°±0.3°, 24.4°±0.3°, 24.7°±0.3°, 25.0°±0.3°, 25.3°±0 Materials containing crystalline forms of the compound of formula (I) with XRPD peaks at 0.3°, 25.6°±0.3°, 26.1°±0.3°, 26.7°±0.3°, 27.0°±0.3°, 27.5°±0.3°, 27.9°±0.3°, 28.3°±0.3°, and 28.9°±0.3°2θ may be referred to herein as "material G".

[0694]

[0765] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern that includes one or more peaks at 8.7°±0.2°, 9.9°±0.2°, and 10.7°±0.2°²θ.

[0695]

[0766] In certain embodiments, the XRPD pattern further includes one or more peaks at 6.9°±0.2°, 7.3°±0.2°, 8.9°±0.2°, 9.5°±0.2°, 9.9°±0.2°, 10.4°±0.2°, 11.0°±0.2°, 11.3°±0.2°, 11.5°±0.2°, 11.7°±0.2°, 12.3°±0.2°, 12.8°±0.2°, 13.8°±0.2°, and 14.8°±0.2°²θ.

[0696]

[0767] In certain embodiments, the XRPD pattern further includes one or more peaks at 17.5°±0.2°, 18.6°±0.2°, 21.3°±0.2°, 21.5°±0.2°, 22.3°±0.2°, and 22.6°±0.2°²θ.

[0697]

[0768] In certain embodiments, the XRPD pattern further includes one or more peaks at 15.2°±0.2°, 15.3°±0.2°, 15.7°±0.2°, 16.5°±0.2°, 16.8°±0.2°, 17.8°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19.8°±0.2°, 20.5°±0.2°, 20.8°±0.2°, 22.1°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, and 25.0°±0.2°²θ.

[0698]

[0769] In certain embodiments, the XRPD pattern further includes one or more peaks at 25.3°±0.2°, 25.6°±0.2°, and 26.1°±0.2°²θ.

[0699]

[0770] In certain embodiments, the XRPD pattern further includes one or more peaks at 26.7°±0.2°, 27.0°±0.2°, 27.5°±0.2°, 27.9°±0.2°, 28.3°±0.2°, and 28.9°±0.2°2θ.

[0700]

[0771] In certain embodiments, the crystalline forms of the compound of formula (I) are 6.9°±0.2°, 7.3°±0.2°, 8.7°±0.2°, 8.9°±0.2°, 9.5°±0.2°, 9.9°±0.2°, 10.4°±0.2°, 10.7°±0.2°, 11.0°±0.2°, 11.3°±0.2°, 11.5°±0.2°, and 11.7°. °±0.2°, 12.3°±0.2°, 12.8°±0.2°, 13.8°±0.2°, 14.8°±0.2°, 15.2°±0.2°, 15.3°±0.2°, 15.7°±0.2°, 16.5°±0.2+°, 16.8°±0.2°, 17.5°±0.2°, 17.8°±0.2°, 18.6°±0.2°, 19.0 °±0.2°, 19.4°±0.2°, 19.8°±0.2°, 20.5°±0.2°, 20.8°±0.2°, 21.3°±0.2°, 21.5°±0.2°, 22.1°±0.2°, 22.3°±0.2°, 22.6°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7° The XRPD pattern has one or more peaks at ±0.2°, 25.0°±0.2°, 25.3°±0.2°, 25.6°±0.2°, 26.1°±0.2°, 26.7°±0.2°, 27.0°±0.2°, 27.5°±0.2°, 27.9°±0.2°, 28.3°±0.2°, and 28.9°±0.2°2θ.

[0701]

[0772] In certain embodiments, the crystalline forms of the compound of formula (I) are 6.9°±0.2°, 7.3°±0.2°, 8.7°±0.2°, 8.9°±0.2°, 9.5°±0.2°, 9.9°±0.2°, 10.4°±0.2°, 10.7°±0.2°, 11.0°±0.2°, 11.3°±0.2°, 11.5°±0.2°, and 11. 0.7°±0.2°, 12.3°±0.2°, 12.8°±0.2°, 13.8°±0.2°, 14.8°±0.2°, 15.2°±0.2°, 15.3°±0.2°, 15.7°±0.2°, 16.5°±0.2+°, 16.8°±0.2°, 17.5°±0.2°, 17.8°±0.2°, 18.6°±0.2°, 1 9.0°±0.2°, 19.4°±0.2°, 19.8°±0.2°, 20.5°±0.2°, 20.8°±0.2°, 21.3°±0.2°, 21.5°±0.2°, 22.1°±0.2°, 22.3°±0.2°, 22.6°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 2 The XRPD pattern has peaks at 4.7°±0.2°, 25.0°±0.2°, 25.3°±0.2°, 25.6°±0.2°, 26.1°±0.2°, 26.7°±0.2°, 27.0°±0.2°, 27.5°±0.2°, 27.9°±0.2°, 28.3°±0.2°, and 28.9°±0.2°2θ.

[0702]

[0773] In certain embodiments, the values ​​are 6.9°±0.2°, 7.3°±0.2°, 8.7°±0.2°, 8.9°±0.2°, 9.5°±0.2°, 9.9°±0.2°, 10.4°±0.2°, 10.7°±0.2°, 11.0°±0.2°, 11.3°±0.2°, 11.5°±0.2°, 11.7°±0.2°, 12.3°±0.2°, 12.8°±0.2°, 13.8°±0.2°, 14.8°±0.2°, 15.2°±0.2°, 15.3°±0.2°, 15.7°±0.2°, 16.5°±0.2+°, 16.8°±0.2°, 17.5°±0.2°, 17.8°±0.2°, 18.6°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19. 8°±0.2°, 20.5°±0.2°, 20.8°±0.2°, 21.3°±0.2°, 21.5°±0.2°, 22.1°±0.2°, 22.3°±0.2°, 22.6°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.0°±0.2°, 25.3°±0 Materials containing crystalline forms of the compound of formula (I) with XRPD peaks at 0.2°, 25.6°±0.2°, 26.1°±0.2°, 26.7°±0.2°, 27.0°±0.2°, 27.5°±0.2°, 27.9°±0.2°, 28.3°±0.2°, and 28.9°±0.2°2θ may be referred to herein as "material G".

[0703]

[0774] In certain embodiments, material G of the compound of formula (I) has substantially the same XRPD pattern as shown in Figure 49. In certain embodiments, material G of the compound of formula (I) has an XRPD pattern including one or more diffraction peaks (2θ) disclosed in Table 41.

[0704]

[0775] In certain embodiments, material G of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 124°C. In certain embodiments, material G of the compound of formula (I) has a DSC thermogram that includes endothermic activity with a peak onset at approximately 194°C. In certain embodiments, material G of the compound of formula (I) has a DSC thermogram that includes one or more endothermic activities with peak onset at approximately 124°C and approximately 194°C. In certain embodiments, material G of the compound of formula (I) has a DSC thermogram that includes exothermic activity with a peak onset at approximately 124°C. In certain embodiments, material G of the compound of formula (I) has a DSC thermogram that is substantially the same as that shown in Figure 50.

[0705]

[0776] In certain embodiments, material G of the compound of formula (I) exhibits a weight loss of about 3.2% by weight or less when heated from about 25°C to about 169°C. The weight loss exhibited by the crystalline form (e.g., material G of the compound of formula (I)) can be determined, for example, using TGA. In certain embodiments, material G of the compound of formula (I) has substantially the same TGA thermogram as shown in Figure 51.

[0706]

[0777] In certain embodiments, material G of the compound of formula (I) includes the anhydrous crystalline form of the compound of formula (I).

[0707] Pharmaceutical composition

[0778] In one embodiment, a pharmaceutical composition generally comprising a compound of formula (I) described herein (e.g., a crystalline free base form and a crystalline salt form) is provided herein.

[0708]

[0779] In one embodiment, the compound of formula (I) described herein is in the form of a salt (for example, the fumarate form described herein, the L-tartrate form described herein, the tosylate form described herein, or the succinate form described herein), [ka] Pharmaceutical compositions generally comprising and pharmaceutically acceptable excipients are provided herein.

[0709]

[0780] In various embodiments, (i) Fumarate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions generally comprising pharmaceutically acceptable excipients are provided herein.

[0710]

[0781] In various embodiments, (i) Crystalline fumarate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions generally comprising pharmaceutically acceptable excipients are provided herein.

[0711]

[0782] In certain embodiments, the crystalline fumarate is a crystalline fumarate as described herein.

[0712]

[0783] In certain embodiments, the crystalline fumarate of the compound of formula (I) is the crystalline monofumarate of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate of the compound of formula (I) is form A of the monofumarate of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate of the compound of formula (I) is form B of the monofumarate of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate of the compound of formula (I) is form C of the monofumarate of the compound of formula (I) described herein.

[0713]

[0784] In certain embodiments, the crystalline fumarate of the compound of formula (I) is the crystalline hemi-fumarate of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate of the compound of formula (I) is form A of the hemi-fumarate of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate of the compound of formula (I) is form B of the hemi-fumarate of the compound of formula (I) described herein.

[0714]

[0785] In various embodiments, (i) L-tartrate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0715]

[0786] In various embodiments, (i) Crystalline L-tartrate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0716]

[0787] In certain embodiments, the crystalline L-tartrate of the compound of formula (I) is the crystalline L-tartrate of the compound of formula (I) described herein.

[0717]

[0788] In various embodiments, (i) Tosylate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0718]

[0789] In various embodiments, (i) Crystalline tosylate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0719]

[0790] In certain embodiments, the crystalline tosylate of the compound of formula (I) is the crystalline tosylate of the compound of formula (I) described herein. In certain embodiments, the crystalline tosylate of the compound of formula (I) is form A of the tosylate of the compound of formula (I) described herein.

[0720]

[0791] In various embodiments, (i) Succinate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0721]

[0792] In various embodiments, (i) Crystalline succinate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0722]

[0793] In certain embodiments, the crystalline succinate of the compound of formula (I) is the crystalline succinate of the compound of formula (I) described herein. In certain embodiments, the crystalline succinate of the compound of formula (I) is form A of the succinate of the compound of formula (I) described herein.

[0723]

[0794] In various embodiments, crystalline monofumarates of the compound of formula (I) described herein (e.g., forms A, B, or C of the monofumarate of the compound of formula (I)) [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0724]

[0795] In various embodiments, crystalline hemifumarates of the compounds of formula (I) described herein (e.g., form A or form B of the hemifumarate of the compound of formula (I)) [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0725]

[0796] In various embodiments, the monofumarate form A of the compound of formula (I) described herein is used. [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0726]

[0797] In various embodiments, the monofumarate form B of the compound of formula (I) described herein is used. [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0727]

[0798] In various embodiments, the monofumarate form C of the compound of formula (I) described herein is used. [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0728]

[0799] In various embodiments, form A of the hemifumarate of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0729]

[0800] In various embodiments, form B of the hemifumarate of the compound of formula (I) described herein is used. [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0730]

[0801] In various embodiments, (i) Cansylate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0731]

[0802] In various embodiments, (i) Phosphates of compounds of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0732]

[0803] In various embodiments, (iii) Crystalline cansylate of the compound of formula (I) [ka] (iv) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0733]

[0804] In various embodiments, (i) Crystalline phosphate of the compound of formula (I) [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0734]

[0805] In various embodiments, (i) Phosphate material A of the compound of formula (I) described herein [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0735]

[0806] In various embodiments, (i) Phosphate material B of the compound of formula (I) described herein [ka] (ii) Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0736]

[0807] In certain embodiments, the crystalline cansylate is a crystalline cansylate described herein.

[0737]

[0808] In certain embodiments, the crystalline phosphate is a crystalline phosphate as described herein.

[0738]

[0809] In certain embodiments, the crystalline cansylate of the compound of formula (I) is the crystalline cansylate form A of the compound of formula (I) described herein.

[0739]

[0810] In various embodiments, the crystalline cansylate form A of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0740]

[0811] In another embodiment, pharmaceutical compositions comprising a crystalline cansylate form A of a compound of formula (I) described herein and a pharmaceutically acceptable excipient are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0741]

[0812] In another embodiment, pharmaceutical compositions comprising a phosphate material A of a compound of formula (I) described herein and a pharmaceutically acceptable excipient are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0742]

[0813] In another embodiment, pharmaceutical compositions comprising a phosphate material B of a compound of formula (I) described herein and a pharmaceutically acceptable excipient are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0743]

[0814] In another embodiment, pharmaceutical compositions are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment, comprising a salt form of the compound of formula (I) described herein (e.g., crystalline monofumarate, crystalline hemifumarate, crystalline L-tartrate, crystalline tosylate, or crystalline succinate), and pharmaceutically acceptable excipients.

[0744]

[0815] In another embodiment, pharmaceutical compositions are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) as described herein (e.g., form A, form B, or form C of the monofumarate of the compound of formula (I) as described herein) and pharmaceutically acceptable excipients.

[0745]

[0816] In another embodiment, pharmaceutical compositions are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment, comprising a crystalline hemi-fumarate of a compound of formula (I) described herein (e.g., form A or form B of the hemi-fumarate of a compound of formula (I) described herein) and a pharmaceutically acceptable excipient.

[0746]

[0817] In another embodiment, pharmaceutical compositions comprising a crystalline L-tartrate of a compound of formula (I) as described herein and a pharmaceutically acceptable excipient are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0747]

[0818] In another embodiment, pharmaceutical compositions are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment, comprising a crystalline tosylate of a compound of formula (I) described herein (e.g., form A of the tosylate of a compound of formula (I) described herein) and a pharmaceutically acceptable excipient.

[0748]

[0819] In another embodiment, pharmaceutical compositions are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment, comprising a crystalline succinate of a compound of formula (I) described herein (e.g., form A of the succinate of a compound of formula (I) described herein) and a pharmaceutically acceptable excipient.

[0749]

[0820] In another embodiment, a pharmaceutical composition comprising form A of the monofumarate of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0750]

[0821] In another embodiment, pharmaceutical compositions comprising form B of the monofumarate of the compound of formula (I) described herein, and pharmaceutically acceptable excipients, for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0751]

[0822] In another embodiment, pharmaceutical compositions comprising form C of the monofumarate of the compound of formula (I) described herein, and pharmaceutically acceptable excipients, for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0752]

[0823] In another embodiment, a pharmaceutical composition comprising form A of the hemi-fumarate of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0753]

[0824] In another embodiment, a pharmaceutical composition comprising form B of the hemi-fumarate of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0754]

[0825] In one embodiment, the crystalline free base of the compound of formula (I) described herein [ka] Pharmaceutical compositions generally comprising and pharmaceutically acceptable excipients are provided herein.

[0755]

[0826] In certain embodiments, the crystalline form of the compound of formula (I) is the crystalline free base form. In certain embodiments, the crystalline form of the compound of formula (I) is the anhydrous crystalline form. In certain embodiments, the crystalline form of the compound of formula (I) is form A of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is form B of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is form C of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is form D of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is form E of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is form H of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is the crystalline solvate. In certain embodiments, the crystalline solvate is the crystalline acetonitrile solvate. In certain embodiments, the crystalline solvate is the crystalline acetone solvate. In certain embodiments, the crystalline solvate is crystalline ethyl acetate solvate. In certain embodiments, the crystalline form of the compound of formula (I) is crystalline hydrate.

[0756]

[0827] In certain embodiments, the pharmaceutical composition described herein comprises material F of the compound of formula (I). In certain embodiments, the pharmaceutical composition described herein comprises material G of the compound of formula (I).

[0757]

[0828] In various embodiments, form A of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0758]

[0829] In various embodiments, form B of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0759]

[0830] In various embodiments, form C of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0760]

[0831] In various embodiments, form D of the potassium salt of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0761]

[0832] In various embodiments, form E of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0762]

[0833] In various embodiments, the compound of formula (I) described herein is in form H [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0763]

[0834] In various embodiments, material F of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0764]

[0835] In various embodiments, the material G of the compound of formula (I) described herein [ka] Pharmaceutical compositions comprising pharmaceutically acceptable excipients are provided herein.

[0765]

[0836] In another embodiment, pharmaceutical compositions comprising a crystalline form of the compound of formula (I) described herein (e.g., a crystalline free base form and / or a crystalline salt form described herein) and pharmaceutically acceptable excipients are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject of interest.

[0766]

[0837] In another embodiment, pharmaceutical compositions are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment, comprising a crystalline free base form of a compound of formula (I) described herein (e.g., form A, form B, form C, form D, form E, or form H) and pharmaceutically acceptable excipients.

[0767]

[0838] In another embodiment, pharmaceutical compositions are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment, comprising a crystalline cansylate of a compound of formula (I) described herein (e.g., crystalline cansylate form A of a compound of formula (I) described herein) and a pharmaceutically acceptable excipient.

[0768]

[0839] In another embodiment, pharmaceutical compositions comprising a material (e.g., phosphate material A of the compound of formula (I) or phosphate material B of the compound of formula (I)) described herein, and pharmaceutically acceptable excipients, for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0769]

[0840] In another embodiment, a pharmaceutical composition comprising form A of the compound of formula (I) described herein and a pharmaceutically acceptable excipient is provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0770]

[0841] In another embodiment, a pharmaceutical composition comprising form B of the compound of formula (I) described herein and a pharmaceutically acceptable excipient is provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0771]

[0842] In another embodiment, a pharmaceutical composition comprising form C of the compound of formula (I) described herein and a pharmaceutically acceptable excipient is provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0772]

[0843] In another embodiment, a pharmaceutical composition comprising form D of the compound of formula (I) described herein and a pharmaceutically acceptable excipient is provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0773]

[0844] In another embodiment, a pharmaceutical composition comprising form E of the compound of formula (I) described herein and a pharmaceutically acceptable excipient is provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0774]

[0845] In another embodiment, a pharmaceutical composition comprising form H of the compound of formula (I) described herein and a pharmaceutically acceptable excipient is provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0775]

[0846] In another embodiment, pharmaceutical compositions comprising a compound F of formula (I) as described herein and a pharmaceutically acceptable excipient are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0776]

[0847] In another embodiment, pharmaceutical compositions comprising material G of a compound of formula (I) as described herein and pharmaceutically acceptable excipients are provided herein for the treatment of a condition, disease, or disorder described herein (e.g., cancer) in a subject requiring such treatment.

[0777]

[0848] In certain embodiments, the amounts of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein are approximately 22 mg to approximately 226 mg, approximately 35 mg to approximately 226 mg, approximately 45 mg to approximately 226 mg, approximately 55 mg to approximately 226 mg, approximately 65 mg to approximately 226 mg, approximately 75 mg to approximately 226 mg, approximately 85 mg to approximately 226 mg, approximately 95 mg to approximately 226 mg, approximately 105 mg to approximately 226 mg, approximately 115 mg to approximately 226 mg, approximately 125 mg to approximately 226 mg, approximately 135 mg to approximately 226 mg, approximately 145 mg to approximately 226 mg, approximately 155 mg to approximately 226 mg, approximately 165 mg to approximately 226 mg, approximately 175 mg to approximately 226 mg, approximately 185 mg to approximately 226 mg, approximately 195 mg to approximately 226 mg, approximately 22 mg to approximately 190 mg. Approximately 22mg to approximately 180mg, approximately 22mg to approximately 170mg, approximately 22mg to approximately 160mg, approximately 22mg to approximately 150mg, approximately 22mg to approximately 140mg, approximately 22mg to approximately 130mg , about 22 mg to about 120 mg, about 22 mg to about 110 mg, about 22 mg to about 100 mg, about 22 mg to about 90 mg, about 22 mg to about 80 mg, about 22 mg to about 70 mg, about 2 The dosage ranges from approximately 2mg to 60mg, approximately 22mg to 50mg, approximately 22mg to 40mg, approximately 22mg to 30mg, approximately 35mg to 185mg, approximately 45mg to 175mg, approximately 55mg to 165mg, approximately 65mg to 155mg, approximately 75mg to 145mg, approximately 85mg to 135mg, approximately 95mg to 125mg, or approximately 105mg to 115mg.

[0778]

[0849] In certain embodiments, the amounts of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical compositions described herein are approximately 177 mg to approximately 900 mg, approximately 250 mg to approximately 900 mg, approximately 300 mg to approximately 900 mg, approximately 350 mg to approximately 900 mg, approximately 400 mg to approximately 900 mg, approximately 450 mg to approximately 900 mg, approximately 500 mg to approximately 900 mg, approximately 550 mg to approximately 900 mg, approximately 600 mg to approximately 900 mg, approximately 650 mg to approximately 900 mg, approximately 700 mg to approximately 900 mg, approximately 750 mg to approximately 900 mg, approximately 800 mg to approximately 900 mg, approximately 850 mg to approximately 900 mg, approximately 177 mg to approximately 850 mg, and approximately 17 The dosages are approximately 7mg to 800mg, approximately 177mg to 750mg, approximately 177mg to 700mg, approximately 177mg to 650mg, approximately 177mg to 600mg, approximately 177mg to 550mg, approximately 177mg to 500mg, approximately 177mg to 450mg, approximately 177mg to 400mg, approximately 177mg to 350mg, approximately 177mg to 300mg, approximately 177mg to 250mg, approximately 250mg to 850mg, approximately 300mg to 800mg, approximately 350mg to 750mg, approximately 400mg to 700mg, approximately 450mg to 650mg, approximately 500mg to 600mg, or approximately 550mg to 600mg.

[0779]

[0850] In certain embodiments, the amounts of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical compositions described herein are approximately 22 mg to approximately 451 mg, approximately 50 mg to approximately 451 mg, approximately 75 mg to approximately 451 mg, approximately 100 mg to approximately 451 mg, approximately 125 mg to approximately 451 mg, approximately 150 mg to approximately 451 mg, approximately 175 mg to approximately 451 mg, and approximately 200 mg to approximately 45 1mg, about 225mg to about 451mg, about 250mg to about 451mg, about 275mg to about 451mg, about 300mg to about 451mg, about 325mg to about 451mg, about 350mg ~451mg, 375mg~451mg, 22mg~375mg, 22mg~350mg, 22mg~325mg, 22mg~300mg, 22mg~ Approximately 275 mg, approximately 22 mg to approximately 250 mg, approximately 22 mg to approximately 225 mg, approximately 22 mg to approximately 200 mg, approximately 22 mg to approximately 175 mg, approximately 22 mg to approximately 150 mg, approximately 22 mg to approximately 1 25mg, about 22mg to about 100mg, about 22mg to about 75mg, about 22mg to about 50mg, about 50mg to about 375mg, about 75mg to about 350mg, about 100mg to about 325m g is approximately 125mg to 300mg, 150mg to 275mg, 175mg to 250mg, 200mg to 225mg, 50mg to 100mg, 100mg to 150mg, 150mg to 200mg, 200mg to 250mg, 250mg to 300mg, 300mg to 350mg, or 350mg to 451mg.

[0780]

[0851] In certain embodiments, the amounts of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the pharmaceutical composition described herein are approximately 22 mg, approximately 30 mg, approximately 35 mg, approximately 40 mg, approximately 45 mg, approximately 50 mg, approximately 55 mg, approximately 60 mg, approximately 65 mg, approximately 70 mg, approximately 75 mg, approximately 80 mg, approximately 85 mg, approximately 90 mg, approximately 95 mg, approximately 100 mg, approximately 105 mg, approximately 110 mg, approximately 115 mg, approximately 120 mg, approximately 125 mg, approximately 130 mg, and approximately 13 mg. 5mg, about 140mg, about 145mg, about 150mg, about 155m, about 160mg, about 165mg, about 170mf, about 175mg, about 180mg, about 185mg, about 190mg, about 195mg, about 200mg, about 210 mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 350 mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490 mg, about 500mg, about 510mg, about 520mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630 The amounts are approximately mg, 640 mg, 650 mg, 660 mg, 670 mg, 680 mg, 690 mg, 700 mg, 710 mg, 720 mg, 730 mg, 740 mg, 750 mg, 760 mg, 770 mg, 780 mg, 790 mg, 800 mg, 810 mg, 820 mg, 830 mg, 840 mg, 850 mg, 860 mg, 870 mg, 880 mg, 890 mg, or 900 mg.

[0781]

[0852] In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 22 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 50 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 75 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 100 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 125 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 150 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 175 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 200 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 250 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 300 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 350 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 400 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 450 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 500 mg. In certain embodiments, the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the pharmaceutical composition described herein is about 550 mg.In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 600 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 650 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 700 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 750 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 800 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 850 mg. In certain embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt in the pharmaceutical composition described herein is about 900 mg.

[0782]

[0853] In certain embodiments, the pharmaceutically acceptable amounts of the compound of formula (I) in the pharmaceutical composition described herein are approximately 22 mg to approximately 226 mg, approximately 35 mg to approximately 226 mg, approximately 45 mg to approximately 226 mg, approximately 55 mg to approximately 226 mg, approximately 65 mg to approximately 226 mg, approximately 75 mg to approximately 226 mg, approximately 85 mg to approximately 226 mg, approximately 95 mg to approximately 226 mg, Approximately 105mg to approximately 226mg, approximately 115mg to approximately 226mg, approximately 125mg to approximately 226mg, approximately 135mg to approximately 226mg, approximately 145mg to approximately 226mg, approximately 155mg to Approximately 226 mg, approximately 165 mg to approximately 226 mg, approximately 175 mg to approximately 226 mg, approximately 185 mg to approximately 226 mg, approximately 195 mg to approximately 226 mg, approximately 22 mg to approximately 190 mg, approximately 2 2mg to about 180mg, about 22mg to about 170mg, about 22mg to about 160mg, about 22mg to about 150mg, about 22mg to about 140mg, about 22mg to about 130mg, about 22mg to about 120mg, about 22mg to about 110mg, about 22mg to about 100mg, about 22mg to about 90mg, about 22mg to about 80mg, about 22mg to about 70mg, about 22 The ranges are approximately 60 mg to 105 mg, 50 mg to 105 mg, 40 mg to 105 mg, 30 mg to 105 mg, 185 mg to 105 mg, 175 mg to 105 mg, 165 mg to 105 mg, 145 mg to 105 mg, 135 mg to 105 mg, 125 mg to 105 mg, or 115 mg to 105 mg.

[0783]

[0854] In certain embodiments, the pharmaceutically acceptable amounts of the compound of formula (I) in the pharmaceutical compositions described herein are approximately 177 mg to approximately 900 mg, approximately 250 mg to approximately 900 mg, approximately 300 mg to approximately 900 mg, approximately 350 mg to approximately 900 mg, approximately 400 mg to approximately 900 mg, approximately 450 mg to approximately 900 mg, approximately 500 mg to approximately 900 mg, approximately 550 mg to approximately 900 mg, approximately 600 mg to approximately 900 mg, approximately 650 mg to approximately 900 mg, approximately 700 mg to approximately 900 mg, approximately 750 mg to approximately 900 mg, approximately 800 mg to approximately 900 mg, approximately 850 mg to approximately 900 mg, approximately 177 mg to approximately 850 mg, and approximately 177 mg. The amounts are approximately 800mg for g, 750mg for g, 700mg for g, 650mg for g, 600mg for g, 550mg for g, 500mg for g, 450mg for g, 400mg for g, 350mg for g, 300mg for g, 250mg for g, 850mg for g, 800mg for g, 800mg for g, 750mg for g, 700mg for g, 700mg for g, 450mg for g, 650mg for g, 500mg for g, or 600mg for g.

[0784]

[0855] In certain embodiments, the pharmaceutically acceptable amounts of the compound of formula (I) in the pharmaceutical compositions described herein are approximately 22 mg to approximately 451 mg, approximately 50 mg to approximately 451 mg, approximately 75 mg to approximately 451 mg, approximately 100 mg to approximately 451 mg, approximately 125 mg to approximately 451 mg, approximately 150 mg to approximately 451 mg, approximately 175 mg to approximately 451 mg, and approximately 200 mg to approximately 451 mg. , about 225 mg to about 451 mg, about 250 mg to about 451 mg, about 275 mg to about 451 mg, about 300 mg to about 451 mg, about 325 mg to about 451 mg, about 350 mg to about 451mg, about 375mg to about 451mg, about 22mg to about 375mg, about 22mg to about 350mg, about 22mg to about 325mg, about 22mg to about 300mg, about 22mg to about 2 75mg, about 22mg to about 250mg, about 22mg to about 225mg, about 22mg to about 200mg, about 22mg to about 175mg, about 22mg to about 150mg, about 22mg to about 12 5mg, about 22mg to about 100mg, about 22mg to about 75mg, about 22mg to about 50mg, about 50mg to about 375mg, about 75mg to about 350mg, about 100mg to about 325mg The dosages are approximately 125mg to 300mg, 150mg to 275mg, 175mg to 250mg, 200mg to 225mg, 50mg to 100mg, 100mg to 150mg, 150mg to 200mg, 200mg to 250mg, 250mg to 300mg, 300mg to 350mg, or 350mg to 451mg.

[0785]

[0856] In certain embodiments, the pharmaceutically acceptable amounts of the compound of formula (I) in the pharmaceutical compositions described herein are approximately 22 mg, approximately 30 mg, approximately 35 mg, approximately 40 mg, approximately 45 mg, approximately 50 mg, approximately 55 mg, approximately 60 mg, approximately 65 mg, approximately 70 mg, approximately 75 mg, approximately 80 mg, approximately 85 mg, approximately 90 mg, approximately 95 mg, approximately 100 mg, approximately 105 mg, approximately 110 mg, approximately 115 mg, approximately 120 mg, approximately 125 mg, approximately 130 mg, and approximately 135 mg. , about 140mg, about 145mg, about 150mg, about 155m, about 160mg, about 165mg, about 170mf, about 175mg, about 180mg, about 185mg, about 190mg, about 195mg, about 200mg, about 210mg , about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 350mg , about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490m g, about 500mg, about 510mg, about 520mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630m g is approximately 640 mg, 650 mg, 660 mg, 670 mg, 680 mg, 690 mg, 700 mg, 710 mg, 720 mg, 730 mg, 740 mg, 750 mg, 760 mg, 770 mg, 780 mg, 790 mg, 800 mg, 810 mg, 820 mg, 830 mg, 840 mg, 850 mg, 860 mg, 870 mg, 880 mg, 890 mg, or 900 mg.

[0786]

[0857] In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 22 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 50 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 75 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 100 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 125 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 150 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 175 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 200 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 250 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 300 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 350 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 400 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 450 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 500 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 550 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 600 mg.In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 650 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 700 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 750 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 800 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 850 mg. In certain embodiments, the amount of pharmaceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition described herein is about 900 mg.

[0787]

[0858] In various embodiments, (i) a compound of formula (I) in an amount of approximately 22 mg to approximately 451 mg, or a pharmaceutically acceptable salt thereof; and (ii) Pharmaceutical compositions comprising one or more pharmaceutically acceptable excipients are provided herein.

[0788]

[0859] In various embodiments, (i) pharmaceutically acceptable salts of the compound of formula (I) in amounts ranging from approximately 177 mg to approximately 900 mg; and (ii) Pharmaceutical compositions comprising one or more pharmaceutically acceptable excipients are provided herein.

[0789]

[0860] In another embodiment, pharmaceutical compositions are provided herein for the treatment of cancers described herein (e.g., bladder cancer, breast cancer, carcinoma, cervical cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, kidney cancer, lung cancer, neuroendocrine carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer) in a subject requiring attention, comprising about 22 mg to about 177 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0790]

[0861] In another embodiment, pharmaceutical compositions are provided herein for the treatment of cancers described herein (e.g., bladder cancer, breast cancer, carcinoma, cervical cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, kidney cancer, lung cancer, neuroendocrine carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer) in the target area in which a treatment is desired, comprising about 177 mg to about 900 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0791]

[0862] In another embodiment, pharmaceutical compositions are provided herein for the treatment of cancers described herein (e.g., bladder cancer, breast cancer, carcinoma, cervical cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, kidney cancer, lung cancer, neuroendocrine carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer) in a subject requiring treatment, comprising about 22 mg to about 226 mg of a pharmaceutically acceptable salt of the compound of formula (I) and one or more pharmaceutically acceptable excipients.

[0792]

[0863] In another embodiment, pharmaceutical compositions are provided herein for the treatment of cancers described herein (e.g., bladder cancer, breast cancer, carcinoma, cervical cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, kidney cancer, lung cancer, neuroendocrine carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer) in the target area in which a treatment is desired, comprising about 177 mg to about 900 mg of a pharmaceutically acceptable salt of a compound of formula (I) and one or more pharmaceutically acceptable excipients.

[0793]

[0864] In certain embodiments, the pharmaceutically acceptable salt of the compound of formula (I) is a fumarate. In certain embodiments, the pharmaceutically acceptable salt of the compound of formula (I) is a monofumarate (e.g., a crystalline monofumarate as described herein). In certain embodiments, the pharmaceutically acceptable salt of the compound of formula (I) is a hemifumarate (e.g., a crystalline hemifumarate as described herein).

[0794]

[0865] The pharmaceutical compositions described herein may be administered by a variety of routes, including, but not limited to, oral (enteral), parenteral (injection), rectal, transdermal, intradermal, intrathecal, subcutaneous (SC), intravenous (IV), intramuscular (IM), and intranasal administration. In certain embodiments, the pharmaceutical compositions described herein are administered orally.

[0795]

[0866] The pharmaceutical compositions described herein may also be administered chronically ("chronic administration"). Chronic administration refers to the administration of a compound or its pharmaceutical composition over a long period, for example, three months, six months, one year, two years, three years, five years, etc., or may continue indefinitely, for example, for the remainder of the subject's life. In certain embodiments, chronic administration is intended, for example, to provide a certain level of the compound in the blood within the therapeutic range over a long period.

[0796]

[0867] The pharmaceutical compositions described herein may be provided in unit dosage forms to facilitate precise administration. The term “unit dosage form” refers to a physically distinct unit suitable as a unit dose for human subjects and other mammals, each unit containing a predetermined amount of active substance calculated to produce a desired therapeutic effect, together with a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes for liquid compositions, or, in the case of solid compositions, pills, tablets, capsules, etc.

[0797]

[0868] In certain embodiments, the pharmaceutical compositions provided herein are administered to patients in solid dosage form. In certain embodiments, the solid dosage form is a capsule.

[0798]

[0869] The descriptions of pharmaceutical compositions provided herein primarily concern pharmaceutical compositions suitable for administration to humans; however, those skilled in the art will understand that such compositions are generally suitable for administration to all types of animals. Modifications of pharmaceutical compositions suitable for administration to humans to make them suitable for administration to various animals are well understood, and those skilled in the art of veterinary pharmacology can design and / or carry out such modifications using conventional experiments. General considerations in the formulation and / or manufacture of pharmaceutical compositions can be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005.

[0799] Methods of use and treatment

[0870] The salt forms and pharmaceutical compositions of the compound of formula (I) described herein are thought to have therapeutic effects on subjects suffering from cancer. Accordingly, one aspect of the present invention provides a therapeutic method for treating the aforementioned diseases and conditions using the salt forms of the compound of formula (I) and the pharmaceutical compositions described herein. Various aspects and embodiments of the therapeutic method are described below.

[0800]

[0871] The crystalline forms (e.g., crystalline salt forms and crystalline free base forms) and pharmaceutical compositions of the compound of formula (I) described herein are intended to provide therapeutic benefits to subjects suffering from cancer. Accordingly, one aspect of this disclosure provides a therapeutic method for treating the aforementioned diseases and conditions using the crystalline forms of the compound of formula (I) and the pharmaceutical compositions described herein. Various aspects and embodiments of the therapeutic method are described below.

[0801]

[0872] (1) Cancer

[0873] In one embodiment, a method for treating cancer in a target subject is provided herein. This method generally involves treating cancer by administering an effective amount of a salt form of the compound of formula (I) (e.g., the fumarate, tosylate, L-tartrate, or succinate described herein) or a pharmaceutical composition described herein to a target subject.

[0802]

[0874] In another embodiment, a method for treating a solid tumor in a target area is provided herein. This method generally involves administering an effective amount of a salt form of the compound of formula (I) (e.g., the fumarate, tosylate, L-tartrate, or succinate described herein) or a pharmaceutical composition described herein to the target area. In a particular embodiment, the solid tumor is a progressive solid tumor.

[0803]

[0875] In another embodiment, a method for treating hematological cancers in a subject of interest is provided herein. This method generally involves administering an effective amount of a salt form of the compound of formula (I) (e.g., the fumarate, tosylate, L-tartrate, or succinate described herein) or a pharmaceutical composition described herein to a subject.

[0804]

[0876] In various embodiments, the method involves administering an effective amount of the crystalline monofumarate of the compound of formula (I) (for example, form A, form B, or form C of the monofumarate of the compound of formula (I)) to the target.

[0805]

[0877] In various embodiments, the method involves administering an effective amount of the crystalline hemi-fumarate of the compound of formula (I) (for example, form A or form B of the hemi-fumarate of the compound of formula (I)) to the target.

[0806]

[0878] In various embodiments, the method involves administering an effective amount of the crystalline L-tartrate of the compound of formula (I)) to a target.

[0807]

[0879] In various embodiments, the method involves administering an effective amount of the crystalline tosylate of the compound of formula (I) (for example, form A of the tosylate of the compound of formula (I)) to the target.

[0808]

[0880] In various embodiments, the method involves administering an effective amount of the crystalline succinate of the compound of formula (I) (for example, form A of the succinate of the compound of formula (I)) to the target.

[0809]

[0881] In various embodiments, the method involves administering an effective amount of form A of the hemifumarate of the compound of formula (I)) to the target.

[0810]

[0882] In various embodiments, the method involves administering an effective amount of form B of the hemifumarate of the compound of formula (I)) to the target.

[0811]

[0883] In various embodiments, the method includes administering an effective amount of the pharmaceutical composition described herein to a subject.

[0812]

[0884] In certain embodiments, a salt form of the compound of formula (I) is administered orally to the subject once daily for at least one year. In some embodiments, a salt form of the compound of formula (I) is administered orally to the subject once daily for at least two years.

[0813]

[0885] In one embodiment, a method for treating cancer in a target subject is provided herein. This method generally involves treating cancer by administering an effective amount of a compound of formula (I) in crystalline form (e.g., crystalline free base form and / or crystalline salt form as described herein) or a pharmaceutical composition as described herein to a target subject.

[0814]

[0886] In another embodiment, a method for treating a solid tumor in a target subject is provided herein. This method generally involves administering an effective amount of the compound of formula (I) in crystalline form (e.g., the crystalline free base form and / or the crystalline salt form described herein) or a pharmaceutical composition described herein to the target subject. In a particular embodiment, the solid tumor is a progressive solid tumor.

[0815]

[0887] In another embodiment, a method for treating hematological cancers in a subject of interest is provided herein. This method generally involves administering an effective amount of the compound of formula (I) in crystalline form (e.g., crystalline free base form or crystalline salt form as described herein) or a pharmaceutical composition as described herein to the subject.

[0816]

[0888] In various embodiments, the method involves administering an effective amount of the compound of formula (I) in crystalline free base form (e.g., form A, form B, form C, form D, form E and / or form H) to the target.

[0817]

[0889] In various embodiments, the method involves administering a material (e.g., material F and / or material G) containing an effective amount of the crystalline free base form of the compound of formula (I) to a target.

[0818]

[0890] In various embodiments, the method involves administering an effective amount of the crystalline salt form of the compound of formula (I) (for example, the crystalline cansylate of the compound of formula (I) as described herein) to the subject.

[0819]

[0891] In various embodiments, the method involves administering a material (e.g., phosphate material A and / or phosphate material B) containing an effective amount of the crystalline salt form of the compound of formula (I) to a target.

[0820]

[0892] In various embodiments, the method involves administering an effective amount of the crystalline cansylate of the compound of formula (I) (e.g., crystalline cansylate form A of the compound of formula (I)) to the target.

[0821]

[0893] In various embodiments, the method includes administering an effective amount of form A of the compound of formula (I) to a target.

[0822]

[0894] In various embodiments, the method includes administering an effective amount of form B of the compound of formula (I) to a target.

[0823]

[0895] In various embodiments, the method includes administering an effective amount of form C of the compound of formula (I) to a target.

[0824]

[0896] In various embodiments, the method includes administering an effective amount of form D of the compound of formula (I) to a target.

[0825]

[0897] In various embodiments, the method includes administering an effective amount of form E of the compound of formula (I) to a target.

[0826]

[0898] In various embodiments, the method involves administering an effective amount of form H of the compound of formula (I) to a target.

[0827]

[0899] In various embodiments, the method includes administering an effective amount of the compound of formula (I) to material F.

[0828]

[0900] In various embodiments, the method involves administering an effective amount of the compound of formula (I) to material G.

[0829]

[0901] In various embodiments, the method involves administering an effective amount of the crystalline cansylate form A of the compound of formula (I) to a target.

[0830]

[0902] In various embodiments, the method includes administering an effective amount of phosphate material A of the compound of formula (I) to the target.

[0831]

[0903] In various embodiments, the method includes administering an effective amount of phosphate material B of the compound of formula (I) to the target.

[0832]

[0904] In various embodiments, the method includes administering an effective amount of the pharmaceutical composition described herein to a subject.

[0833]

[0905] In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered orally to a subject.

[0834]

[0906] In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered to the subject once, twice, three, four, or five times daily. In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered to the subject once daily. In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered to the subject twice daily.

[0835]

[0907] In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered to the subject for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years. In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered to the subject over the lifetime of the subject.

[0836]

[0908] In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered orally to the subject once, twice, three, four, or five times a day for at least one year. In certain embodiments, the crystalline form of the compound of formula (I) described herein is administered orally to the subject once, twice, three, four, or five times a day for at least two years.

[0837]

[0909] In certain embodiments, administering a therapeutically effective dose of the compound of formula (I) or a pharmaceutically acceptable salt thereof includes administering approximately 22 mg to approximately 451 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a target.

[0838]

[0910] In certain embodiments, administering a therapeutically effective dose of the compound of formula (I) or a pharmaceutically acceptable salt thereof includes oral administration of about 22 mg to about 451 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0839]

[0911] In certain embodiments, administering a therapeutically effective dose of the compound of formula (I) or a pharmaceutically acceptable salt thereof includes daily oral administration of approximately 22 mg to approximately 451 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0840]

[0912] In certain embodiments, administering a therapeutically effective dose of the compound of formula (I) or a pharmaceutically acceptable salt thereof includes orally administering to a subject about 22 mg to about 451 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof once daily.

[0841]

[0913] In certain embodiments, administering a therapeutically effective dose of the compound of formula (I) or a pharmaceutically acceptable salt thereof includes orally administering to a subject about 22 mg to about 451 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof twice daily.

[0842]

[0914] In certain embodiments, the subject is in a fasted state. In certain embodiments, the subject is not in a fasted state. In certain embodiments, administering a therapeutically effective dose of the compound of formula (I), or a pharmaceutically acceptable salt thereof, includes administering the effective dose to the subject within approximately 30 minutes after the completion of a meal.

[0843]

[0915] In certain embodiments, administering a therapeutically effective dose of the compound of formula (I) or a pharmaceutically acceptable salt thereof involves administering approximately 22 mg to approximately 451 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject within approximately 30 minutes after the completion of a meal...

Claims

1. Equation (I) 【Chemistry 1】 The fumarate of the compound.

2. The fumarate according to claim 1, wherein the fumarate is a monofumarate.

3. The fumarate according to claim 1, wherein the fumarate is a hemifumarate.

4. Equation (I) 【Chemistry 2】 Crystalline fumarate of the compound.

5. The crystalline fumarate according to claim 4, wherein the crystalline fumarate has an X-ray powder diffraction (XRPD) pattern including one or more peaks at approximately 16.9°, approximately 17.9°, and approximately 24.1°²θ.

6. The crystalline fumarate according to claim 4 or 5, wherein the crystalline fumarate is a crystalline monofumarate.

7. The crystalline fumarate according to any one of claims 4 to 6, wherein the crystalline fumarate has substantially the same XRPD pattern as that shown in Figure 1.

8. The crystalline fumarate according to any one of claims 4 to 6, wherein the crystalline fumarate has substantially the same XRPD pattern as that shown in Figure 3.

9. The crystalline fumarate according to any one of claims 4 to 6, wherein the crystalline fumarate has substantially the same XRPD pattern as that shown in Figure 5.

10. The crystalline fumarate according to any one of claims 4 to 6, wherein the crystalline fumarate is a crystalline hemifumarate.

11. The crystalline fumarate according to any one of claims 4, 5, and 10, wherein the crystalline fumarate has substantially the same XRPD pattern as that shown in Figure 8.

12. The crystalline fumarate according to any one of claims 4, 5, and 10, wherein the crystalline fumarate has substantially the same XRPD pattern as shown in Figure 14.

13. The crystalline fumarate according to any one of claims 4 to 12, wherein the crystalline fumarate is an anhydrous crystalline fumarate.

14. The crystalline fumarate according to any one of claims 4 to 12, wherein the crystalline fumarate is a crystalline hydrate.

15. The crystalline fumarate according to claim 14, wherein the crystalline hydrate is a crystalline monohydrate.

16. Equation (I) 【Transformation 3】 Crystalline monofumarate of the compound.

17. The crystalline monofumarate according to claim 16, wherein the crystalline monofumarate has an XRPD pattern including one or more peaks at approximately 5.2° 2θ.

18. The crystalline monofumarate according to claim 17, wherein the XRPD pattern further includes one or more peaks at approximately 7.6° and approximately 14.4°²θ.

19. The crystalline monofumarate according to claim 17 or 18, wherein the XRPD pattern further includes one or more peaks at approximately 15.8°, approximately 21.2°, approximately 24.5°, and approximately 25.0°²θ.

20. The crystalline monofumarate according to any one of claims 17 to 19, wherein the XRPD pattern further includes one or more peaks at approximately 15.1°, approximately 16.7°, approximately 17.3°, approximately 17.9°, approximately 19.4°, approximately 19.9°, approximately 20.6°, and approximately 22.7°²θ.

21. The crystalline monofumarate according to any one of claims 17 to 20, wherein the XRPD pattern further includes one or more peaks at approximately 30.4° and approximately 31.4°²θ.

22. The crystalline monofumarate according to any one of claims 16 to 21, wherein the crystalline monofumarate has substantially the same XRPD pattern as that shown in Figure 1.

23. The crystalline monofumarate according to any one of claims 16 to 21, wherein the crystalline monofumarate has substantially the same XRPD pattern as that shown in Figure 3.

24. The crystalline monofumarate according to any one of claims 16 to 21, wherein the crystalline monofumarate has substantially the same XRPD pattern as that shown in Figure 5.

25. The crystalline monofumarate according to any one of claims 16 to 24, wherein the crystalline monofumarate is a crystalline hydrate.

26. The crystalline monofumarate according to claim 25, wherein the crystalline hydrate is a crystalline monohydrate.

27. Equation (I) 【Chemistry 4】 Form A of the monofumarate of the compound.

28. The monofumarate morph A according to claim 27, wherein the monofumarate morph A has an XRPD pattern including one or more peaks at approximately 5.0°, approximately 7.4°, and approximately 8.2°²θ.

29. Form A of the monofumarate according to claim 28, wherein the XRPD pattern further includes one or more peaks at approximately 9.7°, approximately 10.1°, approximately 10.7°, approximately 11.4°, approximately 11.9°, approximately 13.2°, approximately 14.7°, and approximately 14.8°²θ.

30. Form A of the monofumarate according to claim 28 or 29, wherein the XRPD pattern further includes one or more peaks at approximately 15.2°, approximately 16.1°, approximately 16.6°, approximately 17.5°, approximately 19.5°, approximately 20.2°, approximately 21.1°, approximately 23.9°, and approximately 24.2°²θ.

31. Form A of the monofumarate according to any one of claims 28 to 30, wherein the XRPD pattern further includes one or more peaks at approximately 17.9°, approximately 18.4°, approximately 19.2°, approximately 19.9°, approximately 20.8°, approximately 21.9°, approximately 22.9°, approximately 23.1°, approximately 23.5°, and approximately 24.8°²θ.

32. Form A of monofumaric acid according to any one of claims 28 to 31, wherein the XRPD pattern further includes one or more peaks at approximately 25.1°, approximately 25.4°, approximately 27.4°, and approximately 27.8°²θ.

33. Form A of the monofumarate according to any one of claims 28 to 32, wherein the XRPD pattern further includes one or more peaks at approximately 28.9°, approximately 30.1°, approximately 30.4°, approximately 31.3°, approximately 31.5°, approximately 32.8°, and approximately 33.6°²θ.

34. Form A of the monofumarate according to any one of claims 28 to 33, wherein approximately ±0.3°²θ.

35. The form A of the monofumarate according to any one of claims 27 to 34, wherein the form A of the monofumarate has substantially the same XRPD pattern as that shown in Figure 1.

36. The form A of the monofumarate according to any one of claims 27 to 35, wherein the form A of the monofumarate has a differential scanning calorimetry (DSC) thermogram containing one or more endothermic temperatures with peaks starting at approximately 32°C and approximately 133°C.

37. The form A of the monofumarate according to any one of claims 27 to 36, wherein the form A of the monofumarate has substantially the same DSC thermogram as that shown in Figure 2.

38. The form A of the monofumarate according to any one of claims 27 to 37, wherein when the form A of the monofumarate is heated from about 25°C to about 130°C, it exhibits a weight loss of about 1.2% by weight or less.

39. The form A of the monofumarate according to any one of claims 27 to 38, wherein the form A of the monofumarate is a crystalline hydrate.

40. Equation (I) 【Transformation 5】 Form B of the monofumarate of the compound.

41. The form B of the monofumarate according to claim 40, wherein the form B of the monofumarate has an XRPD pattern including a peak at approximately 7.5° 2θ.

42. Form B of the monofumarate according to claim 41, wherein the XRPD pattern further includes one or more peaks at approximately 4.7°, approximately 9.7°, approximately 13.3°, approximately 13.8°, approximately 14.0°, approximately 14.2°, and approximately 15.0°²θ.

43. Form B of the monofumarate according to claim 41 or 42, wherein the XRPD pattern further includes one or more peaks at approximately 17.4°, approximately 21.5°, approximately 22.2°, approximately 22.6°, approximately 23.1°, approximately 23.4°, approximately 24.4°, and approximately 24.7°²θ.

44. Form B of the monofumarate according to any one of claims 41 to 43, wherein the XRPD pattern further includes one or more peaks at approximately 15.4°, approximately 15.8°, approximately 16.6°, approximately 17.0°, approximately 17.8°, approximately 18.5°, approximately 18.8°, approximately 19.5°, approximately 19.8°, approximately 20.3°, approximately 20.6°, and approximately 24.1°²θ.

45. Form B of the monofumarate according to any one of claims 41 to 44, wherein the XRPD pattern further includes one or more peaks at approximately 26.8°, approximately 28.1°, and approximately 29.7°²θ.

46. Form B of the monofumarate according to any one of claims 41 to 45, wherein the XRPD pattern further includes one or more peaks at approximately 25.3°, approximately 26.0°, approximately 27.6°, approximately 30.2°, approximately 30.8°, approximately 31.5°, and approximately 33.5°²θ.

47. Form B of the monofumarate according to any one of claims 41 to 46, wherein approximately ±0.3°²θ.

48. The form B of the monofumarate according to any one of claims 40 to 47, wherein the form B of the monofumarate has substantially the same XRPD pattern as that shown in Figure 3.

49. The form B of the monofumarate according to any one of claims 40 to 48, wherein the form B of the monofumarate has a DSC thermogram containing one or more endothermic temperatures with peak onset at approximately 41°C, approximately 112°C, and approximately 122°C.

50. The form B of the monofumarate according to any one of claims 40 to 49, wherein the form B of the monofumarate has substantially the same DSC thermogram as that shown in Figure 4.

51. The form B of the monofumarate according to any one of claims 40 to 50, wherein when the form B of the monofumarate is heated from about 25°C to about 155°C, it exhibits a weight loss of about 4.6% or less by weight.

52. The form B of the monofumarate according to any one of claims 40 to 51, wherein the form B of the monofumarate is a crystalline hydrate.

53. Equation (I) 【Transformation 6】 Form C of the monofumarate of the compound.

54. The form C of the monofumarate according to claim 53, wherein the form C of the monofumarate has an XRPD pattern including a peak at approximately 5.2°2θ.

55. Form C of the monofumarate according to claim 54, wherein the XRPD pattern further includes one or more peaks at approximately 7.6°, approximately 10.6°, approximately 13.8°, and approximately 14.4°²θ.

56. Form C of the monofumarate according to claim 54 or 55, wherein the XRPD pattern further includes one or more peaks at approximately 15.8°, approximately 21.2°, approximately 24.5°, and approximately 25.0°²θ.

57. Form C of the monofumarate according to any one of claims 54 to 56, wherein the XRPD pattern further includes one or more peaks at approximately 15.1°, approximately 16.7°, approximately 17.3°, approximately 17.9°, approximately 19.4°, approximately 19.9°, approximately 20.6°, and approximately 22.7°²θ.

58. Form C of the monofumarate according to any one of claims 54 to 57, wherein the XRPD pattern further includes one or more peaks at approximately 25.7°, approximately 26.6°, approximately 28.9°, approximately 30.4°, approximately 31.4°, and approximately 32.0°²θ.

59. Form C of the monofumarate according to any one of claims 54 to 58, wherein approximately ±0.3°²θ.

60. The form C of the monofumarate according to any one of claims 53 to 59, wherein the form C of the monofumarate has substantially the same XRPD pattern as that shown in Figure 5.

61. The form C of the monofumarate according to any one of claims 53 to 60, wherein the form C of the monofumarate has a DSC thermogram containing one or more endothermic peaks that begin at about 30°C and about 125°C.

62. The form C of the monofumarate according to any one of claims 53 to 61, wherein the form C of the monofumarate has substantially the same DSC thermogram as that shown in Figure 6.

63. The form C of the monofumarate according to any one of claims 53 to 62, wherein when the form C of the monofumarate is heated from about 25°C to about 80°C, it exhibits a weight loss of about 0.9% by weight or less.

64. Equation (I) 【Transformation 7】 Crystalline hemifumarate of the compound.

65. The crystalline hemi-fumarate according to claim 64, wherein the crystalline hemi-fumarate has an XRPD pattern including one or more peaks at approximately 8.5°, approximately 11.0°, and approximately 12.0°²θ.

66. The crystalline hemifumarate according to claim 65, wherein the XRPD pattern further includes one or more peaks at approximately 16.9°, approximately 17.9°, and approximately 24.1°²θ.

67. The crystalline hemifumarate according to claim 65 or 66, wherein the XRPD pattern further includes one or more peaks at approximately 25.7°, approximately 27.7°, and approximately 34.1°²θ.

68. A crystalline hemifumarate according to any one of claims 65 to 67, wherein approximately means ±0.3°²θ.

69. The crystalline hemifumarate according to any one of claims 64 to 68, wherein the crystalline hemifumarate has substantially the same XRPD pattern as that shown in Figure 8.

70. The crystalline hemifumarate according to any one of claims 64 to 68, wherein the crystalline hemifumarate has substantially the same XRPD pattern as that shown in Figure 13.

71. The crystalline hemifumarate according to any one of claims 64 to 70, wherein the crystalline hemifumarate is in an anhydrous crystalline form.

72. The crystalline hemifumarate according to any one of claims 64 to 70, wherein the crystalline hemifumarate is a crystalline hydrate.

73. Equation (I) 【Transformation 8】 Form A of the hemifumarate of the compound.

74. The hemi-fumarate form A according to claim 73, wherein form A of the hemi-fumarate has an XRPD pattern including one or more peaks at approximately 9.9° and approximately 11.0°²θ.

75. Form A of the hemifumarate according to claim 74, wherein the XRPD pattern further includes one or more peaks at approximately 6.4°, approximately 8.3°, approximately 12.1°, approximately 13.2°, approximately 14.3°, and approximately 14.5°²θ.

76. Form A of the hemifumarate according to claim 74 or 75, wherein the XRPD pattern further includes one or more peaks at approximately 16.9°, approximately 17.2°, approximately 17.8°, approximately 18.5°, approximately 20.2°, approximately 22.1°, and approximately 22.5°²θ.

77. Form A of the hemifumarate according to any one of claims 74 to 76, wherein the XRPD pattern further includes one or more peaks at approximately 15.1°, approximately 16.1°, approximately 19.5°, approximately 19.8°, approximately 21.2°, approximately 21.5°, approximately 23.3°, approximately 24.3°, approximately 24.5°, and approximately 25.0°²θ.

78. Form A of the hemifumarate according to any one of claims 74 to 77, wherein the XRPD pattern further includes one or more peaks at approximately 25.5°, approximately 26.3°, approximately 27.2°, approximately 28.9°, and approximately 31.1°²θ.

79. Form A of the hemifumarate according to any one of claims 74 to 78, wherein the XRPD pattern further includes one or more peaks at approximately 27.8°, approximately 28.0°, approximately 28.3°, approximately 29.5°, approximately 31.9°, approximately 32.5°, approximately 32.7°, approximately 33.6°, approximately 34.1°, and approximately 34.4°²θ.

80. Form A of the hemifumarate according to any one of claims 74 to 79, wherein approximately ±0.3°²θ.

81. The hemi-fumarate form A according to any one of claims 73 to 80, wherein form A of the hemi-fumarate has substantially the same XRPD pattern as that shown in Figure 8.

82. The form A of the hemifumarate according to any one of claims 73 to 81, wherein the form A of the hemifumarate has a DSC thermogram that includes endothermic activity with a peak starting at approximately 206°C.

83. The form A of the hemi-fumarate according to any one of claims 73 to 82, wherein the form A of the hemi-fumarate has substantially the same DSC thermogram as that shown in Figure 9.

84. The form A of the hemifumarate according to any one of claims 73 to 83, wherein when the form A of the hemifumarate is heated from about 25°C to about 150°C, it exhibits a weight loss of about 0.5% by weight or less.

85. The form A of the hemifumarate according to any one of claims 73 to 84, wherein the form A of the hemifumarate is in an anhydrous crystalline form.

86. Equation (I) 【Chemistry 9】 Form B of the hemifumarate of the compound.

87. The hemi-fumarate form B according to claim 86, wherein form B of the hemi-fumarate has an XRPD pattern including one or more peaks at approximately 5.4° and 8.7°²θ.

88. Form B of the hemifumarate according to claim 87, wherein the XRPD pattern further includes one or more peaks at approximately 10.4°, approximately 11.0°, approximately 11.9°, and approximately 12.6°²θ.

89. Form B of the hemifumarate according to claim 87 or 88, wherein the XRPD pattern further includes one or more peaks at approximately 16.5°, approximately 16.9°, approximately 17.4°, approximately 17.9°, and approximately 23.9°²θ.

90. Form B of the hemifumarate according to any one of claims 87 to 89, wherein the XRPD pattern further includes one or more peaks at approximately 25.7°, approximately 27.7°, and approximately 34.1°²θ.

91. Form B of the hemifumarate according to any one of claims 87 to 90, wherein approximately ±0.3°²θ.

92. The hemi-fumarate form B according to any one of claims 86 to 91, wherein form B of the hemi-fumarate has substantially the same XRPD pattern as that shown in Figure 13.

93. The form B of the hemifumarate according to any one of claims 86 to 92, wherein the form B of the hemifumarate has a DSC thermogram containing one or more endothermic temperatures with peak onset at approximately 118°C, approximately 182°C, and approximately 202°C.

94. The form B of the hemi-fumarate according to any one of claims 86 to 93, wherein the form B of the hemi-fumarate has substantially the same DSC thermogram as that shown in Figure 14.

95. The form B of the hemifumarate according to any one of claims 86 to 94, wherein when the form B of the hemifumarate is heated from about 25°C to about 150°C, it exhibits a weight loss of about 1.1% by weight or less.

96. The form B of the hemifumarate according to any one of claims 86 to 95, wherein the form B of the hemifumarate is a crystalline hydrate.

97. (i) Fumarate of the compound of formula (I) 【Chemistry 10】 (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

98. (i) Crystalline fumarate of the compound of formula (I) 【Chemistry 11】 (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

99. The pharmaceutical composition according to claim 98, wherein the crystalline fumarate is the crystalline fumarate described in any one of claims 4 to 15.

100. (i) Crystalline monofumarate of the compound of formula (I) 【Chemistry 12】 (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

101. The pharmaceutical composition according to claim 100, wherein the crystalline monofumarate is the crystalline monofumarate described in any one of claims 16 to 26.

102. (i) Form A of the monofumarate of the compound of formula (I) described in any one of claims 27 to 39; and (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

103. (i) Form B of the monofumarate of the compound of formula (I) described in any one of claims 40 to 52; and (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

104. (i) Form C of the monofumarate of the compound of formula (I) described in any one of claims 53 to 63; and (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

105. (i) Crystalline hemifumarate of the compound of formula (I) 【Chemistry 13】 (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

106. The pharmaceutical composition according to claim 105, wherein the crystalline hemifumarate is the crystalline hemifumarate described in any one of claims 64 to 72.

107. (i) form A of the hemifumarate of the compound of formula (I) described in any one of claims 73 to 85; and (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

108. (i) form B of the hemifumarate of the compound of formula (I) according to any one of claims 86 to 96; and (ii) A pharmaceutical composition containing pharmaceutically acceptable excipients.

109. A dosage form comprising the pharmaceutical composition according to any one of claims 97 to 108.

110. The dosage form according to claim 109, wherein the dosage form is a solid dosage form.

111. The dosage form according to claim 109 or 110, wherein the dosage form is an oral dosage form.

112. The dosage form according to any one of claims 109 to 111, wherein the dosage form is a capsule.

113. A method for treating cancer in a target subject, comprising administering to the target in an effective amount any of the following: a fumarate of the compound of formula (I) according to any one of claims 1 to 3; a crystalline fumarate of the compound of formula (I) according to any one of claims 4 to 15; a crystalline monofumarate of the compound of formula (I) according to any one of claims 16 to 26; form A of the monofumarate of the compound of formula (I) according to any one of claims 27 to 39; form B of the monofumarate of the compound of formula (I) according to any one of claims 40 to 52; form C of the monofumarate of the compound of formula (I) according to any one of claims 53 to 63; a crystalline hemifumarate of the compound of formula (I) according to any one of claims 64 to 72; form A of the hemifumarate of the compound of formula (I) according to any one of claims 73 to 85; form B of the monofumarate of the compound of formula (I) according to any one of claims 86 to 96; or a pharmaceutical composition according to any one of claims 97 to 108.

114. The method according to claim 113, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, carcinoma, cervical cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, kidney cancer, lung cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer.

115. The method according to claim 114, wherein the breast cancer is triple-negative breast cancer or metastatic breast cancer; the carcinoma is cancer of unknown primary origin (CUP), endometrial cancer, head and neck squamous cell carcinoma, Merkel cell carcinoma, squamous cell carcinoma, or urothelial carcinoma; the gastric cancer is adenocarcinoma or gastrointestinal stromal tumor; the kidney cancer is renal cell carcinoma (RCC); the lung cancer is small cell lung cancer (SCLC) or non-small cell lung cancer; the hepatocellular carcinoma is hepatocellular carcinoma; or the skin cancer is malignant melanoma.

116. The method according to claim 113, wherein the cancer is selected from the group consisting of renal cell carcinoma, gastric cancer, breast cancer, and small cell lung cancer.

117. The method according to claim 113, wherein the cancer is selected from the group consisting of classical Hodgkin lymphoma, primary thymic-mediastinal lymphoma, multiple myeloma, and B-cell malignancy.

118. The method according to claim 117, wherein the B-cell malignant tumor is non-Hodgkin lymphoma or chronic lymphocytic leukemia.

Images